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Stellingen 
 
1. Leden van de Rho-GTPase familie vormen een sleutelrol in de regulatie van 
vaatontwikkeling - dit proefschrift. 
 
2. Intra-oculaire injectie van siRNA gericht tegen een specifiek gen geeft een 
betrouwbaar beeld van het in vivo effect van dit gen op de retinale vaatontwikkeling - 
dit proefschrift. 
 
3. De stimulerende werking van 9430020K01Rik (KIAA1462) op endotheelcel 
proliferatie tijdens angiogenese, verloopt via modulatie van de RhoA activiteit - dit 
proefschrift. 
 
4. Tagln2 onderdrukt vaatuitgroei door actine depolymerisatie en vermindering van de 
VEGFR-2 turnover - dit proefschrift. 
 
5. Tijdens angiogenese is Thsd1 essentieel voor vaatstabilisatie - dit proefschrift. 
 
6. Remming van angiogenese ter bestrijding van tumorgroei heeft mogelijk een averechts 
effect - Physiol Rev. 2011;91(3):1071-1121. 
 
7. Dagelijkse consumptie van pure chocolade verlaagd het risico op coronair vaatlijden - 
Curr Atheroscler Rep. 2011;13(6):447-452. 
 
8. In families met een erfelijke afwijking in het mitochondriaal DNA hebben kinderen 
met drie biologische ouders de toekomst - Hum Mol Genet. 2011;20(R2):R168-R174. 
 
9. Ook laboratoriummuizen zitten er graag warmpjes bij - PLoS One. 2012;7(3):e32799. 
 
10. Binnen de plantenbiologie heeft ‘auxine’ dezelfde uitwerking op wetenschappers, als 
‘VEGF’ binnen de vasculaire ontwikkelingsbiologie: ze hebben beide een stimulerend 
effect - Nat Rev Genet. 2009;10(5):305-317. 
 
11. Mensen die zich helemaal niet inlaten met de wetenschappen en zich alleen door de 
natuur laten leiden, zijn verreweg het gelukkigst - Desiderius Erasmus. 
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For centuries, many scientists are fascinated by the organisation of the vascular network. 
The Greek philosopher and polymath Aristotle (384 BC) was one of the first man who 
described the vasculature. He wrote: “the system of blood vessels in the body may be 
compared to those of water-courses which are constructed in gardens: they start from one 
source, or spring, and branch off into numerous channels, and then into still more, and so 
on progressively, so as to carry a supply to every part of the garden”.1 Over time, many 
models of the vascular system have been developed. In 1628, it was the English biologist 
and physician William Harvey (1578 AD) who published in his book Exercitatio Anatomica 
de Motu Cordis et Sanguinis in Animalibus (Anatomical Exercises on the Motion of the 
Heart and Blood in Animals) our current model of the vascular system that blood circulates 
in a closed circuit.2 Until then, less was known about blood vessel development. With the 
discovery of the microscope in the 17th century by Antonie van Leeuwenhoek (1632 AD), 
scientists observed for the first time vessel sprouting in thin transparent tissues. It was John 
Hunter - a Scottish surgeon (1728 AD) - who identified growing vessels in healing wounds 
and embryos.3,4 The first observation of angiogenesis was made in 1853 by Meyer who 
described spindle-shaped structures arising from capillaries in tadpole tails, which later 
became tubular.5,6 Over the last decades, knowledge about blood vessel development has 
increased by the advances of molecular biology. Today, scientists unravel the factors that 
stimulate angiogenesis in ischemic tissues and wound healing, and those that inhibit tumour 
growth and metastasis to develop better medical treatments for cancer and cardiovascular 
diseases. 
 
 
Vessel formation 
 
During embryonic development, the vascular network is formed by both vasculogenesis 
and angiogenesis to provide oxygen to the developing organism. Hypoxic conditions 
initiate vessel formation by upregulating angiogenic factors like vascular endothelial 
growth factor (VEGF).7,8 
 
Vasculogenesis 
Vasculogenesis refers to the initial events of blood vessel formation in which angioblasts - 
endothelial precursor cell - differentiate into endothelial cells (EC), which assemble into a 
primitive vascular plexus.1 
In the mouse at embryonic day (E)7.5 vascular development starts with the 
differentiation of mesodermal cells into haemangioblasts, leading to the formation of 
primitive blood islands. Then, haemangioblasts at the centre forms haematopoietic stem 
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cells, while those on the edge give rise to angioblasts. They further differentiate into ECs 
and assemble into tubular structures, forming the primitive vascular plexus (Figure 1A).9 
 
 
Figure 1. Vessel formation. (A) Vasculogenesis: the formation of blood vessels. Transcription factor Brachyury 
is needed for mesodermal cell differentiation into haemangioblasts, followed by the formation of primitive blood 
islands. Haemangioblasts give rise to angioblasts and haematopoietic stem cells. The angioblasts assemble into a 
primitive vascular plexus. Cell markers (blue). (B) Angiogenesis: the formation of new capillaries by sprouting 
from pre-existing small blood vessels. Quiescent vessels expand by sprouting: growth of a newly formed vessel 
branch or stalk toward an angiogenic stimulus (for a more detailed description see Figure 2), intussusception: 
splitting of an existing blood vessel in two, and bridging: splitting of an existing vessel by the formation of 
transendothelial bridges. 
Introduction 
 
 17
Angiogenesis 
The formation of new capillaries by sprouting from pre-existing small blood vessels is 
known as angiogenesis.1 
In the mouse at E8.5 the primitive vascular plexus expand by subsequent sprouting. 
Thereafter, angiogenesis can also take place by intussusception - the internal division of 
pre-existing vessels without sprouting - and vessels can also divide longitudinal into 
daughter vessels by the formation of transendothelial bridges (Figure 1B).10 
 
VEGF 
Vessel formation is regulated by many different angiogenic factors. One of the best known 
is VEGF, also known as VEGF-A. There are four different isoforms: VEGF121, VEGF165, 
VEGF189 and VEGF206, of which VEGF165 is the most active one. VEGF165 is a freely 
diffusible protein, but can also be sequestered in the extracellular matrix (ECM).11-13 Mouse 
embryos lacking one VEGF allele dies between E11 and 12. They display defective 
vascularisation in several organs.14 
VEGF stimulates angiogenesis by signalling through VEGF receptor 2 (VEGFR-2), 
also known as fetal liver kinase (Flk1) or kinase domain receptor (Kdr), and its neuropilin 
(NRP) co-receptor 1 and 2. Binding of VEGF to VEGFR-2 results in dimerisation and 
ligand-dependent tyrosine phosphorylation, activating downstream signalling cascades.11,12 
Kdr-knockout mice die in utero between E8.5 and 9.5 as a consequence of disturbed blood 
island formation and organised blood vessel development.15 Thus, VEGF and VEGFR-2 are 
important factors in vascular development. 
 
 
Molecular basis of vessel branching 
 
The various processes involved in blood vessel formation will be explained in more detail 
based on sprouting angiogenesis, starting with a quiescent vessel (Figure 2A).7 Sprouting 
begins in the presence of pro-angiogenic factors and will continue until quiescence is re-
established.16 
 
Hypoxia-inducible factor 
In response to hypoxic conditions, pro-angiogenic factors will be upregulated. Vessel 
perfusion or the amount of oxygen is measured by oxygen sensing enzymes - prolyl 
hydroxylase domain proteins (PHD) - expressed at the surface of ECs. When sufficient 
oxygen is available, PHDs hydroxylate the hypoxia-inducible transcription factor (HIF), 
after which it is targeted for proteasomal degradation by the Von Hippel-Lindau tumour-
suppressor protein.12,16-19 
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Figure 2. Vessel branching. The various processes involved in sprouting angiogenesis: (A) Quiescent vessels 
consist of a monolayer of endothelial cells (EC), interconnected by adherens and tight junctions. These ECs are 
enfolded by pericytes which suppress EC proliferation. Both cell types are anchored via integrins to a common 
basement membrane composed of extracellular matrix proteins to prevent resident ECs leaving their position. (B) 
Tip cell formation requires pericyte detachment, basement membrane degradation and disruption of EC junctions. 
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(C) Tip cells navigate in response to attractant and repulsive signals, and adhere to the extracellular matrix to 
migrate. Stalk cells behind the tip cell proliferate (for a more detailed description see Figure 3) and form a lumen. 
VE-cadherin is upregulated by phalanx cells for vessel stabilisation. (D) After tip cell fusion the initial endothelial 
barrier function is restored by VE-cadherin. Lumen formation allows perfusion which promote basement 
membrane deposition, mural cell recruitment and production of survival signals. Vessel regression appear when 
perfusion remains (for a more detailed description see Figure 4). Factors involved in the molecular basis of vessel 
branching (blue). 
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In hypoxic conditions, PHDs become inactive which results in diminished HIF 
degradation. So HIF can interact with hypoxia responsive elements to induce transcriptional 
activity of pro-angiogenic factors, initiating vessel sprouting.12,16-18 Absence of HIF in mice 
results in abnormal vascular development and embryonic lethality.20 Thus, HIF functions as 
a switch of vessel branching. 
 
Tip cell selection 
When a quiescent vessel sense a pro-angiogenic factor, pericytes will detach from the 
vessel wall by proteolytic degradation of the basement membrane, mediated by matrix 
metalloproteinases (MMP). Thereafter, break down of the basement membrane results in 
the liberation of several pro-angiogenic factors sequestered in the ECM like VEGF and 
fibroblast growth factor (FGF), and generate also anti-angiogenic factors by cleaving 
plasma proteins, matrix molecules or the proteases themselves to prevent excessive 
sprouting.21-23 VEGF stimulates vasodilatation via endothelial nitric oxide synthase (eNOS) 
activation and release of NO, and induce the disruption of intercellular connections between 
ECs leading to an increased permeability of the vessel wall. Plasma proteins will 
extravasate and lay down a temporal ECM to which the ECs migrate.7,12 FGF works pro-
angiogenic by inducing the release of pro-angiogenic factors in a positive feedback loop.24 
Further pericyte detachment is stimulated by the release of angiopoietin 2 (Ang2) by ECs 
(Figure 2B).25 
Once the pericytes have detached from the basement membrane and degradation of the 
ECM has taken place, one EC - known as the tip cell - become selected to lead the newly 
formed vessel branch or stalk. The neighbours of the tip cell become stalk cells. This 
selection process is controlled by the Notch pathway. In response to a VEGF gradient, all 
ECs upregulate the expression of the Notch ligand Dll4 by activation of VEGFR-2. The EC 
expressing Dll4 more quickly or at higher levels become a tip cell. Dll4 then activates 
Notch in the neighbouring ECs or stalk cells, downregulating VEGFR-2 while upregulating 
VEGF receptor 1 (VEGFR-1) which is involved in limiting tip cell formation. In this way, 
stalk cells become less responsive to the sprouting activity of VEGF.7,16,26,27 Overall, tip 
cells express higher levels of Dll4, while stalk cells reveal high Notch activity which 
promotes EC proliferation.28 
 
Proliferation 
The link between proliferative signals from cell surface receptors, such as VEGFR-2 or 
integrin, to transcription factors which finally modulate cell cycle progression is formed by 
the Ras-Raf-MEK-ERK pathway. Ligand binding to its surface receptor leads to activation 
of focal adhesion kinase (FAK) via its N-terminal FERM domain. Structurally, FAK also 
contains a central tyrosine kinase domain, proline-rich regions and a focal adhesion-
targeting (FAT) domain at the C-terminus. Receptor ligation to the FERM domain leads to 
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autophosphorylation of Y397 in the central tyrosine kinase domain. c-Src is recruited, 
unfolding to transphosphorylate Y925 in the FAT domain. Via the Grb-2/mSOS complex 
the Ras-Raf-MEK-ERK pathway is activated (Figure 3A).9 
 
 
Figure 3. Proliferation. (A) Overview of the Ras-Raf-MEK-ERK pathway. FAK transduce signals from the 
membrane receptor to the Grb-2/mSOS complex which induce Ras activity by the exchange of GDP with GTP. 
Then, Raf is translocated to the cell membrane where it is activated by Rac1 or Cdc42, after which it activates its 
downstream effectors MEK and ERK. (B) ERK modulate transcription factors which are involved in the 
expression of cell cycle regulators such as cyclins, CDKs, CDK inhibitors and other regulatory proteins. 
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Ras is activated due to the exchange of GDP with GTP. Then, Raf is translocated to the 
cell membrane where it can be activated by Rac1 or Cdc42 of the Rho-GTPase family. The 
effect of Raf activation on cell cycle progression depends on the level and duration of Raf 
activation. In the short term, Raf stimulates cyclin-induced cell cycle progression, while 
prolonged Raf signalling leads to cell cycle arrest induced by the cyclin-dependent kinase 
(CDK) inhibitor p21.29 Raf phosphorylates its substrate MAPK/ERK kinase (MEK) which 
activates extracellular signal-regulated kinase (ERK). Next, ERK modulate numerous 
transcription factors which are involved in cell cycle regulation.30 
These transcription factors regulate the expression of cyclins (cyclin D1, D2 and E), 
CDKs (CDK2, 4 and 6), CDK inhibitors (p16, p21 and p27), and regulatory proteins like 
retinoblastoma (Rb) and p53. All these proteins activate or inactivate ‘check points’ which 
determine the progression of the cell cycle from one phase to the next. During these ‘check 
points’ the cell status is monitored to ensure that an earlier process is complete. In response 
to DNA damage, repair genes can be activated or the cell undergo programmed cell death 
or apoptosis. In some cases, proliferative ECs receive cell cycle arrest signals which induce 
lumen formation or morphogenic differentiation (Figure 3B).9,30,31 
 
Tip cell guidance 
The tip cell has to sense the environment for guidance cues. For this reason, filopodia are 
formed at the tip cell which is regulated by Cdc42. One of the attractive cues is VEGF, 
while slit proteins, netrin 1, semaphorins and ephrin works repulsive (Figure 2C).16,27 
The response to VEGF differ from tip cells, stalk cells and phalanx cells because of 
their unique molecular characteristics. Tip cells exhibit a migratory response to VEGF and 
show an upregulation of Dll4. Stalk cells undergo proliferation and show upregulation of 
Notch, while VEGF signalling in phalanx cells leads to a survival response mediated by 
increased levels of VE-cadherin.32 
Slit proteins bind to its Roundabout 4 (Robo4) receptor and is involved in vessel 
stabilisation.16 Netrin 1 binds the UNC5B receptor and suppress vessel growth by 
stimulating filopodia retraction of ECs.33 Most semaphorins suppress angiogenesis by 
binding NRP1 - co-receptor of VEGFR-2 - in a competitive way with VEGF.34,35 Ephrin 
binds to the ephrin (EPH) receptor and regulates vessel morphogenesis, especially arterial 
and venous specification. Ephrin-B2 is mainly expressed in arterial ECs, whereas ephrin-B4 
marks venous ECs.16,36 Finally, all these guidance cues determine the direction of tip cell 
migration. 
 
Migration 
Migration to a gradient of soluble guidance cues is known as chemotaxis. Two other 
mechanisms also determine EC migration: haptotaxis, migration toward a gradient of 
immobilised ligands such as integrins or components of the ECM, and mechanotaxis, 
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migration generated by mechanical forces like shear stress. The process of migration can be 
divided into six following steps: sensing of guidance cues by filopodia, cellular extension 
by the formation of lamellipodia, attachment of the protrusions to the ECM via focal 
adhesion (FA) sites, contraction of stress fibres, rear release by FA disassembly and finally 
recycling of the adhesive and signalling components.11,37 
When filopodia at the tip cell has determined the direction of migration, lamellipodia 
are formed for protrusion at the leading edge. Formation of lamellipodia is associated with 
microtubule elongation by actin polymerisation, promoted by Rac activity. Activation of 
Rac is induced by VEGFR-2 or integrins.38 The next step in migration is FA assembly. FAs 
are sites where ECs are anchored to the ECM of the basement membrane via integrins. 
Intracellular, integrins are linked to the actin cytoskeleton by proteins such as FAK, 
vinculin, paxillin and talin. As mentioned before, FAK has an important role in signal 
transduction to induce EC proliferation. After that, FAK also regulates FA assembly and 
disassembly which allows adhesion and release of the EC important for migration.39 FAK-
knockout mice die in utero between E8.5 and 9.0 as a result of defective migration and 
abnormal angiogenesis.9 Integrin signalling at FA sites can be activated by changes in the 
density of the ECM or by shear stress. Pressure forces generated by shear stress at the 
apical surface of the EC are transmitted to the integrins at the basal side of the endothelium 
via the actin cytoskeleton. Beside Rac activation for lamellipodia formation, integrins can 
also activate RhoA which is an important mediator in stress fibre formation and 
contraction, pulling the trailing edge to the direction of migration.40 After that, adhesive and 
signalling components were recycled.11 In general, integrins, FAK, and the Rho-GTPases 
Cdc42, Rac and RhoA have an important role in cell migration. 
 
Lumen formation 
When the newly formed vessel branch increases in length by EC proliferation and 
migration, a vascular lumen has to be formed. Lumen formation takes place by two 
different mechanisms: cell hollowing, in which a lumen is created by fusion of intracellular 
vacuoles and interconnections with vacuoles from neighbouring cells, or cord hollowing, in 
which a luminal cavity is created by changes in cell shape via contraction of the actin 
cytoskeleton and rearrangement of cellular junctions, followed by exposure to negatively 
charged glycoproteins at the luminal side of the ECs.16,41 
 
Vessel stabilisation 
When two newly formed vessel branches or sprouts come close together, filopodia of both 
tip cells interact and start to form a branch anastomosis by tip cell fusion.7 This process is 
facilitated by macrophages.42 Once the contact between tip cells is established, VE-cadherin 
primarily strengthened the connection by the formation of adherens junctions.43 
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VE-cadherin is a transmembrane protein of which the extracellular domain shows 
homotypic interactions forming zipper-like adhesions, while the cytoplasmic domain is 
linked by β-catenin and p120 - also known as CTNND1 - to the actin cytoskeleton for 
junction stabilisation. Loss of β-catenin results in defective cell adhesion and failure of 
cadherin-catenin complexes to associate with the actin cytoskeleton. Complex formation of 
CTNND1 with VE-cadherin maintains VE-cadherin at the plasma membrane, whereas VE-
cadherin alone cycles on and off the plasma membrane by exocytosis and endocytosis.44-46 
Soluble CTNND1 regulates the activity of the Rho-GTPases, especially RhoA. As 
mentioned before, RhoA plays an important role in stress fibre formation during migration, 
but also in EC proliferation by Rb-induced G1–S-phase transition.47 VE-cadherin mediates 
contact inhibition of cell growth by diminishing VEGFR-2-stimulated EC proliferation. 
Mice deficient for VE-cadherin show a normal differentiation of ECs, but vascular 
remodelling and integrity are defected, resulting in vascular malformations and death at 
midgestation.48 It seems that VE-cadherin is more required during angiogenesis instead of 
vasculogenesis. 
Further stabilisation of the newly formed vessel branch takes place by deposition of 
ECM proteins into the basement membrane and recruitment of mural cells (Figure 2D).7,8 
Four molecular pathways are involved in mural cell recruitment: platelet-derived growth 
factor (PDGF) - PDGF receptor (PDGFR)-β, sphingosine-1-phosphate receptor (S1PR) or 
endothelial differentiation sphingolipid G-protein-coupled receptor 1 (EDG1), angiopoietin 
1 (Ang1) - Tie2 receptor, and the transforming growth factor (TGF)-β signalling pathway. 
Tip cells release PDGF to attract mural cells expressing PDGFR-β. In response, these 
mural cells anchor to the newly formed basement membrane, which encloses the layer of 
stalk cells.49,50 Lack of PDGFR-β in mice results in insufficient recruitment of mural cells, 
leading to an increase in EC growth, loss of vessel integrity and haemorrhage.51 To 
consolidate the EC-pericyte contacts, stalk cells upregulate EDG1 expression at the apical 
surface of the EC, which induces N-cadherin trafficking to the basal side of the 
endothelium where they form connections between ECs and pericytes.8,52 EDG1-knockout 
mice exhibit an alteration in ECM production and EC-pericyte interaction which results in 
diminished vessel maturation.53 Also EC-EC contacts have to tighten up to make the newly 
formed vessel branch leak-resistant. This process is regulated by Ang1 - produced by mural 
cells - which upregulate the endothelial Tie2 receptor, leading to Tie2 clustering in trans at 
cell-cell junctions. After that, Ang1 also stimulates ECM protein deposition in the basement 
membrane, mural coverage, and release of PDGF and TGF-β by ECs.7,8,25 Next, mural cells 
differentiate into vascular smooth muscle cells (vSMC) induced by TGF-β signalling. 
Downstream of TGF-β, the balance between Alk1 and Alk5, which is regulated by endoglin 
(Eng), determines the pro-angiogenic or anti-angiogenic effect of TGF-β. The Alk1 
pathway induces break down of the basement membrane by upregulating MMP expression, 
while Alk5 prevents ECM degradation via plasminogen activator inhibitor (PAI)-1 
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expression in ECs which indirectly inhibits MMP activation.8,54 Deficiency of Eng impairs 
mural cell development and results in arteriovenous malformations.55 
 
Vessel quiescence 
Finally, the expression of pro-angiogenic factors is reduced as a consequence of oxygen 
delivery by blood vessel perfusion, inducing a quiescent phenotype of ECs. To maintain 
vessel quiescence, ECs have to produce survival factors in low levels such as VEGF or 
FGF.12,56 Other survival factors are cerebral cavernous malformation (CCM) proteins 1-3. 
Loss of these proteins results in the development of abnormal vascular structures, 
characterised by thin-walled, dilated blood vessels with gaps between the ECs.57 Blood 
vessel perfusion or shear stress also activates Krüppel-like factor 2 (Klf2) which upregulate 
eNOS expression and the anticoagulant factor Thrombomodulin, keeping blood vessels 
dilated, perfused and free of clots. Thereafter, Klf2 downregulates VEGFR-2 preventing tip 
cell formation. All these survival factors extend the endothelial half-life time to several 
years.7,16 
 
Vessel regression 
Hypoperfused vessel branches show less Klf2 expression which results in vessel regression 
by programmed cell death or apoptosis, characterised by cell shrinkage, chromatin 
condensation and fragmentation of the cell into apoptotic bodies that are absorbed by 
macrophages.16,31,58 
Beside hypoxia and loss of survival factors, apoptosis can also be initiated by 
detachment of ECs from their surrounding tissue, DNA damage or disruption of the cell 
cycle. Based on the way of initiation, two main pathways of apoptosis can be distinguished: 
the extrinsic or death-receptor pathway, and the intrinsic or mitochondrial pathway.31,59 
The extrinsic pathway is activated by binding of tumour necrosis factor (TNF) at the 
death-receptor. The intracellular death domain of the death-receptor attracts the Fas-
associated death domain (FADD) protein, forming a death-inducing signalling complex 
(DISC) which activates the ‘initiator’ cysteine aspartyl-specific protease (caspase) 8 and 10 
by proteolytic cleavage (Figure 4A).59,60 The intrinsic pathway can be activated via 
upregulation of p53 expression as a consequence of DNA damage, or loss of survival 
factors, resulting in less FAK-PI3K-Akt signalling.9,30 Also crosstalk between the two 
pathways is possible via activated caspase 8. All of these signals are mediated by the pro-
apoptotic Bcl2 family proteins - BAX, BAD and BID - leading to cytochrome c release 
from the intermembraneous space of mitochondria into the cytosol where an apoptosome is 
formed, composed of cytochrome c, apoptotic protease activating factor 1 (APAF1), ATP 
and the inactive ‘initiator’ caspase 9. At the apoptosome caspase 9 is activated by 
proteolytic cleavage (Figure 4B).59,61 The ‘initiator’ caspases activate the ‘executioner’ 
caspases 3, 6 and 7 which will cleave each other to amplify the proteolytic cascade. 
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Figure 4. Vessel regression. Apoptosis can be induced through (A) death receptors at the cell surface (extrinsic 
pathway) or through (B) mitochondria (intrinsic pathway). Induction of apoptosis leads to activation of the 
‘initiator’ caspases 8 and 9, followed by activation of the ‘executioner’ caspase 3, cleaving the death substrates 
which finally results in apoptosis. 
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Finally, cellular death substrates are cleaved, resulting in cellular self destruction. For 
example, cleavage of nuclear lamins results in chromatin condensation, whereas cleavage 
of cytoskeleton proteins - like actin - leads to cell fragmentation and the formation of 
apoptotic bodies.59,62,63 
 
 
Vascular development and pathology 
 
Vessel formation leads to a vascular network that reaches nearly every part of the body. For 
this reason, deviations of normal vascular development or disruptions in the maintenance of 
the inner vascular lining contribute to the aetiology or worsening of many diseases. One of 
these is atherosclerosis. 
 
Atherosclerosis 
Atherosclerosis develops mainly at places with disturbed shear stress, like branch points. In 
combination with elevated levels of serum cholesterol and subsequent accumulation of 
oxidised low-density lipoprotein (LDL) in the intimal layer, endothelial dysfunction will 
develop, which is characterised by an imbalance of endothelium-derived vessel relaxing 
factors and contracting factors.64,65 Endothelial dysfunction leads to plaque formation, 
characterised by chronic vascular inflammation and the accumulation of lipids, cholesterol, 
calcium, fibrous elements and cellular debris within the intimal layer of arteries. During 
plaque formation microvessels sprouted from the vasa vasorum - a network of small blood 
vessels in the adventitial layer that supply large blood vessels - into the medial layer of the 
vessel wall, making the plaque highly vulnerable for rupture and thrombus formation which 
can finally result in myocardial infarction or stroke.66-69 
Inward vessel growth sprouted from the vasa vasorum is initiated by a highly hypoxic 
microenvironment in the core area of the plaque and pro-angiogenic factors such as 
PDGF.70 This process of vessel branching is associated with increased MMP activity in the 
surrounding tissue like in normal angiogenesis. Also the intercellular connections between 
ECs become disrupted, diminishing endothelial barrier function. Normally, plasma proteins 
will extravasate and lay down a temporal ECM to which the ECs migrate, but in case of 
atherosclerotic plaque formation, next to this, inflammatory cells will enter the medial layer 
which promote further inflammation.7,12,71 The highly inflammatory environment leads to 
failure of vessel stabilisation as seen by a lack of EC-pericyte contacts. Loss of these 
pericytes makes it possible for ECs to hyperproliferate resulting in tortuous vessel branches 
that are highly susceptible to intraplaque haemorrhage. Repeated intraplaque haemorrhages 
leads to atherosclerotic plaque instability, fissuring and rupture, followed by thrombus 
formation which can finally result in blood vessel occlusion and clinical manifestations.71-73 
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ApoE-knockout mice 
To study atherosclerosis, transgenic mice were generated. Mice are normally very resistant 
to develop atherosclerosis, but genetic manipulations - apolipoprotein E (ApoE)-knockout - 
in combination with a high cholesterol diet results in massive hypercholesterolemia, leading 
to extensive atherosclerotic plaque formation that has many features in common with 
human lesions. This process is accelerated by placing a cylindrical device with a tapered 
lumen around the carotid artery, which leads to a high shear stress field. Deviations in shear 
stress upstream and downstream from the device deregulates EC function and maintenance 
of the inner vascular lining, which results in atherosclerotic plaque formation. In ApoE-
knockout mice subendothelial microvessel formation has been observed in advanced 
atherosclerotic lesions.74,75 
 
 
Indentifying new genes involved in angiogenesis 
 
In the previous sections a general overview has been given about vessel formation in 
normal and pathological conditions, in particularly atherosclerosis. Insight into the 
molecular players during the various stages of vascular development can provide clues to 
improve medical treatment of many diseases. For example, understanding the role of 
different (new) factors in the process of vessel stabilisation may possibly help to diminish 
intraplaque haemorrhage in atherosclerotic plaque formation. In order to identify new 
molecular players involved in angiogenesis, we carried out a genome-wide microarray 
screen for candidate regulatory genes. 
 
Study design 
The gene expression profiles of Flk1-positive angioblasts at various stages of vascular 
development during mouse embryogenesis were compared with the profiles of Flk1-
negative cells. This resulted in a list of genes that were upregulated during vascular 
development. Next, for all one-to-one orthologues to zebrafish of the upregulated genes, 
RNA expression in the vascular network of zebrafish was determined by whole-mount in 
situ hybridisation. If gene expression was seen in the vasculature, the gene was silenced by 
morpholino (MO)-knockdown technology to assess gene function in vivo. Then, the 
mammalian relevance of the gene was studied in a mouse model of retinal vascularisation. 
To further validate the molecular influence on vessel formation, in vitro models such as a 
2D matrigel network-formation assay were used. In these models, gene expression was 
influenced by targeted siRNA knockdown or adenovirus-induced overexpression. When the 
signalling pathway of the gene becomes clear, rescue experiments at different levels of the 
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signalling cascade were carried out. Finally, the functional implications of the gene were 
elucidated in knockout mice. 
 
 
Outline of this thesis 
 
The first part of this thesis focuses on the process of EC proliferation and migration, which 
is important in the outgrowth of a newly formed vessel branch or stalk. In chapter 2, the 
role of 9430020K01Rik in EC proliferation is studied. Loss of 9430020K01Rik resulted in 
impaired vessel outgrowth as a consequence of less Rb phosphorylation, leading to an 
arrest in G1–S-phase transition. Cell cycle progression could also be influenced by the 
activity of cyclins and CDK inhibitors, which is regulated by Klf7, as shown in chapter 3. 
The role of Tagln2 in migration is described in chapter 4. Unravelling the function of 
Tagln2 by targeted siRNA knockdown showed an effect on tip cell formation and 
migration. The second part of this thesis describes the process of vessel stabilisation and 
quiescence. In chapter 5 we describe the role of Thsd1 in normal vessel formation, but also 
in the vulnerable plaque. Thsd1 is crucial for establishing endothelial barrier function by 
Rac1-dependent regulation of the actin cytoskeleton. Vessel quiescence, which is 
maintained by the CCM1-3 proteins, is reviewed in chapter 6. The third part of this thesis 
describes processes in vessel regression. Stimulation of apoptosis by Fgd5 is described in 
chapter 7, while the inhibiting role of Tnfaip8l1 is unfolded in chapter 8. Finally, the results 
obtained in these studies are discussed in chapter 9 of this thesis. 
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Abstract 
 
Objective - Aberrant proliferation of endothelial cells and vascular smooth muscle cells is 
involved in the progression of cardiovascular diseases such as coronary artery disease 
(CAD). Previously, it has been shown that a missense variant in the KIAA1462 gene 
increases the risk of CAD. Using a genome-wide microarray screen for new angiogenic 
factors during embryogenesis, we identified 9430020K01Rik (KIAA1462) as a potential 
regulator of vascular growth. However, the biological function of KIAA1462 remains 
unknown. Here, we sought to characterise the role of KIAA1462 during blood vessel 
formation. 
Methods and Results - Functional knockdown of KIAA1462 in zebrafish embryos 
resulted in epiboly, whereas 9430020K01Rik-knockout mice exhibited suppressed blood 
vessel formation in the retina and heart tissue. Flow cytometric analysis of cultured 
endothelial cells suggested that blockage of G1–S-phase transition in KIAA1462-depleted 
cells might be the cause of impaired vessel development. To clarify the molecular 
mechanism by which KIAA1462 regulates cell proliferation, liquid chromatography-mass 
spectrometry was carried out and reveals CTNND1 as an active binding partner of 
KIAA1462. Knockdown of KIAA1462 impaired downstream signalling of CTNND1 via 
RhoA, leading to inhibition of ROCK2 and Rb and reduced G1–S-phase transition. 
Conclusion - KIAA1462 is essential in endothelial cell proliferation during vascular 
development by direct CTNND1 complex interaction and RhoA-dependent regulation of 
the G1–S-phase transition. 
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Introduction 
 
Cardiovascular diseases - including coronary artery disease (CAD) - is a major and highly 
frequent complication in the aging Western population and has a large impact on morbidity 
and mortality. CAD is the primary cause of myocardial infarction and is mostly the result 
from complications of atherosclerotic plaque formation.1 Atherosclerosis is a disease of the 
vascular wall in which a slow progression of lipid deposition and inflammation lead to 
narrowing of the vessel lumen and finally obstruction of coronary flow.2-5 Leukocyte 
extravasation - characteristic for inflammation - and vascular homeostasis are regulated by 
the endothelium, a monolayer of endothelial cells (EC) lining the vessel wall. These ECs 
are connected by adherens, tight and gap junctions. Previous studies have shown that 
endothelial junctional proteins - like VE-cadherin - play an essential role in the regulation 
of vascular permeability, cell proliferation and angiogenesis.6,7 Pathological misbalance 
causes endothelial dysfunction which is a prominent feature in the development, 
progression and clinical manifestation of atherosclerosis and CAD.8 Considering the clear 
association between endothelial function and cardiovascular disease, the molecular 
mechanisms that are involved in maintaining vascular homeostasis and prevention of CAD 
are crucial for the development of new diagnostics and therapeutics. However, the genetic 
regulation underlying endothelial dysfunction and subsequent CAD remains unknown. 
Recently, genome-wide association studies have detected a missense variant 
(p.S1002T) in the KIAA1462 gene - on chromosome 10p11.23 - which increases the risk of 
CAD by 15%.9,10 Although this finding marks KIAA1462 as a genetic risk factor for CAD, 
the exact role in the pathophysiology remains to be elucidated. 
In search of new angiogenic factors - using a genome-wide microarray screen -, we 
identified KIAA1462 as a candidate gene which is possibly involved in angiogenesis and 
endothelial regulation. The KIAA1462 gene encodes a 148 kDa protein without any known 
domains, but contains a proline-rich region. Thereafter, KIAA1462 shows some structural 
similarity with Rho-associated coiled-coil containing protein kinase (ROCK), suggesting a 
potential role in Rho signalling.11-13 Immunolocalisation studies revealed that KIAA1462 is 
a component of VE-cadherin-based cell-cell junctions in ECs.14 However, the protein 
function of KIAA1462 in angiogenesis and the pathophysiology of CAD remains to be 
clarified. 
In this study, we sought to characterise the role of KIAA1462 during blood vessel 
formation and pathogenesis of CAD in vitro using primary cell cultures and in vivo using a 
zebrafish and a murine retinal vascular development model. Functional knockdown of 
KIAA1462 in zebrafish resulted in epiboly, whereas 9430020K01Rik-knockout mice - the 
mouse orthologue of KIAA1462 - exhibited suppressed blood vessel formation in the retina 
and heart tissue. KIAA1462 depletion in cultured ECs showed blockage of G1–S-phase 
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transition, regulated by RhoA activity via catenin (cadherin-associated protein), delta 1 
(CTNND1). Our results reveal the importance of KIAA1462-mediated modulation of RhoA 
and EC proliferation in angiogenesis. 
 
 
Methods 
 
This study was carried out in accordance with the Council of Europe Convention 
(ETS123)/Directive (86/609/EEC) for the protection of vertebrate animals used for 
experimental and other scientific purposes and with the approval of the National and Local 
Animal Care Committee. 
 
Zebrafish 
Zebrafish (Danio rerio) were maintained under standard laboratory conditions. 
 
Morpholino injection 
Morpholinos (MO) against Loc100001168 (KIAA1462) were obtained from Gene Tools 
(Philomath, USA) and resuspended in Milli-Q water containing 0.2% phenol red. Different 
doses of the MO were injected into single-cell stage zebrafish embryos as previously 
described.15 The following zebrafish MO was used: 5’-ATT GGT TCT GCG CTC TGA 
GAA AAG C-3’ (MO Loc100001168-ATG). 
 
Mice 
Plugged FVB/N mice (Mus musculus) were ordered at Harlan (Indianapolis, USA). 
C57BL/6J mice were obtained from laboratory stock. They were maintained under standard 
husbandry conditions. 
 
Isolation of Flk1-positive and Flk1-negative cells from mouse embryos 
From eight to sixteen days post-fertilisation (dpf), embryos were collected from plugged 
FVB/N mice and homogenised. Cells were stained with PE-conjugated anti-mouse Flk1 
antibody 1:50 (555308; BD, Breda, The Netherlands). Hoechst (Sigma-Aldrich, 
Zwijndrecht, The Netherlands) was used to select dead cells. Flk1-positive/Hoechst-
negative cells and Flk1-negative/Hoechst-negative cells were sorted on a BD 
FACSCantoTM (Breda, The Netherlands). Isolation of mRNA was carried out using the 
RNeasy Mini Kit from Qiagen (Venlo, The Netherlands). 
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Microarray analysis 
Double stranded cDNA was generated from 5 μg mRNA. Biotin-labelled RNA was 
synthesised using the BioArrayTM HighYieldTM RNA Transcript Labeling Kit from ENZO 
Life Sciences (Raamsdonksveer, The Netherlands). After clean-up and fragmentation, 
approximately 20 μg of labelled cRNA was hybridised to the GeneChip® Mouse Genome 
430 2.0 Array (Affymetrix, Santa Clara, USA). Rosetta Resolver® (Rosetta Biosoftware, 
Cambridge, USA) was used to get quantile normalised raw data from the arrays. These data 
were merged into OmniViz® (BioWisdom, Cambridge, UK) and a threshold minimum for 
intensities was set at 30. Fold differences were calculated from log averages determined by 
the different experimental conditions. 
 
Mouse model of retinal vascularisation 
Two-day old C57BL/6J mice pups were anesthetised by placement on ice. One microlitre 
of 9430020K01Rik targeting siRNA (si-9430020K01Rik) (1.33 μg/μl) was injected into the 
left eye using a 33-Gauge needle (World Precision Instruments, Berlin, Germany). As a 
control, one microlitre of scrambled non-targeting siRNA (si-sham) (1.33 μg/μl) was 
injected into the right eye. siRNA was obtained from Thermo Fisher Scientific (Breda, The 
Netherlands). The following mix of mouse si-9430020K01Rik was used: 5’-AGG AAA 
GGG CAG AGA GGA UUU-3’ – 5’-GGA AAA GGC CCC AGG AAA AUU-3’ – 5’-
AGA GCC AGC CAU UGG GAA AUU-3’. Mice pups were killed five days after intra-
ocular injection. The retinas were stained with Alexa Fluor® 488-conjugated isolectin GS-
IB4 1:200 (I21411; Invitrogen, Bleiswijk, The Netherlands) before assessment under a 
fluorescence microscope (Axiovert S100; Carl Zeiss, Sliedrecht, The Netherlands). Image 
analysis of the number of junctions, tubules and total tubule length was carried out using 
Angiosys Image Analysis Software 1.0 (TCS CellWorks, Buckingham, UK). Validation of 
adequate 9430020K01Rik knockdown in the retina (two days after intra-ocular injection) 
was achieved by quantitative real time PCR using the following mouse primers: 5’-CAG 
CAC CAT GTG AGG ACA AA-3’ (forward) and 5’-ATG CGG TTT TCA GAG TTG CT-
3’ (reverse) (Biolegio, Nijmegen, The Netherlands). 
 
Generation of 9430020K01Rik-knockout mice 
9430020K01Rik-knockout mice were generated starting with JM8A3 mouse embryonic 
stem cells (ES cell) from Knockout Mouse Project (KOMP, www.komp.org) Repository, 
project ID: CDS46781 in which out-of-frame exon 3 is replaced with a LacZ reporter gene 
and Neomycin selection marker by homologous recombination. After that, the Neomycin 
selection marker was removed by treatment of ES cells with cre recombinase. Neo-negative 
cells were used to generate a C57BL/6.9430020K01Riktm1(KOMP)Mbp/MCL-knockout mouse 
line. Founder mice and offspring were genotyped on DNA-isolated toe biopsies by PCR 
using the following mouse primers: 5’-CCA CCA TAG GGA CCA ATG TTT CAA AGG 
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TGG-3’ (forward wt and KO), and 5’-GTT CTT TCC AGT CCC TGG GAC ACA GGG 
AGC-3’ (reverse wt) and 5’-CCT TGG GCA AGA ACA TAA AGT GAC CCT CCC-3’ 
(reverse KO) (Biolegio, Nijmegen, The Netherlands). Transgenic mice used in the present 
study were homozygous. 
 
Isolectin staining 
Formalin-fixed, paraffin-embedded sections of heart tissue of 9430020K01Rik-knockout 
mice were mounted on super-frost glass slides. Deparaffinised slides were treated with 3% 
hydrogen peroxide in methanol (20 min) to block the endogenous peroxidase activity, 
followed by rinsing with phosphate-buffered saline (PBS). After that, slides were pre-
incubated for 15 minutes with 5% bovine serum albumin (BSA)/PBS to block non-specific 
binding and then incubated overnight at 4°C with peroxidase-conjugated isolectin GS-IB4 
1:20 (L5391; Sigma-Aldrich, Zwijndrecht, The Netherlands). After rinsing PBS, slides 
were visualised with 3,3’-diaminobenzidine (Dako DAB solution K3468; Dako, Heverlee, 
Belgium) (30 sec) as the chromogen. Slides were counter-stained with haematoxylin for 10 
seconds. Negative controls were prepared using omission of peroxidase-conjugated 
isolectin GS-IB4. 
 
Cell cultures 
Primary cultures of human umbilical vein endothelial cells (HUVEC) were cultured in 
EBM®-2 medium supplemented with a commercial BulletKit, 10% foetal calf serum (FCS) 
and 1% penicillin/streptomycin (Lonza, Breda, The Netherlands). Primary aorta-derived 
human vascular smooth muscle cells (vSMC) were cultured in SmGM®-2 medium 
supplemented with a commercial BulletKit, 10% FCS and 1% penicillin/streptomycin 
(Lonza, Breda, The Netherlands). HeLa and sarcoma cells were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% FCS (Cambrex, Wiesbaden, 
Germany). Cells were cultured at 37°C in 5% CO2. Passages three to six were used 
throughout the study. 
 
Immunofluorescence 
HUVECs - transfected with si-sham or KIAA1462 targeting siRNA (si-KIAA1462) - were 
grown in gelatin-coated 48-wells. After 24 hours, the cells were fixed in 4% formaldehyde 
and permeabilised with 0.2% Triton® X-100. Cells were incubated overnight at 4°C with 
antibodies against KIAA1462 1:50 (custom made; Eurogentec, Maastricht, The 
Netherlands), CTNND1 1:10 (HPA015955; Sigma-Aldrich, Zwijndrecht, The Netherlands) 
or VE-cadherin 1:50 (sc-6458; Santa Cruz Biotechnology, Heidelberg, Germany). For the 
detection of the primary antibodies Alexa Fluor® 488 or 546 1:100 (Invitrogen, Bleiswijk, 
The Netherlands) was used. The nucleus was stained with 4,6-diamidino-2-phenylindole 
(DAPI) in Vectashield® mounting medium (H-1200; Vector Laboratories, Burlingame, 
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USA). Cells were visualised with a fluorescence microscope (Axiovert S100; Carl Zeiss, 
Sliedrecht, The Netherlands). 
 
Targeted siRNA knockdown 
HUVEC were grown to 60-70% confluence and DharmaFECT1 Transfection Reagent was 
used to transfect 5 ng siRNA (Thermo Fisher Scientific, Breda, The Netherlands). The 
following mix of human si-KIAA1462 was used: 5’-CGG GAA GAG GUG AGA GUA 
AUU-3’ – 5’-CAG CAU CAC GCG AGG AUA AUU-3’ – 5’-GGA UGA GAG UCC 
UGA GCU UUU-3’. Si-sham was used as a control. Knockdown of KIAA1462 was 
validated by quantitative real time PCR analysis and Western blot two days post-
transfection using the following human primers: 5’-AGA GCT GGA GTG AGG AGC TG-
3’ (forward) and 5’-TCC ATT CCG TTG CTA ACC TC-3’ (reverse) (Biolegio, Nijmegen, 
The Netherlands), and anti-human KIAA1462 antibody 1:100 (custom made; Eurogentec, 
Maastricht, The Netherlands). Beta-actin primers 5’-TCC CTG GAG AAG AGC TAC GA-
3’ (forward) and 5’-AGC ACT GTG TTG GCG TAC AG-3’ (reverse) (Biolegio, 
Nijmegen, The Netherlands) were used as housekeeping gene, while beta-actin antibody 
1:500 (ab8229; Abcam, Cambridge, UK) was used as a loading control. 
 
2D matrigel network-formation assay 
To induce network-formation, HUVECs - transfected with si-sham or si-KIAA1462 - were 
cultured on a 2D MatrigelTM matrix (BD, Breda, The Netherlands). The tubules were 
stained by Calcein-AM (BD, Breda, The Netherlands) after 24 hours of network-formation. 
Each condition was assessed by fluorescence microscopy (Axiovert S100; Carl Zeiss, 
Sliedrecht, The Netherlands). Image analysis of the number of junctions, tubules and total 
tubule length was carried out using Angiosys Image Analysis Software 1.0 (TCS 
CellWorks, Buckingham, UK). 
 
Cell proliferation assay 
EC proliferation in vitro was evaluated by culturing HUVECs - transfected with si-sham or 
si-KIAA1462 - in gelatin-coated 6-wells and counting them at different time points. 
In brief, 50,000 cells were seeded and incubated in EBM®-2 medium supplemented 
with 0.2% FCS for 4 hours to synchronise the cell cycle. Thereafter, HUVECs were 
trypsinised after 0, 8, 24 and 48 hours, and counted with a Bürker-Türk. At all time points 
the amount of cells was expressed as percentage, whereas time point zero the amount of 
cells was expressed as 100%. 
 
Cell cycle assay 
For cell cycle experiments, HUVECs - transfected with si-sham or si-KIAA1462 - were 
trypsinised and fixed in 70% ice-cold ethanol overnight at 4°C. After being washed in PBS, 
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the cells were resuspended in 300 μl PBS containing 69 μM propidium iodide (PI), 37 mM 
sodium citrate and 200 μg RNase. Cell cycle profile was measured on a BD FACSCantoTM 
(Breda, The Netherlands). 
To analyse bromodeoxyuridine (BrdU) incorporation during replication, cells were 
incubated for 24 hours with 1 μM BrdU at 37°C in 5% CO2. After fixation in 70% ice-cold 
ethanol overnight at 4°C, cells were washed in PBS and resuspended in pepsin solution for 
20 minutes. Thereafter, the cells were washed in PBS with 0.1% BSA and 0.5% Tween 20, 
resuspended in 2 M HCl for 12 minutes at 37°C, and then neutralised in 0.1 M Na2B4O7 
(pH 8.5). After being washed in PBS with 0.1% BSA and 0.5% Tween 20, cells were 
incubated with FITC-conjugated anti-human BrdU antibody 1:50 (ab74545; Abcam, 
Cambridge, UK) for 1 hour on ice. Next, the cells were washed in PBS with 0.1% BSA and 
0.5% Tween 20, and resuspended in PBS with 0.1% BSA containing PI and RNase. BrdU 
incorporation was measured on a BD FACSCantoTM (Breda, The Netherlands). 
 
LC-MS 
Binding partners of KIAA1462 were identified by liquid chromatography-mass 
spectrometry (LC-MS) as previously described.16 
 
Co-immunoprecipitation 
To immunoprecipitate protein complexes, magnetic beads (Dynabeads®; Invitrogen, 
Bleiswijk, The Netherlands) were conjugated with 10 µg anti-human KIAA1462 antibody 
(custom made; Eurogentec, Maastricht, The Netherlands). The coated magnetic beads were 
then added to protein cell lysates of HUVECs (20 µg total protein in 100 µl incubation 
buffer supplied by the Dynabeads® system) and incubated overnight at 4°C. The beads were 
washed three times in washing buffer (Invitrogen, Bleiswijk, The Netherlands) before the 
immunoprecipitated protein complexes were eluted from the magnetic beads with elution 
buffer (Invitrogen, Bleiswijk, The Netherlands). Protein complexes were analysed using a 
12.5% SDS-PAGE gel, followed by immunoblotting using anti-human antibodies against 
KIAA1462 1:100 (custom made; Eurogentec, Maastricht, The Netherlands) and CTNND1 
1:500 (HPA015955; Sigma-Aldrich, Zwijndrecht, The Netherlands). 
 
qPCR 
To determine whether knockdown of KIAA1462 interfered with cellular processes, qPCR 
analysis was carried out using HUVEC cDNA in combination with the following human 
primers: 5’-AGA GCT GGA GTG AGG AGC TG-3’ (forward) and 5’-TCC ATT CCG 
TTG CTA ACC TC-3’ (reverse) for KIAA1462, and 5’-TGG GAA TCT TTT CCT GTC 
TG-3’ (forward) and 5’-GAA CAC TGA GAC AGT ATG CC-3’ (reverse) for SKP2 
(Biolegio, Nijmegen, The Netherlands). Beta-actin primers 5’-TCC CTG GAG AAG AGC 
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TAC GA-3’ (forward) and 5’-AGC ACT GTG TTG GCG TAC AG-3’ (reverse) (Biolegio, 
Nijmegen, The Netherlands) were used as housekeeping gene. 
 
Western blot 
To determine whether knockdown of KIAA1462 interfered with cellular processes, 
Western blot analysis was carried out using HUVEC protein lysates. At 72 hours post-
transfection, HUVECs were serum starved for 4 hours and replenished with EBM®-2 
medium supplemented with a commercial BulletKit for 40 minutes. Cells were lysed in 
NP40 Cell Lysis Buffer (Invitrogen, Bleiswijk, The Netherlands) and analysed on a 12.5% 
SDS-PAGE gel, followed by immunoblotting using anti-human antibodies against 
KIAA1462 1:100 (custom made; Eurogentec, Maastricht, The Netherlands), RhoA 1:100 
(ab54835; Abcam, Cambridge, UK), ROCK2 1:100 and phosphorylated-ROCK2 (T249) 
1:500 (ab56661 and ab83514; Abcam, Cambridge, UK), and retinoblastoma (Rb) 1:500 and 
phosphorylated-Rb (T821) 1:500 (ab39690 and ab122893; Abcam, Cambridge, UK). Beta-
actin antibody 1:500 (ab8229; Abcam, Cambridge, UK) was used as a loading control. 
Protein bands were visualised by the Odyssey® Infrared Imaging System and analysed by 
Odyssey 3.0 software (LI-COR Biotechnology, Cambridge, UK). 
 
RhoA activation assay 
RhoA activity was measured using the G-LISA® RhoA Activation Assay Biochem KitTM 
from Cytoskeleton (Denver, USA) according to the instruction manual. 
 
Statistical analysis 
Data were reported as mean ± standard error of the mean (SEM). Statistical significance 
was evaluated using a Student’s t-test and was accepted at P < 0.05 (* P < 0.05, ** P < 0.01 
in the figures). 
 
 
Results 
 
Expression of 9430020K01Rik is upregulated during mouse embryogenesis 
To identify new genes involved in angiogenesis, a genome-wide microarray analysis was 
carried out followed by validation of the results by qPCR. Gene expression profiles of Flk1-
positive angioblasts at various stages of murine embryonic development were compared 
with the profiles of Flk1-negative cells. 9430020K01Rik was upregulated in Flk1-positive 
angioblasts from 8 to 16 dpf. Expression levels were highest upregulated around 8 to 10 
dpf, which coincides with the period of early angiogenesis in murine development and 
suggests a potential role of 9430020K01Rik in blood vessel formation (Figure 1). 
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Figure 1. 9430020K01Rik is upregulated in Flk1-positive angioblasts during mouse development. 
Endogenous expression level of 9430020K01Rik in Flk1-positive angioblasts during murine embryonic 
development from 8 to 16 days post-fertilisation (dpf) compared with Flk1-negative cells as analysed by qPCR. 
The expression level of 9430020K01Rik in Flk1-negative cells was arbitrarily set to one (n = 4; mean ± SEM). 
The highest upregulation was detected around day 8 to 10, which coincides with the period of angiogenesis in 
murine development. 
 
 
9430020K01Rik knockdown in the developing retinal vasculature of neonatal mice 
suppresses blood vessel formation 
To assess the function of 9430020K01Rik in vivo, the gene was silenced during the 
development of the retinal vasculature of neonatal mice. To determine the optimal moment 
of 9430020K01Rik knockdown, 9430020K01Rik mRNA expression in the murine retina 
was evaluated during postnatal development by qPCR analysis. 9430020K01Rik mRNA 
levels were adjusted to CD31 mRNA levels to compensate for changes in percentage of 
ECs. High expression levels of 9430020K01Rik were mainly observed around 3 days post-
partum, which corresponds with the period of plexus formation (Figure 2A). Based on these 
findings, 9430020K01Rik knockdown was induced in the first week of retinal vascular 
development by intra-ocular injection of a siRNA pool composed of three different 
9430020K01Rik targeting siRNA sequences in two-day old wild-type C57BL/6J mouse 
pups and compared with controls injected with a scrambled non-targeting siRNA pool. 
Efficient knockdown of 9430020K01Rik was observed two days after intra-ocular injection 
(Figure 3). Loss of 9430020K01Rik expression affected the outgrowth of the vasculature 
toward the retinal borders (Figure 2B). 
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Figure 2. 9430020K01Rik depletion during murine retinal vascular development results in diminished 
vascular growth. (A) Endogenous expression level of 9430020K01Rik in the developing retinal vasculature of 
neonatal mice from 3 to 15 days after birth compared with CD31 expression in the retina (n = 3; mean ± SEM). 
9430020K01Rik is highly expressed around day 3, which coincides with the period of plexus formation. (B) 
Retinas stained with isolectin GS-IB4. (C-E) Quantification by means of the dimensions of the vascular network 
showed a reduction in the total number of vessels after 9430020K01Rik knockdown (943-KD): (C) number of 
junctions, (D) number of tubules and (E) total tubule length (n = 10; mean ± SEM). 
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Assessment and quantification of the number of vascular branches, the total number of 
vessels and the total tubule length after visualisation of the vasculature by isolectin GS-IB4 
staining, showed a reduction in the total number of vessels between si-9430020K01Rik and 
si-sham injected eyes five days after intra-ocular injection, while there was no difference 
observed in the number of vascular branches and the total tubule length (Figure 2C-E). 
These data indicate that 9430020K01Rik has an essential role in vessel outgrowth during 
vascular development. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. 9430020K01Rik depletion in the developing retinal vasculature of neonatal mice after siRNA 
targeting. Endogenous expression level of 9430020K01Rik in the retina after intra-ocular injection of 
9430020K01Rik targeting siRNA (943-KD) showed a reduction in expression levels of 9430020K01Rik as 
analysed by qPCR (n = 10; mean ± SEM). 
 
 
KIAA1462 is highly expressed in cultured endothelial cells and vascular smooth 
muscle cells 
To clarify the molecular mechanism underlying the impaired vessel outgrowth, we first 
validated the endothelial expression of 9430020K01Rik in cultured cells. The expression 
level of the 9430020K01Rik human orthologue - also known as KIAA1462 - was 
determined in a number of different cell types. In a comparison between HUVECs, vSMCs, 
HeLa and sarcoma cells, the highest mRNA expression level of KIAA1462 was observed in 
HUVECs and vSMCs (Figure 4). Intracellular immunofluorescent detection of KIAA1462 
in HUVECs demonstrated that the protein was mainly located at the plasma membrane 
(Figure 5A). 
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Figure 4. KIAA1462 expression in different cell types in culture. KIAA1462 was highly expressed in HUVEC 
and vSMC compared with HeLa and sarcoma cells, as demonstrated by qPCR analysis (n = 3; mean ± SEM). 
 
 
 
 
Figure 5. KIAA1462 knockdown in cultured endothelial cells inhibits vascular network-formation. (A) 
KIAA1462 was mainly located at cell-cell contacts, as demonstrated by immunofluorescent staining. KIAA1462 
(red) and nuclei (blue) (n = 3). 
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Knockdown of KIAA1462 inhibits vascular network-formation in vitro 
To further assess the function of KIAA1462 in cultured ECs, knockdown of KIAA1462 in 
HUVECs was induced by transfection of si-KIAA1462 and compared with si-sham 
transfected and untransfected controls. In si-KIAA1462 transfected cells, endogenous 
KIAA1462 expression was significantly lower than in the control cultures on both mRNA 
(Figure 6A) and protein level (Figure 6B). 
To investigate the effect of KIAA1462 knockdown on vascular network-formation, in 
vitro network-formation experiments with HUVECs were carried out. Knockdown of 
KIAA1462 had an inhibitory effect on the number of junctions, capillary tubules and the 
total tubule length when compared with cultures transfected with equimolar of si-sham or 
untransfected controls (Figure 5B-E). These data corresponds with the in vivo findings in 
which vessel outgrowth was also impaired. The process of vessel growth is determined by 
many different factors. One of these is cell proliferation. 
 
 
(B) Assessment of network-formation capacity for KIAA1462-silenced ECs (KIAA1462-KD) in a 2D matrigel 
experiment. Tubules were stained by Calcein-AM uptake. (C-E) Quantification of the vascular network showed a 
delay in network-formation in KIAA1462-KD HUVECs: (C) number of junctions, (D) number of tubules and (E) 
total tubule length (n = 5; mean ± SEM). 
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Figure 6. siRNA-mediated knockdown of KIAA1462 in cultured endothelial cells. (A) qPCR analysis of 
HUVECs transfected with KIAA1462 targeting siRNA (KIAA1462-KD) showed a reduction in mRNA expression 
levels of KIAA1462. (B) Western blot analysis of KIAA1462-KD in HUVECs showed a reduction in protein 
expression levels of KIAA1462 (n = 3; mean ± SEM). 
 
 
KIAA1462 knockdown in HUVECs reduces cell proliferation through a blockade of 
G1–S-phase transition 
To determine the effect of KIAA1462 on cell proliferation in vitro, a proliferation assay 
was carried out. Cell proliferation was reduced after knockdown of KIAA1462 in HUVECs 
(Figure 7A). Sufficient cell cycle progression is necessary for proliferation. We therefore 
assessed the effect of KIAA1462 silencing on the cell cycle. Flow cytometric analysis of PI 
demonstrated that knockdown of KIAA1462 in HUVECs blocks the G1–S-phase transition 
(Figure 7B-D). To further validate these findings, BrdU incorporation during cell cycle was 
measured. BrdU incorporation was decreased after knockdown of KIAA1462 in HUVECs 
(Figure 7E, F). Together, these data suggest that KIAA1462 regulates cell proliferation by 
G1–S-phase transition. 
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Figure 7. KIAA1462 regulates cell proliferation through G1–S-phase transition. (A) Averaged curves of cell 
proliferation of HUVECs.          : control,          : sham adenovirus,          : KIAA1462 knockdown (KIAA1462-
KD). (B) Representative flow cytometric analysis of HUVECs. (C-D) Quantification of the G1 and S–G2-phase of 
the cell cycle in HUVECs showed a blockade in G1–S-phase transition after KIAA1462-KD, as analysed by flow 
cytometry: (C) G1-phase and (D) S–G2-phase (n = 3; mean ± SEM). 
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(E) Representative flow cytometric analysis of HUVECs. (F) Quantification of BrdU incorporation during cell 
cycle in HUVECs showed a decrease in BrdU incorporation after KIAA1462-KD, as analysed by flow cytometry 
(n = 4; mean ± SEM). 
 
 
Interaction of KIAA1462 with CTNND1 modulates RhoA activity 
To clarify the influence of KIAA1462 on cell cycle control, we identified the binding 
partners of KIAA1462 by LC-MS. As shown in Table 1 and Figure 8, CTNND1 is one of 
the candidates to form a protein complex with KIAA1462, since CTNND1 as well as 
KIAA1462 are both situated at the plasma membrane. This was verified by co-localisation 
studies of KIAA1462 and CTNND1 in cultured ECs, which demonstrated a co-localisation 
of both proteins at the cell membrane (Figure 9A). To validate the binding of CTNND1 to 
KIAA1462, co-immunoprecipitation was carried out. It was showed that KIAA1462 and 
CTNND1 could indeed form a protein complex (Figure 9B). 
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Table 1. Candidate binding partners of KIAA1462 identified by LC-MS. 
 
Binding partners of KIAA1462 by LC-MS The Human Protein Atlas (Version 10.0) 
gene description subcellular location 
ACTR2 
ARP2 actin-related protein 2 homolog 
(yeast) 
cytoplasm 
AFAP1L1 actin filament-associated protein 1-like 1 nucleus, mitochondria 
ARHGAP11A Rho-GTPase activating protein 11A nucleus, nucleoli, cytoplasm 
ATAD3B 
ATPase family, 
AAA domain containing 3B 
- 
ATP1A1 
ATPase, Na+/K+ transporting, 
alpha 1 polypeptide 
- 
CALD1 caldesmon 1 
plasma membrane, 
cytoskeleton (actin filaments) 
CDK1 cyclin-dependent kinase 1 cytoplasm, nucleus 
CSRP1 cysteine and glycine-rich protein 1 cytoplasm, cytoskeleton (actin filaments) 
CTNNB1 
catenin (cadherin-associated protein), 
beta 1 
plasma membrane 
CTNND1 
catenin (cadherin-associated protein), 
delta 1 
plasma membrane 
DDX17 
DEAD (Asp-Glu-Ala-Asp) box 
helicase 17 
- 
DDX3X 
DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 3, X-linked 
cytoplasm 
DST dystonin 
nucleus, cytoplasm, 
cytoskeleton (microtubules) 
EEF1G 
eukaryotic translation elongation factor 1 
gamma 
- 
EEF2 eukaryotic translation elongation factor 2 cytoplasm, Golgi apparatus 
FBLIM1 filamin binding LIM protein 1 vesicles, cell junctions 
FLOT1 flotillin 1 
Golgi apparatus, 
plasma membrane, vesicles 
FLOT2 flotillin 2 nucleus, cytoplasm, mitochondria 
FXR1 
fragile X mental retardation, 
autosomal homolog 1 
cytoplasm 
GNB1 
guanine nucleotide binding protein 
(G protein), beta polypeptide 1 
plasma membrane, Golgi apparatus 
GNB2 
guanine nucleotide binding protein 
(G protein), beta polypeptide 2 
plasma membrane, Golgi apparatus 
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Binding partners of KIAA1462 by LC-MS The Human Protein Atlas (Version 10.) 
gene description subcellular location 
GSN gelsolin cytoskeleton (actin filaments) 
H2AFV H2A histone family, member V - 
KIAA1462 KIAA1462 plasma membrane, vesicles 
LMNA lamin A/C nucleus 
LRRFIP1 
leucine-rich repeat (in FLII) interacting 
protein 1 
cytoplasm 
MCM7 
minichromosome maintenance complex 
component 7 
nucleus 
PABPC1 poly(A) binding protein, cytoplasmic 1 cytoplasm 
PCMT1 
protein-L-isoaspartate (D-aspartate) 
O-methyltransferase 
cytoplasm 
PDLIM5 PDZ and LIM domain 5 
Golgi apparatus, cytoskeleton 
(actin filaments), nucleoli, cytoplasm 
PKM2 pyruvate kinase, muscle cytoplasm, plasma membrane 
PLS3 plastin 3  - 
PPIA 
peptidylprolyl isomerase A 
(cyclophilin A) 
- 
PRKDC 
protein kinase, DNA-activated, 
catalytic polypeptide 
- 
PRPF3 
PRP3 pre-mRNA processing factor 3 
homolog (S. cerevisiae) 
nucleus, cytoplasm 
PTRF 
polymerase I 
and transcript release factor 
- 
RAN RAN, member RAS oncogene family - 
RAP1B RAP1B, member RAS oncogene family - 
RPL27A ribosomal protein L27a - 
RPL9 ribosomal protein L9 cytoplasm, nucleoli 
RPS3A ribosomal protein S3A - 
RPS7 ribosomal protein S7 - 
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Binding partners of KIAA1462 by LC-MS The Human Protein Atlas (Version 10.0) 
gene description subcellular location 
RPS9 ribosomal protein S9 - 
SYNCRIP 
synaptotagmin binding, 
cytoplasmic RNA interacting protein 
- 
SYNPO synaptopodin 
nucleus, cytoplasm, 
cytoskeleton (actin filaments) 
TCP1 t-complex 1 
nucleus, cytoplasm, plasma membrane, 
Golgi apparatus, cell junctions 
TJP1 tight junction protein 1 
cell junctions, cytoplasm, 
Golgi apparatus 
TJP2 tight junction protein 2 
plasma membrane, cytoplasm, 
cell junctions 
TOM1 target of myb 1 (chicken) cytoplasm, centrosome 
TOM1L2 target of myb 1-like 2 (chicken) nucleus 
TPM1 tropomyosin 1 (alpha) cytoplasm, cytoskeleton (actin filaments) 
VDAC1 voltage-dependent anion channel 1 - 
XRCC6 
X-ray repair complementing defective 
repair in Chinese hamster cells 6 
- 
ZYX zyxin cytoplasm, focal adhesions 
 
Left and middle column shows the precipitated proteins with KIAA1462 antibody identified by liquid 
chromatography-mass spectrometry (LC-MS). The subcellular location of the proteins - as presented in the right 
column - was derived from The Human Protein Atlas (Version 10.0). 
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Figure 8. Candidate binding partners of KIAA1462 identified by LC-MS. Protein complexes were 
immunoprecipitated using Dynabeads® magnetic beads coated with IgG isotype or KIAA1462 antibody and 
separated on 12.5% SDS-PAGE gel, followed by Coomassie blue staining. Liquid chromatography-mass 
spectrometry (LC-MS) was used to identify the precipitated proteins with IgG isotype antibody (lane 2) or 
KIAA1462 antibody (lane 3). 
 
 
Previously, it has been demonstrated that CTNND1 modulates RhoA activity.17 
Therefore, KIAA1462 may influence RhoA activity via CTNND1. To verify this, activated 
RhoA levels (RhoA-GTP) were measured. This showed that KIAA1462 depletion impaired 
RhoA activity (Figure 9C-E). Combined, these data indicate that KIAA1462 modulates 
RhoA activity via CTNND1 interaction. 
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Figure 9. KIAA1462 binds CTNND1 and modulates RhoA activity. (A) KIAA1462 co-localise with CTNND1 
in HUVECs, as demonstrated by immunofluorescent staining. KIAA1462 (green), CTNND1 (red), co-localised 
area (yellow) and nuclei (blue) (n = 3). (B) Immunoprecipitation of KIAA1462 in HUVECs showed an effective 
pull down of KIAA1462 (upper panel) and co-immunoprecipitation of CTNND1 (lower panel). 
Immunoprecipitation using a rat IgG isotype control showed no effective pull down of KIAA1462 or CTNND1 
(representative picture for n = 3). (C, D) Western blot analysis of HUVECs transfected with KIAA1462 targeting 
siRNA (KIAA1462-KD) showed a decline in (C) KIAA1462 and (D) RhoA protein levels. (E) KIAA1462-KD in 
HUVECs resulted in a decrease in RhoA-GTP levels as shown by GAP-assay measurements (n = 3; mean ± 
SEM). 
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RhoA activity affects G1–S-phase transition 
Activated RhoA promotes G1–S-phase transition and cell proliferation via ROCK 
phosphorylation, or regulation of SKP2 gene transcription and Rb phosphorylation.11-13 
Western blot analysis demonstrated that indeed both downstream signalling cascades were 
affected (Figure 10A, B, E, F); knockdown of KIAA1462 decreased signal transduction via 
ROCK2 by downregulation of ROCK2 phosphorylation (Figure 10A, B). On the other 
hand, knockdown of KIAA1462 also diminishing the expression of ubiquitin ligase SKP2, 
illustrated by a decline in mRNA levels measured by qPCR analysis (Figure 10C, D). 
Finally, Rb was less phosphorylated (Figure 10E, F). Overall, these data demonstrate that 
KIAA1462 regulates G1–S-phase transition via downstream signalling of RhoA. 
 
 
Figure 10. KIAA1462 affects the downstream effectors of RhoA. (A, B, E, F) Western blot analysis of 
HUVECs transfected with KIAA1462 targeting siRNA (KIAA1462-KD) showed a limited activation of the 
downstream effectors of RhoA-GTP, including: (B) ROCK2-P and (F) Rb-P, whereas (A) ROCK2 and (E) Rb 
were not affected. (C, D) qPCR analysis of KIAA1462-KD in HUVECs showed a reduction in expression levels 
of (C) KIAA1462 and (D) SKP2 (n = 3; mean ± SEM). 
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Knockdown of KIAA1462 in zebrafish arrests gastrulation at 80-90% epiboly 
In zebrafish, changes in signal transduction via ROCK or SKP2/Rb could greatly effect 
embryonic development.18,19 To determine the effect of KIAA1462 knockdown, zebrafish 
embryos were injected with an ATG Loc100001168 targeting MO and compared with 
uninjected controls. 
Silencing of KIAA1462 expression resulted in an arrest of embryonic development 
between shield stage and 90% epiboly (84% of the injected embryos, n = 200). This effect 
on zebrafish embryogenesis indicates that KIAA1462 also in vivo modulates the 
downstream signalling cascades of RhoA. 
 
9430020K01Rik-knockout mice exhibits suppressed blood vessel formation in the 
retina and heart tissue 
To confirm the in vitro and in vivo findings of 9430020K01Rik silencing, we generated a 
C57BL/6.9430020K01Riktm1(KOMP)Mbp/MCL-knockout mouse line (Figure 11A). Validation of 
adequate 9430020K01Rik knockout was achieved by PCR, using toe biopsies from 
9430020K01Rik-knockout mice and non-transgenic controls. Figure 11B showed DNA 
fragments of wild-type and knockout alleles. 
 
Figure 11. Vascular development in 9430020K01Rik-knockout mice. (A) 9430020K01Rik alleles, distances 
are not drawn to scale: 1. wild-type allele, 2. out-of-frame exon 3 is replaced with a LacZ reporter gene and 
Neomycin selection marker, and 3. Neomycin marker is removed to generate the 
C57BL/6.9430020K01Riktm1(KOMP)Mbp/MCL-knockout mouse line. (B) PCR analysis to discriminate between wild-
type and knockout (post-Cre) alleles: 1. wild-type, 2. heterozygote, 3. knockout, 4. blanco (H2O), and 5. DNA 
ladder.
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Knockout of 9430020K01Rik affected the outgrowth of the vasculature toward the retinal 
borders in the same way due to 9430020K01Rik silencing by intra-ocular injection of si-
9430020K01Rik (Figure 11C). Assessment and quantification of the number of vascular 
branches, the total number of vessels and the total tubule length after visualisation of the 
vasculature by isolectin GS-IB4 staining, showed a reduction in the total number of 
junctions and the total number of vessels between 9430020K01Rik-knockout mice and 
wild-type littermates (controls), while there was no difference observed in the total tubule 
length (Figure 11D-F). 
 
 
(C) Retinas stained with isolectin GS-IB4. (D-F) Quantification by means of the dimensions of the vascular 
network showed a reduction in the total number of junctions and the total number of vessels in 9430020K01Rik-
knockout mice (943-KO): (D) number of junctions, (E) number of tubules and (F) total tubule length (n = 3; mean 
± SEM). 
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Immunohistochemistry studies on sections from heart tissue - taken from 9430020K01Rik-
knockout mice or wild-type littermates - using isolectin GS-IB4, demonstrated a reduction 
of capillary density in heart tissue of 9430020K01Rik-knockout mice compared with wild-
type controls (Figure 11G). These data confirm an essential role of 9430020K01Rik in 
vessel outgrowth during vascular development. 
 
 
(G) Heart tissue stained with isolectin GS-IB4 showed a reduction in capillary density in 9430020K01Rik-
knockout mice compared with wild-type littermates (representative picture for n = 3). 
 
 
 
Discussion 
 
In this study we demonstrated that 9430020K01Rik (KIAA1462) regulates vessel 
outgrowth during vascular development in mice. Knockout of 9430020K01Rik in mice 
resulted in diminished blood vessel formation in the developing retinal vasculature and 
reduced capillary density in heart tissue. Functional knockdown of Loc100001168 in 
zebrafish arrested gastrulation at 80-90% epiboly. 
In vitro, we demonstrated that loss of KIAA1462 lead to decreased RhoA activation, 
which resulted in diminished G1–S-phase transition during cell cycle progression. Co-
immunoprecipitation identified CTNND1 as binding partner of KIAA1462. Further 
evaluation of KIAA1462 signalling demonstrated an important role for KIAA1462 in 
RhoA-mediated cell cycle progression; KIAA1462 mediates RhoA activation via CTNND1 
binding, and downstream signalling via the ROCK2 and Rb cascades. Knockdown of 
KIAA1462 significantly decreased RhoA-induced EC proliferation. 
The KIAA1462 gene encodes a 148 kDa protein without any known domains, but 
contains a proline-rich region. Although proline often plays a purely structural role in 
proteins, it has a high non-specific binding ability because it functions as a strong hydrogen 
bond acceptor. Proline-rich regions are often involved in the formation of multi-molecular 
complexes.20 Previously, it has been shown that KIAA1462 is as a component of the VE-
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cadherin junctional complex in cultured ECs.14 Clustering of VE-cadherin at the cell-cell 
borders promotes complex formation of multiple proteins, including; signalling, regulatory 
and scaffold proteins. One of these proteins that interacts with VE-cadherin is CTNND1 
which acts as a regulator of Rho-GTPases and its downstream targets, including ROCK.21,22 
ROCK activity is associated with endothelial dysfunction which is one of the main causes 
of CAD.8.23 In addition, genome-wide association studies have detected a missense variant 
(p.S1002T) in the KIAA1462 gene which increases the risk of CAD by 15%.9,10 Based on 
the high expression level of KIAA1462 in the EC subset, we hypothesised that KIAA1462 
was also involved in the angiogenic process. Here, we show that indeed KIAA1462 acts as 
a potent regulator of EC proliferation by interaction with CTNND1, modifying RhoA 
activity during vascular growth. 
In our study, KIAA1462 was co-localised with CTTND1 at the plasma membrane of 
ECs. Additional co-immunoprecipitation studies showed that KIAA1462 and CTNND1 
also indeed formed a protein complex. CTNND1 belongs to a subfamily of armadillo 
proteins and is a component of the VE-cadherin complex in adherens junctions.24-27 
Likewise, CTNND1 binding to VE-cadherin was verified (data not shown). Beside the 
structural role of CTNND1 in cell-cell contacts, it also modulates nuclear transcription and 
regulates the activation of Rho-GTPases - especially RhoA - and its downstream signalling 
cascades.22,28 The ability of CTNND1 to stabilise cadherin complexes at the plasma 
membrane and to regulate the activity of RhoA, depends on the subcellular localisation of 
CTNND1. Previous work has indicated that CTNND1 exists in an equilibrium between two 
states; bound to cadherins or free in the cytoplasm.17 Soluble, cytoplasmic CTNND1 
inhibits the exchange of GDP with GTP of RhoA, downregulating RhoA activity.29 Our 
data clearly show that KIAA1462 is involved in RhoA activation and that KIAA1462 binds 
CTNND1 in the VE-cadherin junctional complex. We propose that KIAA1462 plays an 
important role in the equilibrium of CTNND1 by stabilising the interaction of CTNND1 
with VE-cadherin at the plasma membrane, lowering the fraction of soluble, cytoplasmic 
CTNND1 which results in an increase of RhoA activity. 
RhoA influences cell morphogenesis through remodelling of the cytoskeleton and 
regulates in this way cell proliferation in late G1-phase.11,30 Downstream effectors of RhoA 
includes the ROCK family protein kinases and the mammalian homolog of Drosophila 
diaphanous (mDia) family of formins. Except interphase, formins also exert their effects 
during embryonic development.31 Previous studies show that diaphanous-related formin 2 
(zDia2) is required for cellular movements during epiboly and convergent extension in 
zebrafish gastrulation. MO-induced knockdown of zDia2 in zebrafish is characterised by 
late epiboly arrest at 80-90% epiboly and mild convergent extension defects.18,32 Inhibition 
of ROCK also leads to abnormal cytokinesis and epiboly in zebrafish.19 We found in 
zebrafish a similar phenotype like zDia2 and ROCK after MO blocking of Loc100001168. 
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Our data show that KIAA1462 acts in the same pathway as the ROCK family protein 
kinases and zDia2. 
zDia2 has a high sequence homology with mDia which shuttles between the cytoplasm 
and nucleus.33 Here, it promotes the ubiquitin ligase SKP2 expression.18 When expressed, 
SKP2 ubiquitylates the cell cycle inhibitor p27Kip1 and regulates its degradation. p27Kip1 is 
an inhibitor of the cyclin D1-CDK4 complex, which phosphorylates the Rb protein in late 
G1.13,34 In line with these findings, our data demonstrate that loss of KIAA1462 inhibited 
SKP2 expression, which was associated with a decrease in Rb phosphorylation. 
ROCK family protein kinases - the other downstream effector of RhoA - can be 
subdivided in two isoforms: ROCK1 and ROCK2.35-37 Our data clearly show that loss of 
KIAA1462 lead to diminished ROCK2 activation. ROCK2 is highly expressed in the heart 
and brain, and plays a strong role in capillary development.38-41 Our data confirmed these 
findings, since 9430020K01Rik knockout in mice diminished capillary density in heart 
tissue. These findings further proof that KIAA1462 regulates both downstream cascades of 
RhoA and finally in this way EC proliferation (Figure 12). 
In conclusion, here we have identified 9430020K01Rik (KIAA1462) as a new 
regulator of EC proliferation during angiogenesis by binding to CTNND1 in the VE-
cadherin junctional complex at the plasma membrane of ECs, followed by activation of the 
RhoA-mediated ROCK2 and Rb signalling pathway, which ultimately lead to G1–S-phase 
transition that promotes EC proliferation and vessel outgrowth. To our knowledge, this 
study is the first report of the function of 9430020K01Rik (KIAA1462) in ECs during 
normal embryonic and postnatal blood vessel formation. As mentioned before, ROCK 
family protein kinases can be subdivided in two isoforms. Since ROCK1 and ROCK2 
functions in a redundant manner, loss of ROCK2 activity can be compensated by ROCK1. 
Activation of ROCK1 in bone marrow-derived macrophages is critical to the development 
of early atherosclerosis by mediating foam cell formation and macrophage 
chemotaxis.37,40,42 In line with these findings, the missense variant (p.S1002T) in the 
KIAA1462 gene could result in ROCK2-compensated activation by ROCK1, leading to a 
severed development of atherosclerosis, increasing the risk of CAD. Additional molecular 
and population based research is needed to provide further evidence fore the role of 
KIAA1462 in the development of atherosclerosis and CAD. 
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Figure 12. Molecular pathway of KIAA1462 during angiogenesis. KIAA1462 regulates endothelial cell 
proliferation by its interaction with CTNND1 in the VE-cadherin junctional complex at the plasma membrane of 
endothelial cells, limiting the amount of free CTNND1 in the cytoplasm. Because of this RhoA activity increases, 
which results in downstream activation of ROCK2 and Rb. These proteins modulate cell proliferation by 
stimulating G1–S-phase transition. 
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Abstract 
 
Objective - Cell cycle withdrawal is necessary for transition from an undetermined to a 
restricted endothelial cell fate. Krüppel-like factors are involved in the expression of cell 
cycle regulatory proteins. Here, we demonstrate an essential role for Krüppel-like factor 7 
(Klf7) in the regulation of endothelial cell proliferation and differentiation during vascular 
development. 
Methods and Results - In vitro analysis of gene function in endothelial cells showed that 
Klf7 affects p21Cip1/Waf1 activity. Overexpression of Klf7 stimulated p21Cip1/Waf1, leading to 
diminished G1–S-phase transition which finally resulted in decreased cell proliferation. 
Conclusion - We conclude that Klf7 is crucial for the regulation of endothelial cell 
proliferation and differentiation via modulation of p21Cip1/Waf1 activity during vascular 
development. 
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Introduction 
 
During vascular development angioblasts differentiate into endothelial cells (EC).1 
Transition from an undetermined to a restricted EC fate depends on the time of withdrawal 
from the cell cycle.2 Cell cycle progression is regulated by many different proteins, 
including cyclins, cyclin-dependent kinases (CDK) and CDK inhibitors. In particular, the 
CDK inhibitor p21Cip1/Waf1 plays an important role in cell cycle control: p21Cip1/Waf1-
mediated G1-arrest allow cell cycle withdrawal and cell differentiation.3-5 Increased 
p21Cip1/Waf1 expression also induce genes associated with senescence and age-related 
conditions such as atherosclerosis and Alzheimer disease.6,7 The expression of cell cycle 
regulatory proteins is controlled by several transcription factors, which can be divided 
according to the structural motif that contacts the DNA - one such motif is the zinc finger.8 
This motif is found by Krüppel-like factors (Klf) which contain three highly conserved 
Cys2-His2 zinc fingers at the carboxyl terminus of the protein and enable Klfs to bind GC-
rich promoters.9-11 Klfs function as activator, repressor or both of a large variety of genes.12 
Previous studies have demonstrated that the Klf family play important roles in cell 
proliferation, differentiation and apoptosis in several different organ systems during 
embryonic development, adult life and cancer-related angiogenesis.13-15 One such Klf 
family member is Krüppel-like factor 7 (Klf7), also known as ubiquitously Klf (UKLF) 
because of its widely expression in adult tissue, in particular the nervous system where it 
has an essential role in neurite outgrowth and survival.2,16-18 After that, it has also been 
demonstrated that Klf7 is specifically expressed in vascular ECs.14,18 In spite of this, our 
knowledge of the role of Klf7 in EC function remains limited. In this study, we have 
identified a particular role for Klf7 in blood vessel development. 
Recently, we have carried out a genome-wide microarray analysis in search of genes 
involved in the regulation of new vessel formation. Gene expression profiles of isolated 
Flk1-positive angioblasts during murine embryonic development were compared with the 
profiles of Flk1-negative cells. One of the genes that was identified as a new potential 
regulator of vascular development was Klf7. The Klf7 gene encodes a ~34 kDa protein 
which contains three domains: at the carboxyl terminus a DNA binding domain made of 
three zinc fingers separated by TGEKP(Y/F)X spacers, at the central part a nuclear 
localisation signal (NLS), a leucine-zipper motif and a hydrophobic serine-rich region 
functioning as a protein interaction domain, and at the amino terminus an acidic 
transactivation domain.13,18 However, the basic biological function of Klf7 in angiogenesis 
remains fully unknown. 
In this study, we sought to characterise the function of Klf7 in ECs during blood vessel 
formation in vitro using primary cell cultures. Our data show that Klf7 plays an important 
role in the regulation of EC proliferation. Overexpression of Klf7 led to diminished G1–S-
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phase transition. Further in vitro studies demonstrate that Klf7 stimulates p21Cip1/Waf1 
activity. Together, these findings contribute to the basic understanding of how Klf7 plays 
an important role in EC proliferation during vascular development. 
 
 
Methods 
 
This study was carried out in accordance with the Council of Europe Convention 
(ETS123)/Directive (86/609/EEC) for the protection of vertebrate animals used for 
experimental and other scientific purposes and with the approval of the National and Local 
Animal Care Committee. 
 
Mice 
Plugged FVB/N mice (Mus musculus) were ordered at Harlan (Indianapolis, USA). They 
were maintained under standard husbandry conditions. 
 
Isolation of Flk1-positive and Flk1-negative cells from mouse embryos 
From eight to sixteen days post-fertilisation (dpf), embryos were collected from plugged 
FVB/N mice and homogenised. Cells were stained with PE-conjugated anti-mouse Flk1 
antibody 1:50 (555308; BD, Breda, The Netherlands). Hoechst (Sigma-Aldrich, 
Zwijndrecht, The Netherlands) was used to select dead cells. Flk1-positive/Hoechst-
negative cells and Flk1-negative/Hoechst-negative cells were sorted on a BD 
FACSCantoTM (Breda, The Netherlands). Isolation of mRNA was carried out using the 
RNeasy Mini Kit from Qiagen (Venlo, The Netherlands). 
 
Microarray analysis 
Double stranded cDNA was generated from 5 μg mRNA. Biotin-labelled RNA was 
synthesised using the BioArrayTM HighYieldTM RNA Transcript Labeling Kit from ENZO 
Life Sciences (Raamsdonksveer, The Netherlands). After clean-up and fragmentation, 
approximately 20 μg of labelled cRNA was hybridised to the GeneChip® Mouse Genome 
430 2.0 Array (Affymetrix, Santa Clara, USA). Rosetta Resolver® (Rosetta Biosoftware, 
Cambridge, USA) was used to get quantile normalised raw data from the arrays. These data 
were merged into OmniViz® (BioWisdom, Cambridge, UK) and a threshold minimum for 
intensities was set at 30. Fold differences were calculated from log averages determined by 
the different experimental conditions. 
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Cell cultures 
Primary cultures of human umbilical vein endothelial cells (HUVEC) were cultured in 
EBM®-2 medium supplemented with a commercial BulletKit, 10% foetal calf serum (FCS) 
and 1% penicillin/streptomycin (Lonza, Breda, The Netherlands). Primary aorta-derived 
human vascular smooth muscle cells (vSMC) were cultured in SmGM-2 medium 
supplemented with a commercial BulletKit, 10% FCS and 1% penicillin/streptomycin 
(Lonza, Breda, The Netherlands). HeLa and sarcoma cells were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% FCS (Cambrex, Wiesbaden, 
Germany). Cells were cultured at 37°C in 5% CO2. Passages three to six were used 
throughout the study. 
 
Immunofluorescence 
HUVECs were grown in gelatin-coated 48-wells. After 24 hours, the cells were fixed in 4% 
formaldehyde and permeabilised with 0.2% Triton® X-100. Cells were incubated overnight 
at 4°C with Klf7 antibody 1:125 (HPA030490; Sigma-Aldrich, Zwijndrecht, The 
Netherlands). For the detection of the primary antibody, Alexa Fluor® 488 1:100 
(Invitrogen, Bleiswijk, The Netherlands) was used. Actin filaments were stained with 
rhodamin-phalloidin 1:40 (R415; Invitrogen, Bleiswijk, The Netherlands). The nucleus was 
stained with 4,6-diamidino-2-phenylindole (DAPI) in Vectashield® mounting medium (H-
1200; Vector Laboratories, Burlingame, USA). Cells were visualised with a fluorescence 
microscope (Axiovert S100; Carl Zeiss, Sliedrecht, The Netherlands). 
 
Klf7 adenovirus-induced overexpression 
HUVECs were cultured in EBM®-2 medium supplemented with a commercial BulletKit 
and infected with Klf7 adenovirus (pAd-Klf7) (MOI 50) or sham adenovirus (MOI 50) as 
control. Overexpression of Klf7 was validated by qPCR analysis and Western blot two days 
post-infection using the following human primers: 5’-GAC AGC TAC ACA GCC GTC 
AA-3’ (forward) and 5’-AGC TGA GAG CAG CCT TCT TG-3’ (reverse) for Klf7 
(Biolegio, Nijmegen, The Netherlands), and anti-human Klf7 antibody 1:125 (HPA030490; 
Sigma-Aldrich, Zwijndrecht, The Netherlands). Beta-actin primers 5’-TCC CTG GAG 
AAG AGC TAC GA-3’ (forward) and 5’-AGC ACT GTG TTG GCG TAC AG-3’ 
(reverse) (Biolegio, Nijmegen, The Netherlands) were used as housekeeping gene, while 
beta-actin antibody 1:500 (ab8229; Abcam, Cambridge, UK) was used as a loading control. 
 
2D matrigel network-formation assay 
To induce network-formation, HUVECs - infected with sham adenovirus or pAd-Klf7 - 
were cultured on a 2D MatrigelTM matrix (BD, Breda, The Netherlands). The tubules were 
stained by Calcein-AM (BD, Breda, The Netherlands) after 24 hours of network-formation. 
Each condition was assessed by fluorescence microscopy (Axiovert S100; Carl Zeiss, 
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Sliedrecht, The Netherlands). Image analysis of number of junctions, tubules and total 
tubule length was carried out using Angiosys Image Analysis Software 1.0 (TCS 
CellWorks, Buckingham, UK). 
 
Cell proliferation assay 
EC proliferation in vitro was evaluated by culturing HUVECs - infected with sham 
adenovirus or pAd-Klf7 - in gelatin-coated 6-wells and counting them at different time 
points. 
In brief, 50,000 cells were seeded and incubated in EBM-2 medium supplemented 
with 0.2% FCS for 4 hours to synchronise the cell cycle. Thereafter, HUVECs were 
trypsinised after 0, 8, 24 and 48 hours, and counted with a Bürker-Türk. At all time points 
the amount of cells was expressed as percentage, whereas time point zero the amount of 
cells was expressed as 100%. 
 
Cell cycle assay 
For cell cycle experiments, HUVECs - infected with sham adenovirus or pAd-Klf7 - were 
trypsinised and fixed in 70% ice-cold ethanol overnight at 4°C. After being washed in 
phosphate-buffered saline (PBS), the cells were resuspended in 300 l PBS containing 69 
M propidium iodide (PI), 37 mM sodium citrate and 200 g RNase. Cell cycle profile was 
measured on a BD FACSCantoTM (Breda, The Netherlands). 
 
Apoptosis assay 
To induce apoptosis, HUVECs - 24 hours post-infection - were serum starved for 4 hours 
and replenished with EBM-2 medium supplemented with a commercial BulletKit for 24 
hours. The cells were then harvested and resuspended in FACS buffer containing Annexin 
V and PI (BD, Breda, The Netherlands). After 15 minutes incubation at room temperature, 
Binding Buffer (BD, Breda, The Netherlands) was added before the cells were analysed on 
a BD FACSCantoTM (Breda, The Netherlands). Gating was set to exclude cell doublets and 
cell clumps. 
 
Western blot 
To determine whether overexpression of Klf7 interfered with cellular processes, Western 
blot analysis was carried out using HUVEC protein lysates. At 72 hours post-infection, 
HUVECs were serum starved for 4 hours and replenished with EBM-2 medium 
supplemented with a commercial BulletKit for 30 minutes. Cells were lysed in NP40 Cell 
Lysis Buffer (Invitrogen, Bleiswijk, The Netherlands) and analysed on a 12.5% SDS-PAGE 
gel, followed by immunoblotting using anti-human antibodies against Klf7 1:125 
(HPA030490; Sigma-Aldrich, Zwijndrecht, The Netherlands) and p21Cip1/Waf1 1:500 (sc-
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469; Santa Cruz Biotechnology, Heidelberg, Germany). Beta-actin antibody 1:500 (ab8229; 
Abcam, Cambridge, UK) was used as a loading control. Protein bands were visualised by 
the Odyssey Infrared Imaging System and analysed by Odyssey 3.0 software (LI-COR 
Biotechnology, Cambridge, UK). 
 
Statistical analysis 
Data were reported as mean ± standard error of the mean (SEM). Statistical significance 
was evaluated using a Student’s t-test and was accepted at P < 0.05 (* P < 0.05, ** P < 0.01 
in the figures). 
 
 
Results 
 
Expression of Klf7 is upregulated during mouse embryogenesis 
To identify new genes involved in angiogenesis, a genome-wide microarray analysis was 
carried out followed by validation of the results by qPCR. Gene expression profiles of Flk1-
positive angioblasts at various stages of murine embryonic development were compared 
with the profiles of Flk1-negative cells. Klf7 was upregulated in Flk1-positive angioblasts 
from 8 to 16 dpf. Expression levels were highest upregulated around 9 dpf, which coincides 
with the period of early angiogenesis in murine development and suggests a potential role 
of Klf7 in blood vessel formation (Figure 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Klf7 is upregulated in Flk1-positive angioblasts during mouse development. Endogenous expression 
level of Klf7 in Flk1-positive angioblasts during murine embryonic development from 8 to 16 days post-
fertilisation (dpf) compared with Flk1-negative cells as analysed by qPCR. The expression level of Klf7 in Flk1-
negative cells was arbitrarily set to one (n = 4; mean ± SEM). The highest upregulation was detected around day 9, 
which coincides with the period of early angiogenesis in murine development. 
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Klf7 is highly expressed in cultured endothelial cells 
To validate the endothelial expression of Klf7 in cultured cells, we determined the 
expression level of the Klf7 human orthologue in a number of different cell types. In a 
comparison between HUVECs, vSMCs, HeLa and sarcoma cells, the highest mRNA 
expression level of Klf7 was observed in HUVECs (Figure 2A). Intracellular 
immunofluorescent detection of Klf7 in HUVECs demonstrated that the protein was mainly 
located in the Golgi apparatus (Figure 2B). 
 
 
Figure 2. Klf7 expression in different cell types in culture. (A) Klf7 was highly expressed in HUVEC compared 
with vSMC, HeLa and sarcoma cells, as demonstrated by qPCR analysis (n = 3; mean ± SEM). (B) Klf7 was 
mainly located in the Golgi apparatus, as demonstrated by immunofluorescent staining. Klf7 (green), F-actin (red), 
co-localised area (yellow) and nuclei (blue) (n = 3). 
Klf7 regulates endothelial cell proliferation 
 
 79
Overexpression of Klf7 inhibits vascular network-formation in vitro 
To further assess the function of Klf7 in cultured ECs, overexpression of Klf7 in HUVECs 
was induced by infection of pAd-Klf7 and compared with sham adenovirus infected and 
uninfected controls. In pAd-Klf7 infected cells, endogenous Klf7 expression was 
significantly higher than in the control cultures on both mRNA (Figure 3A) and protein 
level (Figure 3B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Adenovirus-mediated overexpression of Klf7 in cultured endothelial cells. (A) qPCR analysis of 
HUVECs infected with Klf7 adenovirus (Klf7-OE) showed an increase in mRNA expression levels of Klf7. (B) 
Western blot analysis of Klf7-OE in HUVECs showed an increase in protein expression levels of Klf7 (n = 5; 
mean ± SEM). 
 
 
To investigate the effect of Klf7 overexpression on vascular network-formation, in 
vitro network-formation experiments with HUVECs were carried out. Overexpression of 
Klf7 had an inhibitory effect on the number of junctions and capillary tubules when 
compared with cultures infected with equivalent MOI of sham adenovirus or uninfected 
controls (Figure 4A-D). These data indicate that Klf7 has an essential role in vascular 
network-formation. The process of vessel growth is determined by many different factors. 
One of these is cell proliferation. 
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Figure 4. Klf7 overexpression in cultured endothelial cells impairs vascular network-formation. (A) 
Assessment of network-formation capacity for Klf7-overexpressed HUVECs (Klf7-OE) in a 2D matrigel 
experiment. Tubules were stained by Calcein-AM uptake. (B-D) Quantification of the vascular network showed a 
delay in network-formation in Klf7-OE HUVECs: (B) number of junctions, (C) number of tubules and (D) total 
tubule length (n = 5; mean ± SEM). 
 
 
Klf7 overexpression in HUVECs reduces cell proliferation through a blockade of G1–
S-phase transition 
To determine the effect of Klf7 on cell proliferation in vitro, a proliferation assay was 
carried out. Cell proliferation was reduced after overexpression of Klf7 in HUVECs (Figure 
5A). Sufficient cell cycle progression is necessary for proliferation. We therefore assessed 
the effect of Klf7 overexpression on the cell cycle. Flow cytometric analysis of PI 
demonstrated that overexpression of Klf7 in HUVECs blocks the G1–S-phase transition 
(Figure 5B-D). In addition, an increase of apoptosis was observed in pAd-Klf7 infected 
cells compared with sham adenovirus infected and uninfected controls (Figure 5E-G). 
Together, these data suggest that Klf7 regulates cell proliferation by G1–S-phase transition. 
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Figure 5. Klf7 regulates cell proliferation through G1–S-phase transition. (A) Averaged curves of cell 
proliferation of HUVECs.        : control,        : sham adenovirus,        : pAd-Klf7. (B) Representative flow 
cytometric analysis of HUVECs. (C-D) Quantification of the G1 and S–G2-phase of the cell cycle in HUVECs 
showed a blockade in G1–S-phase transition after Klf7 overexpression (Klf7-OE), as analysed by flow cytometry: 
(C) G1-phase and (D) S–G2-phase. 
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(E) Representative flow cytometric analysis of HUVECs. (F-G) Quantification of early and late apoptosis in 
HUVECs showed an increase of apoptosis after Klf7-OE, as analysed by flow cytometry: (F) early apoptosis and 
(G) late apoptosis (n = 4; mean ± SEM). 
 
 
Klf7 regulates p21Cip1/Waf1 activity 
Cell cycle progression is controlled by many different proteins, including cyclins, CDKs 
and CDK inhibitors.3,5 Western blot analysis demonstrated that the downstream signalling 
cascade of Klf7 was affected (Figure 6A, B); overexpression of Klf7 (Figure 6A) increased 
signal transduction via p21Cip1/Waf1 by upregulation of p21Cip1/Waf1 protein levels (Figure 6B). 
These data demonstrate that Klf7 regulates G1–S-phase transition via p21Cip1/Waf1. 
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Figure 6. Klf7 stimulates p21Cip1/Waf1 activity. Western blot analysis of (A) HUVECs infected with Klf7 
adenovirus (Klf7-OE) showed an increased activation of (B) p21Cip1/Waf1 (n = 5; mean ± SEM). 
 
 
 
Discussion 
 
In this study we demonstrated that Klf7 regulates EC proliferation during in vitro vascular 
network-formation. Overexpression of Klf7 led to diminished G1–S-phase transition during 
cell cycle progression. 
We demonstrated that Klf 7 was upregulated at various stages of murine embryonic 
development. Klf-like gene products were also identified before in lower vertebrate and 
invertebrate organisms, in which they control blood vessel formation, erythroid 
differentiation and epidermal development during embryogenesis.19,20 In zebrafish, Klf7 is 
mainly expressed in neuronal tissue, including the olfactory vesicle, cranial ganglia, and 
neurons in the marginal zone and ganglion cell layer of the retina (www.zfin.org). Further 
reports indicate that Klf7 is an important regulator of axon regeneration in zebrafish.21 In 
our study, knockdown of Klf7 in the developing zebrafish with morpholino (MO) injections 
resulted in no obvious defects (data not shown). Unlike a vascular expression pattern and/or 
vascular phenotype for Klf7 in zebrafish wasn’t found, a role for Klf7 in vascular 
development can’t be excluded. It is known that Klf family members have developed 
independently in different species, thus direct functional analogies by comparison of 
mammalian and non-mammalian Klf proteins may be unreliable.9 In addition, it has been 
reported that Klf7 was highly expressed throughout the brain and kidney during murine 
embryogenesis, whereas in adult life Klf7 expression was more restricted to the cerebellum 
and spinal cord.2,17,18 During murine development, Klf7 mRNA accumulate at embryonic 
day (E)9.5 in the central and peripheral nervous system and reach its maximum around 
E11.5-13.5 - the period of synaptogenesis.2 In isolated endothelial precursor cells, we found 
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a maximum of Klf7 expression around E9.0 which corresponds with the period of 
angiogenesis. Also in cultured ECs Klf7 was highly expressed. Based on the period and 
specific expression of Klf7 in the EC subset, we hypothesised that Klf7 may play a 
functional role in blood vessel formation. Indeed, overexpression of Klf7 in a vascular 
network-formation assay resulted in less capillary tubule formation and branching. 
To obtain more insight in the molecular mechanism by which Klf7 affect vascular 
growth, we analysed PI by flow cytometry, demonstrating that overexpression of Klf7 in 
HUVECs blocks the G1–S-phase transition. Further evaluation of the downstream pathway 
of Klf7 identified p21Cip1/Waf1 as a downstream effector of Klf7. It was previously reported 
in 293T cells that Klf7 binds to the proximal promoter of this CDK inhibitor.22 
Overexpression of Klf7 in vitro and in vivo in different cell types resulted in a decrease in 
DNA synthesis, induction of p21Cip1/Waf1 and inhibition of cyclin D1, which leads to a G1-
arrest and induce terminal differentiation or maintenance of a quiescent 
phenotype.2,4,17,18,22,23 Together, these findings provide further proof that Klf7 has a critical 
role in the decision between EC proliferation and cell cycle arrest/differentiation (Figure 7). 
p21Cip1/Waf1 plays also additional roles outside of the nucleus.3,24 Previously, it has been 
demonstrated that p21Cip1/Waf1 is involved in the regulation of actin cytoskeleton dynamics 
through inhibition of the Rho-ROCK-LIMK pathway and in this way promote neurite 
outgrowth.3,17,25,26 Thereafter, p21Cip1/Waf1 also counteract the apoptotic process in human 
HepG2 hepatoma cells by binding pro-caspase 3 and blocks its activation, thus protecting 
cells against apoptosis.7 Followed on G1-arrest, we found in vitro an increase in apoptosis 
after Klf7 overexpression. Reports suggest that prolonged G1-arrest can activate death-
promoting factors, thus in this way probably by-passing the suspected protective effect of 
increased p21Cip1/Waf1 levels.27 
To bind GC-rich promoters, Klf7 has to be transported to the nucleus.18 Reports 
indicate that shuttling of Klf7 is directed by MoKA - a co-activator of Klf7. MoKA and 
Klf7 were co-expressed in cells that withdraw from the cell cycle. High levels of MoKA 
were found in the brain, branchial arches and limbs around E10.5 during murine 
embryogenesis, and low levels in all adult tissues.22 We detected Klf7 in the Golgi 
apparatus where most of the Klf proteins are modified by phosphorylation and 
glycosylation to generate function specificity.18 Co-immunoprecipitation identified MoKA 
as a possible binding partner of Klf7 in cultured ECs, but MoKA was also pulled down by 
the isotype control (data not shown). The different developmental stages in which Klf7 
(maximum around E9.0) and MoKA (maximum around E10.5) were transcribed could 
suggest an independent involvement of the two proteins in different regulatory pathways in 
ECs. The ability of MoKA to bind Klf7 can also depend on the cellular context in which 
both proteins can be find, for example in vitro or in vivo conditions, or primary versus 
established cells.9,11,18 
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Figure 7. Molecular pathway of Klf7 during angiogenesis. (A) Hypothetical: outside of the nucleus, p21Cip1/Waf1 
regulates actin cytoskeleton dynamics through inhibition of the Rho-ROCK-LIMK pathway and in this way 
endothelial cell migration. Klf7 possibly influence this process indirectly. (B) Klf7 regulates endothelial cell 
proliferation by activating p21Cip1/Waf1 transcription and activity which results in diminished cell proliferation by 
inhibiting G1–S-phase transition. MoKA possibly binds Klf7 as co-activator. 
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In conclusion, here we have identified Klf7 as a new regulator of EC proliferation and 
differentiation in vascular development by downstream activation of p21Cip1/Waf1, which 
leads to G1-arrest and ultimately to cell cycle withdrawal. To our knowledge, this study is 
the first report of the function of Klf7 in ECs during normal embryonic and postnatal blood 
vessel formation. Interestingly, three other Klf family members - Klf2, Klf4 and Klf6 - are 
also expressed in vascular ECs.28-31 Klf6 is closely related to Klf7 and show overlapping 
functions in cell differentiation.2,18 Loss of Klf6 is associated with impaired 
haematopoiesis, while overexpression enhance the haematopoietic potential of embryonic 
stem cells.32,33 Based on our findings, Klf7 and Klf6 might be involved also much earlier in 
embryogenesis at the moment when haemangioblasts differentiate into haematopoietic stem 
cells and angioblasts. Additional research is needed to provide further evidence for this 
potential role in primitive vascular plexus formation. 
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Abstract 
 
Objective - Actin-binding proteins are involved in the migratory properties of 
hepatocellular carcinoma cells. However, the function of these proteins in endothelial cells 
(EC) requires further definition. Using a microarray screen for angiogenesis-associated 
genes during embryogenesis, we identified Transgelin 2 (Tagln2) as a new angiopotent 
factor with an undefined biological function. Here, we investigate the contribution of 
Tagln2 to EC migration during vascular development. 
Methods and Results - Verification by in situ hybridisation in zebrafish demonstrated that 
Tagln2 is predominantly expressed in ECs. Knockdown of Tagln2 in zebrafish embryos 
resulted in ectopic sprouting of intersegmental vessels. In line with this finding, knockdown 
of Tagln2 in a murine retina model enhanced vascular outgrowth. Studies in human ECs 
verified the advantageous effect of Tagln2 downregulation on EC migration in vitro and 
identified Tagln2 as a new mediator of VEGF receptor 2 (VEGFR-2) synthesis. 
Conclusion - Tagln2 is a crucial regulator of EC migration and VEGFR-2 turnover, both 
requirements for angiogenesis. 
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Introduction 
 
Migratory properties of endothelial cells (EC) are essential for vascular outgrowth during 
angiogenesis. One of the main factors that determines cell motility is the flexibility of the 
actin cytoskeleton. Microtubule dynamics contribute to the formation of protrusions - or 
lamellipodia - at the leading edge of the cell promoting directed migration, while on the 
other hand stress fibres are important for contraction of the cell body allowing forward 
progression.1-3 Different proteins have been identified in the regulation of actin 
polymerisation, including profilin, cofilin and the Arp2/3 complex. All these proteins bind 
to the actin cytoskeleton and influence actin dynamics.4-7 The tumour suppressor protein 
Transgelin 2 (Tagln2) - a Cdc2-related serine/threonine protein kinase - is also an actin-
binding protein. In hepatocellular carcinoma cells, Tagln2 has an inhibitory effect on cell 
motility through its suppressive effect on actin polymerisation and stress fibre formation. 
The actin binding affinity of Tagln2 is controlled by PFTK1 through phosphorylation of 
Tagln2 serine residues. Reduction of PFTK1 expression in HKCI-4 cells affects the 
phospho-serine status of Tagln2 and results in accumulation of the total amount of Tagln2 
protein. Unphosphorylated Tagln2 shows more physical interaction with actin, which leads 
to actin depolymerisation and a general reduction in migration. In contrast, Tagln2 
downregulation in PFTK1-depleted cells rescues actin stress fibre formation.8 Tagln2 is not 
only highly expressed in hepatocellular carcinoma cells, but also in other types of tumour 
cells and it is a well known marker of differentiated smooth muscle cells. Next to it, Tagln2 
is expressed in ECs too, suggesting a possible involvement in EC function.9-11 In spite of 
this, our knowledge of the role of Tagln2 in ECs remains limited. In this study, we have 
sought to characterise the basic biological function of Tagln2 in ECs during blood vessel 
formation in vitro using primary cell cultures and in vivo in zebrafish and murine vascular 
development. 
Recently, we identified Tagln2 as a new potential regulator of angiogenesis from a 
genome-wide microarray analysis in search of genes involved in the regulation of new 
vessel formation. Gene expression profiles of isolated Flk1-positive angioblasts during 
murine embryonic development were compared with the profiles of Flk1-negative cells. 
Subsequently, our data show that Tagln2 plays an important role in the regulation of EC 
migration during angiogenesis. In vivo, a loss of Tagln2 led to ectopic sprouting of 
intersegmental vessels (ISV) in developing zebrafish, whereas an increased outgrowth of 
the vasculature was detected during postnatal vascular retinal development in mice. Further 
in vitro studies demonstrate that silencing of Tagln2 stimulated EC migration and enhanced 
VEGF receptor 2 (VEGFR-2) synthesis. Together, these findings contribute to the basic 
understanding of how Tagln2 plays an important role in the basic regulation of EC 
migration during vascular development. 
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Methods 
 
This study was carried out in accordance with the Council of Europe Convention 
(ETS123)/Directive (86/609/EEC) for the protection of vertebrate animals used for 
experimental and other scientific purposes and with the approval of the National and Local 
Animal Care Committee. 
 
Zebrafish 
Zebrafish (Danio rerio) were maintained under standard laboratory conditions. The 
transgenic zebrafish line used was Tg(Kdrl:eGFP)s843.12 
 
Whole-mount in situ hybridisation 
Template DNA for probe generation was obtained by direct amplification of the target gene 
from genomic DNA. The reverse primer was tagged with a T3 RNA polymerase promoter 
tail to allow direct in vitro transcription and generation of antisense probes after PCR 
purification. Antisense RNA probes of Tagln2 were generated by in vitro transcription 
using the digoxigenin RNA Labeling Mix from Roche (Woerden, The Netherlands). In situ 
hybridisation was carried out as previously described.13 The following zebrafish primers 
were used: 5’-TTT AAT GGG CAT TTA TTG AG-3’ (forward) and 5’-GGA TCC ATT 
AAC CCT CAC TAA AGG GAA CAG TGT GAG ACA AAG GAA GC-3’ (reverse) 
(Biolegio, Nijmegen, The Netherlands). 
 
Morpholino injection 
Morpholinos (MO) against Tagln2 were obtained from Gene Tools (Philomath, USA) and 
resuspended in Milli-Q water containing 0.2% phenol red. Different doses of the MO were 
injected into single-cell stage zebrafish embryos as previously described.14 MO knockdown 
efficiency was tested by reverse transcriptase PCR. The following zebrafish MOs were 
used: 5’-GGA CGG ACC TTT ATT TGC CAT TTT G-3’ (MO Tagln2-ATG) and 5’-AAC 
TGA TTG CGG TGA CTT ACA CAT C-3’ (MO Tagln2-splice). 
 
Mice 
Plugged FVB/N mice (Mus musculus) were ordered at Harlan (Indianapolis, USA). 
C57BL/6J mice were obtained from laboratory stock. They were maintained under standard 
husbandry conditions. 
 
Isolation of Flk1-positive and Flk1-negative cells from mouse embryos 
From eight to sixteen days post-fertilisation (dpf), embryos were collected from plugged 
FVB/N mice and homogenised. Cells were stained with PE-conjugated anti-mouse Flk1 
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antibody 1:50 (555308; BD, Breda, The Netherlands). Hoechst (Sigma-Aldrich, 
Zwijndrecht, The Netherlands) was used to select dead cells. Flk1-positive/Hoechst-
negative cells and Flk1-negative/Hoechst-negative cells were sorted on a BD 
FACSCantoTM (Breda, The Netherlands). Isolation of mRNA was carried out using the 
RNeasy Mini Kit from Qiagen (Venlo, The Netherlands). 
 
Microarray analysis 
Double stranded cDNA was generated from 5 μg mRNA. Biotin-labelled RNA was 
synthesised using the BioArrayTM HighYieldTM RNA Transcript Labeling Kit from ENZO 
Life Sciences (Raamsdonksveer, The Netherlands). After clean-up and fragmentation, 
approximately 20 μg of labelled cRNA was hybridised to the GeneChip® Mouse Genome 
430 2.0 Array (Affymetrix, Santa Clara, USA). Rosetta Resolver® (Rosetta Biosoftware, 
Cambridge, USA) was used to get quantile normalised raw data from the arrays. These data 
were merged into OmniViz® (BioWisdom, Cambridge, UK) and a threshold minimum for 
intensities was set at 30. Fold differences were calculated from log averages determined by 
the different experimental conditions. 
 
Mouse model of retinal vascularisation 
Two-day old C57BL/6J mice pups were anesthetised by placement on ice. One microlitre 
of Tagln2 targeting siRNA (si-Tagln2) (1.33 μg/μl) was injected into the left eye using a 
33-Gauge needle (World Precision Instruments, Berlin, Germany). As a control, one 
microlitre of scrambled non-targeting siRNA (si-sham) (1.33 μg/μl) was injected into the 
right eye. siRNA was obtained from Thermo Fisher Scientific (Breda, The Netherlands). 
The following mix of mouse si-Tagln2 was used: 5’-CAU GAA UGG UUA AUA UAU A-
3’ – 5’-CGA GUU UGC UGA UUU UAA A-3’ – 5’-GCA GGG ACU UAA UUU AUA 
G-3’ – 5’-UGU GCA AGC UUA UUA AUU C-3’. Mice pups were killed five days after 
intra-ocular injection. The retinas were stained with Alexa Fluor® 488-conjugated isolectin 
GS-IB4 1:200 (I21411; Invitrogen, Bleiswijk, The Netherlands) before assessment under a 
fluorescence microscope (Axiovert S100; Carl Zeiss, Sliedrecht, The Netherlands). Image 
analysis of the number of junctions, tubules and total tubule length was carried out using 
Angiosys Image Analysis Software 1.0 (TCS CellWorks, Buckingham, UK). Validation of 
adequate Tagln2 knockdown in the retina (two days after intra-ocular injection) was 
achieved by quantitative real time PCR using the following mouse primers: 5’-GTC TGG 
AAG ATG TCC GTG GT-3’ (forward) and 5’-CTT CCA GAA GTG GCT CAA GG-3’ 
(reverse) (Biolegio, Nijmegen, The Netherlands). 
 
Cell cultures 
Primary cultures of human umbilical vein endothelial cells (HUVEC) were cultured in 
EBM®-2 medium supplemented with a commercial BulletKit, 10% foetal calf serum (FCS) 
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and 1% penicillin/streptomycin (Lonza, Breda, The Netherlands). Cells were cultured at 
37°C in 5% CO2. Passages three to six were used throughout the study. 
 
Immunofluorescence 
HUVECs - transfected with si-sham or si-Tagln2 - were grown in gelatin-coated 48-wells. 
After 24 hours, the cells were fixed in 4% formaldehyde and permeabilised with 0.2% 
Triton® X-100. Cells were incubated overnight at 4°C with Tagln2 antibody 1:200 
(HPA001925; Sigma-Aldrich, Zwijndrecht, The Netherlands). For the detection of the 
primary antibody Alexa Fluor® 488 1:100 (Invitrogen, Bleiswijk, The Netherlands) was 
used. Actin filaments were stained with rhodamin-phalloidin 1:40 (R415; Invitrogen, 
Bleiswijk, The Netherlands). The nucleus was stained with 4,6-diamidino-2-phenylindole 
(DAPI) in Vectashield® mounting medium (H-1200; Vector Laboratories, Burlingame, 
USA). Cells were visualised with a fluorescence microscope (Axiovert S100; Carl Zeiss, 
Sliedrecht, The Netherlands). 
 
Targeted siRNA knockdown 
HUVECs were grown to 60-70% confluence and DharmaFECT1 Transfection Reagent was 
used to transfect 5 ng siRNA (Thermo Fisher Scientific, Breda, The Netherlands). The 
following mix of human si-Tagln2 was used: 5’-GCU CAU UAA UGC ACU GUA C-3’ – 
5’-GGC AGU AGC CCG AGA UGA U-3’ – 5’-GCA AGA ACG UGA UCG GGU U-3’ – 
5’-GAA CAU GGC CUG UGU GCA G-3’. Si-sham was used as a control. Knockdown of 
Tagln2 was validated by quantitative real time PCR analysis and Western blot two days 
post-transfection using the following human primers: 5’-CCC TGA CAG AAA GGA GCT 
TG-3’ (forward) and 5’-CGG AAC TTC TCG GAT AAC CA-3’ (reverse) (Biolegio, 
Nijmegen, The Netherlands), and anti-human Tagln2 antibody 1:500 (HPA001925; Sigma-
Aldrich, Zwijndrecht, The Netherlands). Beta-actin primers 5’-TCC CTG GAG AAG AGC 
TAC GA-3’ (forward) and 5’-AGC ACT GTG TTG GCG TAC AG-3’ (reverse) (Biolegio, 
Nijmegen, The Netherlands) were used as housekeeping gene, while beta-actin antibody 
1:500 (ab8229; Abcam, Cambridge, UK) was used as a loading control. 
For Tagln - a family member of Tagln2 - the following human primers were used: 5’-
AAC AGC CTG TAC CCT GAT GG-3’ (forward) and 5’-AGT GCC CAT CAT TCT TGG 
TC-3’ (reverse) (Biolegio, Nijmegen, The Netherlands). 
 
Tagln2 adenovirus-induced overexpression 
HUVECs were cultured in EBM®-2 medium supplemented with a commercial BulletKit 
and infected with Tagln2 adenovirus (pAd-Tagln2) (MOI 50) or sham adenovirus (pAd-
sham) (MOI 50) as control. Overexpression of Tagln2 was validated by quantitative real 
time PCR analysis and Western blot two days post-infection. 
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2D matrigel network-formation assay 
To induce network-formation, HUVECs - transfected with si-sham or si-Tagln2 - were 
cultured on a 2D MatrigelTM matrix (BD, Breda, The Netherlands). The tubules were 
stained by Calcein-AM (BD, Breda, The Netherlands) after 24 hours of network-formation. 
Each condition was assessed by fluorescence microscopy (Axiovert S100; Carl Zeiss, 
Sliedrecht, The Netherlands). Image analysis of the number of junctions, tubules and total 
tubule length was carried out using Angiosys Image Analysis Software 1.0 (TCS 
CellWorks, Buckingham, UK). 
 
Migration assay 
EC migration in vitro was evaluated by culturing HUVECs into wells with cell free areas 
created by micro-plug barriers. Migration distance was determined 18 hours after the 
micro-plug barriers were removed as previously described.15 
In brief, cell free areas were created by inserting flexible micro-plugs (AMS 
Biotechnology, Germany) in gelatin-coated 96-wells. HUVECs were harvested with 
Accutase (Lonza, Breda, The Netherlands) 24 hours after transfection with si-sham/pAd-
sham or si-Tagln2/pAd-Tagln2, and 50,000 cells were seeded per well in 100 μl EBM®-2 
medium supplemented with a commercial BulletKit (Lonza, Breda, The Netherlands). After 
24 hours of incubation, the micro-plug barriers were removed before refreshing the 
medium. Cells were stained by Calcein-AM (BD, Breda, The Netherlands) after 18 hours of 
migration. Each condition was assessed by fluorescence microscopy (Axiovert S100; Carl 
Zeiss, Sliedrecht, The Netherlands). Migratory distance was determined using Axio Vision 
Software (Carl Zeiss, Sliedrecht, The Netherlands). 
 
Expression of VEGFR-2 
In HUVECs - transfected with si-sham or si-Tagln2 - the expression of VEGFR-2 was 
determined by qPCR analysis two days post-transfection using the following human 
primers: 5’-AGC GAT GGC CTC TTC TGT AA-3’ (forward) and 5’-ACA CGA CTC 
CAT GTT GGT CA-3’ (reverse) for VEGFR-2 (Biolegio, Nijmegen, The Netherlands). 
Beta-actin primers 5’-TCC CTG GAG AAG AGC TAC GA-3’ (forward) and 5’-AGC 
ACT GTG TTG GCG TAC AG-3’ (reverse) (Biolegio, Nijmegen, The Netherlands) were 
used as housekeeping gene. 
 
Statistical analysis 
Data were reported as mean ± standard error of the mean (SEM). Statistical significance 
was evaluated using a Student’s t-test and was accepted at P < 0.05 (* P < 0.05, ** P < 0.01 
in the figures). 
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Results 
 
Expression of Tagln2 is upregulated during mouse embryogenesis 
To identify new genes involved in angiogenesis, a genome-wide microarray analysis was 
carried out followed by validation of the results by qPCR. Gene expression profiles of Flk1-
positive angioblasts at various stages of murine embryonic development were compared 
with the profiles of Flk1-negative cells. Tagln2 was upregulated in Flk1-positive 
angioblasts from 8 to 16 dpf. Expression levels were highest upregulated around 10 dpf, 
which coincides with the period of angiogenesis in murine development and suggests a 
potential role of Tagln2 in blood vessel formation (Figure 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Tagln2 is upregulated in Flk1-positive angioblasts during mouse development. Endogenous 
expression level of Tagln2 in Flk1-positive angioblasts during murine embryonic development from 8 to 16 days 
post-fertilisation (dpf) compared with Flk1-negative cells as analysed by qPCR. The expression level of Tagln2 in 
Flk1-negative cells was arbitrarily set to one (n = 4; mean ± SEM). The highest upregulation was detected around 
day 10, which coincides with the period of angiogenesis in murine development. 
 
 
Tagln2 is expressed in the developing vasculature in zebrafish 
To validate Tagln2 expression in the developing vascular network, we examined embryonic 
expression of the Tagln2 (SM22α-a) zebrafish orthologue by whole-mount in situ 
hybridisation. Tagln2 transcripts were localised in the main axial vessels - dorsal aorta and 
posterior cardinal vein - and ISVs at 26 hours post-fertilisation (hpf) (Figure 2A). 
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Knockdown of Tagln2 in zebrafish results in ectopic sprouting of intersegmental 
vessels 
To assess the function of Tagln2 in vivo, the gene was silenced in developing zebrafish of 
the Tg(Kdrl:eGFP)s843 line, using MO-knockdown technology. Adequate targeting of 
Tagln2 was verified using RT-PCR analysis. Silencing of Tagln2 resulted in no obvious 
defects of vascular development during the first four days after fertilisation. However, at 5-
6 dpf reduced vascularisation of the gills and hyperplasticity of the ISVs were observed in 
the injected embryos (Figure 2B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Morpholino-induced knockdown of Tagln2 in zebrafish results in ectopic sprouting of 
intersegmental vessels. (A) Whole-mount in situ hybridisation of Kdrl (upper panel) or Tagln2 (lower panel) in 
zebrafish larvae at 26 hours post-fertilisation (hpf), lateral view, anterior is to the left. Compared with Kdrl - 
endothelial specific -, Tagln2 transcripts were localised in the developing vascular network, including main axial 
vessels - dorsal aorta and posterior cardinal vein - (black arrow) and intersegmental vessels (ISV). (B) 
Tg(Kdrl:eGFP)s843 embryos at 6 dpf, lateral view, anterior is to the left. Ectopic sprouting of ISVs (white arrow) 
was observed between the Tagln2 morpholino injected (Tagln2-KD) embryos and the uninjected control (UIC) 
embryos. 
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Tagln2 knockdown in the developing retinal vasculature of neonatal mice promotes 
vascular outgrowth 
To further validate the findings in the zebrafish, Tagln2 function was studied during the 
development of the retinal vasculature of neonatal mice. Tagln2 knockdown was induced in 
the first week of retinal vascular development by intra-ocular injection of a siRNA pool 
composed of four different Tagln2 targeting siRNA sequences in two-day old wild-type 
C57BL/6J mouse pups and compared with controls injected with a scrambled non-targeting 
siRNA pool. Efficient knockdown of Tagln2 was observed two days after intra-ocular 
injection (Figure 3). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Tagln2 depletion in the developing retinal vasculature of neonatal mice after siRNA targeting. 
Endogenous expression level of Tagln2 in the retina after intra-ocular injection of Tagln2 targeting siRNA 
(Tagln2-KD) showed a reduction in expression levels of Tagln2 as analysed by qPCR (n = 10; mean ± SEM). 
 
 
Like in the developing zebrafish, loss of Tagln2 expression had no primarily effect on 
vascular network-formation (Figure 4A). Assessment and quantification of the number of 
vascular branches, the total number of vessels and the total tubule length after visualisation 
of the vasculature by isolectin GS-IB4 staining, identified no differences between si-Tagln2 
and si-sham injected eyes five days after intra-ocular injection (Figure 4B-D). However, the 
outgrowth of the angiogenic front toward the retinal border reached significantly further in 
si-Tagln2 injected eyes than in si-sham injected eyes (Figure 4E, F). Combined, these data 
point towards an essential possible role for Tagln2 in EC migration during blood vessel 
development. 
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Figure 4. Tagln2 depletion during murine retinal vascular development results in increased vascular 
outgrowth toward the retinal border. (A) Whole-mount en-face staining of Tagln2 targeting siRNA (Tagln2-
KD) versus scrambled non-targeting siRNA (sham) injected retinas. Isolectin GS-IB4-FITC was used to visualise 
the retinal vasculature (green in the schematic representation of the retina, whereas dark gray shows the 
avascularised area). 
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(B-D) Quantification by means of the dimensions of the vascular network showed no obvious defects after Tagln2-
KD: (B) number of junctions, (C) number of tubules and (D) total tubule length remain unaffected. (E) Retinas 
stained with isolectin GS-IB4 (endothelial cells, dark gray) demonstrate an increased vascular outgrowth toward 
the retinal border in the Tagln2-KD injected group. (F) Quantification of retinal vascular outgrowth expressed as 
the A:B ratio, where A is the distance from the optic disc to the border of the vascular network and B the distance 
from the optic disc to the retinal border, showed a 13% increase in Tagln2-KD versus sham injected retinas (n = 
10; mean ± SEM). 
 
 
Tagln2 depletion promotes vascular network-formation and enhances endothelial cell 
migration in vitro 
To clarify the molecular mechanism underlying the increased vascular outgrowth, we 
moved to in vitro assays to define Tagln2 function in vascular cells. Tagln2 mRNA 
expression was observed in HUVECs (data not shown). Intracellular immunofluorescent 
detection of Tagln2 in HUVECs demonstrated that the protein was mainly located near the 
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actin cytoskeleton and protein expression disappeared after Tagln2 knockdown (Figure 
5A). 
 
 
Figure 5. Tagln2 knockdown in cultured endothelial cells promotes cell migration. (A) Tagln2 was mainly 
located near the actin cytoskeleton, as demonstrated by immunofluorescent staining, with lack of signal in Tagln2-
silenced ECs (Tagln2-KD). Tagln2 (green), F-actin (red), co-localised area (yellow) and nuclei (blue) (n = 3). 
 
 
Whereas loss of Tagln2 did not affect network-formation in vivo, siRNA-mediated 
knockdown of Tagln2 in HUVECs affected network-formation in a stimulatory manner in a 
standard 2D matrigel analysis - as indicated by an increase in the number of junctions, 
capillary tubules and total tubule length - when compared with cultures transfected with 
equimolar of scrambled non-targeting siRNA and untransfected controls (Figure 5B-E).  
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(B) Assessment of network-formation capacity in Tagln2-KD HUVECs in a 2D matrigel experiment. Tubules 
were stained by Calcein-AM uptake. (C-E) Quantification of the vascular network showed enhanced vascular 
branching in Tagln2-KD HUVECs: (C) number of junctions, (D) number of tubules and (E) total tubule length (n 
= 12; mean ± SEM). 
 
 
Adequate knockdown of the target gene was validated on both mRNA and protein level, 
and did not affect the expression of the family member Tagln (Figure 6A-C). A migration 
assay was carried out to determine the effect of Tagln2 on migration in HUVECs. Similar 
to the in vivo findings, migration was significantly increased in Tagln2-depleted HUVECs 
(Figure 5F). In contrast, HUVECs transfected with an adenoviral plasmid expressing 
human Tagln2 cDNA showed the opposite effect with a significant decline in migration as 
compared with sham adenovirus-treated controls (Figure 5G, Tagln2 overexpression 
validation is shown in Figure 6D, E). The speed of migration is influenced by the rate of 
VEGFR-2 turnover.16 qPCR analysis showed that Tagln2 depletion increased VEGFR-2 
synthesis, implying increased rates of receptor turnover (Figure 5H). Combined, these 
findings demonstrate that Tagln2 contributes to angiogenesis involving EC migration, 
possibly by affecting VEGFR-2 turnover. 
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(F, G) Migration assay in which the white circle indicates the original cell-free area created by micro-plug 
barriers. Bar graph indicates the percentage of cell coverage of the cell-cleared area for the different groups after 
18 hours of migration. Measurement of the migratory distance of ECs in vitro showed (F) enhanced migration of 
Tagln2-KD HUVECs versus sham (n = 7; mean ± SEM), while (G) Tagln2 overexpression (Tagln2-OE) showed a 
diminished migration of Tagln2-OE HUVECs versus sham (n = 4; mean ± SEM). (H) qPCR analysis of Tagln2-
KD in HUVECs showed an increase in expression level of VEGFR-2 versus sham (n = 3; mean ± SEM). 
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Figure 6. siRNA-mediated knockdown and adenovirus-mediated overexpression of Tagln2 in cultured 
endothelial cells. (A) qPCR analysis of HUVECs transfected with Tagln2 targeting siRNA (Tagln2-KD) showed 
a reduction in expression levels of Tagln2. (B) Western blot analysis of Tagln2-KD in HUVECs also showed a 
reduction in expression levels of Tagln2. (C) The expression levels of Tagln were not affected after Tagln2-KD in 
HUVECs as analysed by qPCR. (D) Overexpression of Tagln2 (Tagln2-OE) enhances Tagln2 expression levels as 
analysed by qPCR and (E) Western blot (n = 3; mean ± SEM). 
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Discussion 
 
In this study we have identified Tagln2 as a potent angiogenic regulator during embryonic 
and postnatal vascular development. We showed that Tagln2 was upregulated in the 
developing murine embryo in Flk1-positive angioblasts compared with Flk1-negative cells, 
while whole-mount in situ hybridisation in developing zebrafish larvae validated the 
predominant vascular expression of Tagln2. Furthermore, we demonstrated that Tagln2 is 
essential for EC migration during blood vessel formation in zebrafish and mice. 
Knockdown of Tagln2 in zebrafish and in the developing retinal vasculature of neonatal 
mice resulted in ectopic vessel formation and enhanced EC migration. In vitro, Tagln2 
controls network-formation and EC migration. 
The Tagln2 gene is one of the 72 genes in the human genome that encodes a calponin 
homology actin-binding domain or CH domain - a superfamily of actin-binding domains 
found in both cytoskeletal and signal transduction proteins.17 At protein level, Tagln2 has a 
high homology (65%) with its family member Tagln - also known as SM22α - which is an 
early marker of differentiated smooth muscle cells.8,11 The expression of SM22α is 
regulated by the transforming growth factor (TGF)-β signalling pathway, which is involved 
in mural cell recruitment during stabilisation of the newly formed vessel branches as a 
result of angiogenic sprouting.18 During murine embryogenesis SM22α is mainly expressed 
in vascular smooth muscle cells (vSMC) and cardiac myocytes around embryonic day 
(E)9.5, the same period as Tagln2 expression.19 Like Tagln2, SM22α acts as a tumour 
suppressor gene and inhibits the expression of matrix metalloproteinase 9 (MMP9).20,21 
MMPs are involved in the breakdown of the extracellular matrix (ECM) in physiological 
conditions such as angiogenic sprouting, or in disease processes like metastasis.22-24 Based 
on the high homology of the SM22α and the Tagln2 protein, and the overlapping time 
period of expression during murine embryogenesis, we speculate that Tagln2 may be 
involved in early vessel stabilisation during angiogenesis. 
In our study, knockdown of Tagln2 in zebrafish was characterised by ectopic sprouting 
of the ISVs, indicating a defect in EC migration or vessel stabilisation. ISVs develop via 
migration and division of ECs from the dorsal aorta and the cardinal vein, and are guided 
by attractive and repulsive signals from the external environment. Once these new branches 
touch other sprouts, they establish connections and the sprouting vessels fuse at the most 
dorsal region of the trunk to form the dorsal longitudinal anastomotic vessel (DLAV), 
followed by further vessel stabilisation.25-29 Ectopic branching can be due to prolonged 
angiogenic sprouting behaviour of the ECs within the ISVs. Normally, the endothelium of 
neovessels become quiescent after tip cell fusion by VE-cadherin stabilisation, deposition 
of ECM components, mural cell recruitment and downregulation of the VEGFR-2 
signalling pathway.4,30-32 Several mutants have been identified in zebrafish that display a 
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similar ectopic branching phenotype of the ISVs that is similar to the Tagln2 MO-induced 
silenced zebrafish, including stl (= microsomal triglyceride transfer protein) and cdh5 (= 
VE-cadherin) mutants, and those with defects in the Dll4-Notch signalling pathway 
(rbpsuh, dll4, inhibition of γ-secretase).25,27,33-37 All of these genes are involved directly or 
indirectly in tip cell formation, migration or vessel stabilisation. However, our data clearly 
show that ectopic sprouting of the ISVs took place at a later stage of development - around 
5-6 dpf when the circulatory system has developed normally - which corresponds mostly 
with the stl mutant phenotype.33 The stl gene encodes the microsomal triglyceride transfer 
protein (mtp). Via apolipoprotein B (ApoB) synthesis, mtp modulates VEGF receptor 1 
(VEGFR-1) expression - a decoy receptor for VEGF with an inhibitory role in 
angiogenesis.4,25,33 Loss of VEGFR-1 in zebrafish resembles the phenotype of stl mutants.33 
Thus, stl mutants show an indirect stimulatory effect on VEGFR-2 signalling. In cultured 
ECs, we demonstrated that Tagln2 depletion resulted in a direct stimulatory effect on the 
VEGFR-2 signalling pathway by increasing VEGFR-2 synthesis, which reflects enhanced 
VEGFR-2 turnover, which may inhibit EC transition from active - migratory, proliferative 
and pro-sprouting - into quiescence. In line with our findings on the effect of Tagln2 
silencing on EC migration, high rates of VEGFR-2 turnover are indeed associated with 
migratory cells.16 In addition, previous reports of direct or indirect stimulation of the 
VEGFR-2 signalling in mice show ectopic angiogenic sprouting due to lack of vessel 
stabilisation as a consequence of impaired cell-cell adhesion or less mural cell 
recruitment.30,38,39 Sphingosine-1-phosphate receptor 1 (S1PR1) knockout mice exhibit 
increased formation of ectopic vessel branches with retained pericyte coverage at a 
relatively late developmental stage when vascular stabilisation is essential. S1PR1 
signalling is involved in vascular stabilisation through inhibition of the VEGFR-2 
signalling pathway, protecting blood vessels against prolonged angiogenic behaviour.30 Our 
data clearly show that Tagln2 knockdown stimulated EC migration in retinal vascular 
development of mice, possibly due to a prolonged turnover of VEGFR-2 and subsequent 
angiogenic behaviour of newly formed blood vessels. Unless the outgrowth of the vascular 
network toward the retinal border was more extensive after Tagln2 knockdown compared 
with controls, the total tubule length was unchanged. This could be due to earlier 
remodelling of the vascular network in si-Tagln2 injected eyes, as a consequence of 
reaching the retinal border much earlier compared with controls. 
EC migration is encouraged by actin polymerisation and lamellipodia formation which 
stimulates random formation of cell-cell contacts, reflected in vitro by an increase in the 
number of branching points during a 2D matrigel network-formation assay.1,40,41 In 
accordance with these previous findings, we found that downregulation of the total amount 
of Tagln2 - including the active form - resulted in an increased number of branching points 
of in vitro network-formation, potentially as a result of increased lamellipodia formation 
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due to less actin depolymerisation by Tagln2 (Figure 7). These findings further provide 
supportive data that Tagln2 regulates EC migration by modulation of the actin cytoskeleton. 
 
 
Figure 7. Molecular pathway of Tagln2 during angiogenesis. Active Tagln2 depolymerise the actin 
cytoskeleton, inhibiting lamellipodia formation, which is associated with less cell migration. 
 
 
In conclusion, here we have identified Tagln2 as a new regulator of EC migration and 
vessel stabilisation in vascular development by stimulating actin depolymerisation and 
negatively regulating VEGFR-2 turnover, which leads to a quiescent phenotype of the ECs. 
To our knowledge, this study is the first report of the biological function of Tagln2 in ECs 
during normal embryonic and postnatal blood vessel formation. As mentioned before, the 
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effect of Tagln2 on cell motility has also been described in carcinoma cells.8-10 In line with 
these findings, the gene may also be an interesting research target for the development of 
new therapeutics in the treatment of cancer metastasis in which both cancer cell spreading 
and tumour vascularisation are decisive factors in disease progression. 
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Abstract 
 
Objective - Impairment of the endothelial barrier leads to haemorrhaging and is involved in 
vascular-related disease, including atherosclerosis. The mechanism that regulates vascular 
integrity is complex and requires further definition. Using a microarray screen for 
angiogenesis-associated genes during embryogenesis, we identified Thrombospondin type I 
domain 1 (Thsd1) as a new angiopotent factor with an undefined biological function. Here, 
we investigate the contribution of Thsd1 to vascular integrity. 
Methods and Results - Verification by in situ hybridisation in zebrafish demonstrates that 
Thsd1 is predominantly expressed in endothelial cells (EC). Knockdown of Thsd1 in 
zebrafish embryos and in a murine retina model induced severe haemorrhaging. Vascular 
growth remained unaffected, despite a decline in vascular integrity. Studies in human ECs 
verified the deleterious effect of Thsd1 silencing on endothelial barrier function and 
identified Thsd1 as a new binding partner of the CRT-LRP1 complex. Thsd1 activates 
downstream signalling of LRP1 via FAK-PI3K, leading to Rac1-mediated actin 
cytoskeleton interaction with cell-cell junctions. In human carotid endarteriectomy 
specimens, Thsd1 expression increases in ECs in advanced atherosclerotic lesions with 
intraplaque haemorrhaging compared with stable lesions, implying involvement of Thsd1 in 
neovascular bleeding. In a murine atherosclerosis model, Thsd1 overexpression decreased 
plaque vulnerability by attenuating vascular leakage, while Thsd1 knockdown aggravated 
haemorrhaging, again independent of vascular growth. Pro-atherogenic factors - including 
low oxygen and TNFα - decrease Thsd1 expression, whereas anti-atherogenic IL-10 
increases mRNA expression of protective Thsd1. 
Conclusion - Thsd1 is a crucial regulator of endothelial barrier function during vascular 
development and in the pathobiology of haemorrhaging-prone neovascular growth in 
atherosclerosis. 
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Introduction 
 
The vascular endothelium functions as a selective barrier for protein and fluid exchange 
between the blood stream and the surrounding tissues. The integrity of the vascular 
endothelium is actively controlled by dynamic interaction between the actin cytoskeleton, 
cell-cell junctions and cell-matrix focal adhesions.1 Although physical contacts between 
endothelial cells (EC) are present during the earliest phases of vasculogenesis and 
angiogenesis, a functional vascular barrier is only established after the neovessels have 
undergone critical rearrangements at the molecular level of the actin cytoskeleton and cell-
cell junction sites. This maturation of the endothelial barrier is stringently controlled by 
members of the Rho family of GTPases.2-5 In particular, Rac1 plays a vital role in 
maintaining vascular barrier function: Rac1-mediated adaptation of the actin cytoskeleton 
strengthens the VE-cadherin/actin cytoskeleton bonds, which are crucial for the formation 
of stable endothelial cell-cell junctions.6-9 Disruption of this Rac1 regulatory pathway leads 
to endothelial barrier dysfunction and loss of vascular integrity, and is implicated to be an 
important contributing factor to the onset and progression of vascular-related diseases such 
as diabetic retinopathy and atherosclerosis.1,10 In atherosclerosis, dysfunction of the 
endothelium on top of the fibrous cap triggers extravasation of inflammatory cells that 
contribute to lesion growth. As atherosclerosis progresses, plaques become characterised by 
neovascular growth of vessels which are phenotypically immature, defined by lack of 
endothelial barrier function and increased susceptibility to rupture.11 Although previous 
studies have demonstrated the importance of endothelial barrier function in vascular 
development and disease, our knowledge of the molecular mechanisms that orchestrate the 
basic - Rac1-mediated - principles of regulation remains limited, in particular in the light of 
vascular-related pathologies. In this study, we have identified a new gene with a high level 
of endothelial expression that is a potent regulator of endothelial barrier integrity. 
Recently, we have carried out a genome-wide microarray analysis in search for genes 
involved in the regulation of new vessel formation. Gene expression profiles of isolated 
Flk1-positive angioblasts during murine embryonic development were compared with the 
profiles of Flk1-negative cells. One of the genes that was identified as a new potential 
regulator of vascular development was Thrombospondin type I domain 1 (Thsd1). 
Although Thsd1 was previously described as a marker of haematopoietic stem cells and 
ECs12, the basic biological function of Thsd1 in angiogenesis in vitro and in vivo remains 
fully unknown. 
Here, we sought to characterise the function of Thsd1 in ECs during blood vessel 
formation in vitro using primary cell cultures and in vivo in zebrafish and murine vascular 
development. Our data show that Thsd1 plays an important role in establishing and 
preserving the endothelial barrier function during angiogenesis in vivo, as loss of Thsd1 led 
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to vessel disruption and severe haemorrhaging. Silencing of Thsd1 led to vessel rupture of 
the cranial vasculature in developing zebrafish, whereas extensive haemorrhaging was 
detected during postnatal retinal vascular development in mice. This loss of endothelial 
integrity was unrelated to the angiogenic potential of the ECs, since no difference in 
vascular growth was observed. Further in vitro studies demonstrate that Thsd1 activates the 
calreticulin (CRT) - low density lipoprotein receptor-related protein 1 (LRP1) signalling 
pathway by complex formation with CRT. Loss of this complex interferes with actin 
cytoskeleton modulation - a process shown to be regulated by Rac1 - leading to loss of 
endothelial barrier function by limiting VE-cadherin/actin cytoskeleton interaction. These 
findings points toward an important role for Thsd1 in the basic regulation of vascular 
barrier function. In addition, a strong increase in Thsd1 endothelial expression was 
observed in the neovasculature of advanced human atherosclerotic lesions, suggesting a 
possible Thsd1-mediated feed-back mechanism to counteract loss of vascular integrity of 
intimal neovessels. Evaluation of Thsd1 function in a well-validated flow-based murine 
vulnerable plaque model, clearly demonstrated that siRNA-mediated silencing of 
endogenous Thsd1 further compromised neovascular integrity and worsened intraplaque 
haemorrhaging, whereas overexpression of Thsd1 improved endothelial barrier function 
and significantly reduced vascular bleeding. These in vivo studies identify Thsd1 as a vital 
factor in the formation and conservation of intimal neovessel integrity in advanced 
atherosclerosis. Loss of Thsd1 function results in extensive intraplaque haemorrhaging and 
amplifies the inflamed state of the plaque lesion, leading to a further decline of vulnerable 
plaque stability. Considering the potent vascular stabilising function of the gene, Thsd1 
might be an interesting target for the development of therapeutics in the treatment of 
vascular pathologies in which endothelial barrier function is affected. 
 
 
Methods 
 
A more detailed description of materials and methods is available in the Data Supplement 
(online). Summarised descriptions of the different techniques used in this study are supplied 
below. 
 
This study was carried out in accordance with the Council of Europe Convention 
(ETS123)/Directive (86/609/EEC) for the protection of vertebrate animals used for 
experimental and other scientific purposes and with the approval of the National and Local 
Animal Care Committee. 
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Zebrafish 
Zebrafish (Danio rerio) were maintained under standard laboratory conditions. The 
transgenic zebrafish lines used were Tg(Fli1:eGFP)y1 and Tg(Kdrl:eGFP x Gata1:dsRed)y1. 
 
Whole-mount in situ hybridisation 
As template for in vitro transcription, a Thsd1 cDNA fragment of at least 250 bp was used 
to ensure probe specificity. Antisense RNA probes of Thsd1 were generated by in vitro 
transcription using the digoxigenin RNA Labeling Mix from Roche (Woerden, The 
Netherlands). In situ hybridisation was carried out as previously described.13 
 
o-Dianisidine staining 
Erythrocytes were stained by incubating embryos in a solution containing o-Dianisidine 
(Sigma-Aldrich, Zwijndrecht, The Netherlands) as previously described.13 
 
Mice 
Plugged FVB/N mice (Mus musculus) were ordered at Harlan (Indianapolis, USA). 
C57BL/6.ApoE-knockout mice were obtained from The Jackson Laboratory (Bar Harbor, 
USA). C57BL/6J mice were obtained from laboratory stock. They were maintained under 
standard husbandry conditions. 
 
Mouse model of retinal vascularisation 
Two-day old C57BL/6J mice pups were anesthetised by placement on ice. Thsd1 targeting 
siRNA (si-Thsd1) was injected into the left eye. As a control, scrambled non-targeting 
siRNA (si-sham) was injected into the right eye. Mice pups were killed five days after 
intra-ocular injection. The retinas were stained with Alexa Fluor® 488-conjugated isolectin 
GS-IB4 (Invitrogen, Bleiswijk, The Netherlands) before assessment under a fluorescence 
microscope (Axiovert S100; Carl Zeiss, Sliedrecht, The Netherlands). To rescue the 
phenotype caused by Thsd1 knockdown, another group of two-day old C57BL/6J mice 
pups were treated by intra-ocular injection of si-Thsd1 in both eyes as described, combined 
with or without Rac1 activator (CN02-A, 0.25 U/ml; Cytoskeleton, Denver, USA). 
 
TER-119 staining 
Retinas were incubated with TER-119 antibody (Novus Biologicals, Cambridge, UK) to 
stain erythrocytes. 
 
ApoE-knockout mice vulnerable plaque model 
Ten-week old female ApoE-knockout mice were put on a Western diet containing 15% 
(w/w) cacao and 0.25% (w/w) cholesterol (Arie Blok, Woerden, The Netherlands). Two 
weeks after start of the Western diet, mice were operated and a tapered cast was surgically 
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inserted around the right common carotid artery. Nine weeks after cast placement, mice 
were re-operated and either adenovirus expressing murine Thsd1 (pAd-Thsd1) or si-Thsd1, 
or sham virus (pAd-sham) or si-sham was placed around the right common carotid artery. 
Mice were killed three days after re-operation. One hour before killing, FITC-labelled 
Dextran (Sigma-Aldrich, Zwijndrecht, The Netherlands) was intravenously injected. Next, 
the carotid artery was flushed, taken out, snap frozen in liquid nitrogen, and stored at -80ºC 
until immunohistological staining. 
 
Thsd1 and CD31 expression in human carotid endarterectomy specimens 
Human carotid endarterectomy specimens were collected and processed by the 
Experimental Vascular Pathology group (Maastricht UMC+, The Netherlands). From all 
samples, three randomly taken regions were studied for Thsd1 and CD31 - an endothelial 
cell marker - expression. For every region the Thsd1:CD31 ratio was determined. The 
average of these three regions was used as final Thsd1:CD31 ratio for that sample. All 
samples were stained with antibodies against Thsd1 (Sigma-Aldrich, Zwijndrecht, The 
Netherlands) and CD31 (DakoCytomation, Glostrup, Denmark). An horseradish peroxidase 
(HRP)-labelled secondary antibody in combination with nickel-3,3’-diaminobenzidine (N-
DAB) (Sigma-Aldrich, Zwijndrecht, The Netherlands) was used to visualise the signal. 
 
Cell cultures 
Primary cultures of human umbilical vein endothelial cells (HUVEC) were cultured in 
EBM®-2 medium supplemented with a commercial BulletKit, 10% foetal calf serum (FCS) 
and 1% penicillin/streptomycin (Lonza, Breda, The Netherlands). Primary aorta-derived 
human vascular smooth muscle cells (vSMC) were cultured in SmGM®-2 medium 
supplemented with a commercial BulletKit, 10% FCS and 1% penicillin/streptomycin 
(Lonza, Breda, The Netherlands). HeLa and sarcoma cells were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% FCS (Cambrex, Wiesbaden, 
Germany). Cells were cultured at 37°C in 5% CO2. Passages three to six were used 
throughout the study. 
 
2D matrigel network-formation assay 
To induce network-formation, HUVECs - transfected with si-sham or si-Thsd1 - were 
cultured on a 2D MatrigelTM matrix (BD, Breda, The Netherlands). The tubules were 
stained by Calcein-AM (BD, Breda, The Netherlands) after 24 hours of network-formation. 
Each condition was assessed by fluorescence microscopy (Axiovert S100; Carl Zeiss, 
Sliedrecht, The Netherlands). Image analysis of the number of junctions, tubules and total 
tubule length was carried out using Angiosys Image Analysis Software 1.0 (TCS 
CellWorks, Buckingham, UK). 
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Transwell permeability assay and ECIS measurements 
Endothelial barrier function in vitro was evaluated by culturing HUVECs on porous filters 
and measuring the passage of HRP as previously described.14,15 
For electric cell-substrate impedance sensing (ECIS) measurements, cells were seeded 
on gelatin-coated ECIS arrays, each with 8 wells with 10 gold electrodes per well (Applied 
BioPhysics, Troy, USA). Experiments were carried out following standard protocols as 
previously described.16 
 
Co-immunoprecipitation 
Protein complexes were immunoprecipitated using Dynabeads® magnetic beads from 
Invitrogen (Bleiswijk, The Netherlands) according to the instruction manual and analysed 
using a 12.5% SDS-PAGE gel, followed by immunoblotting using anti-human antibodies 
against Thsd1 (Sigma-Aldrich, Zwijndrecht, The Netherlands), CD36 (Hycult Biotech, 
Uden, The Netherlands), CRT (Thermo Fisher Scientific, Breda, The Netherlands) and 
LRP1 that recognises the heavy chain of the protein (Abcam, Cambridge, UK). 
 
Western blot 
To determine whether knockdown of Thsd1 interfered with cellular processes, Western blot 
analysis was carried out using HUVEC protein lysates. At 72 hours post-transfection, 
HUVECs were serum starved for 4 hours and replenished with EBM®-2 medium 
supplemented with a commercial BulletKit, with or without Rac1 activator (CN02-A, 0.05 
U/ml; Cytoskeleton, Denver, USA) for 30 minutes. Cells were lysed in NP40 Cell Lysis 
Buffer (Invitrogen, Bleiswijk, The Netherlands) and analysed on a 12.5% SDS-PAGE gel, 
followed by immunoblotting using anti-human antibodies against focal adhesion kinase 
(FAK), phosphorylated-FAK (Y397) (FAK-P) (Abcam, Cambridge, UK), 
phosphatidylinositol 3-kinase p85α (PI3K) (Cell Signaling Technology, Leiden, The 
Netherlands), phosphorylated-PI3K p85α (Y508) (PI3K-P) (Santa Cruz Biotechnology, 
Heidelberg, Germany) and Rac1 (Abcam, Cambridge, UK). Beta-actin antibody (Abcam, 
Cambridge, UK) was used as a loading control. Protein bands were visualised by the 
Odyssey® Infrared Imaging System and analysed by Odyssey 3.0 software (LI-COR 
Biotechnology, Cambridge, UK). 
 
Rac1 activation assay 
Rac1 activity was measured using the G-LISA® Rac Activation Assay Biochem KitTM from 
Cytoskeleton (Denver, USA) according to the instruction manual. 
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Statistical analysis 
Data were reported as mean ± standard error of the mean (SEM). Statistical significance 
was evaluated using a Student’s t-test and was accepted at P < 0.05 (* P < 0.05, ** P < 0.01 
in the figures). 
 
 
Results 
 
Vascular specific expression of Thsd1 during mouse and zebrafish development 
To identify new genes involved in angiogenesis, a genome-wide microarray analysis was 
carried out followed by validation of the results by qPCR. Gene expression profiles of Flk1-
positive angioblasts at various stages of murine embryonic development were compared 
with the profiles of Flk1-negative cells. Thsd1 was upregulated in Flk1-positive angioblasts 
from 8 to 16 days post-fertilisation (dpf). Expression levels were highest upregulated 
around 8 to 11 dpf, which coincides with the period of early angiogenesis in murine 
development and suggests a potential role of Thsd1 in blood vessel formation (Figure 1A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Vascular specific expression of Thsd1 during mouse and zebrafish development. (A) Endogenous 
expression level of Thsd1 in Flk1-positive angioblasts during murine embryonic development from 8 to 16 days 
post-fertilisation (dpf) compared with Flk1-negative cells as analysed by qPCR. The expression level of Thsd1 in 
Flk1-negative cells was arbitrarily set to one (n = 4; mean ± SEM). The highest upregulation was detected around 
day 8 to 11, which coincides with the period of early angiogenesis in murine development. 
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Further evidence of a vascular-related expression profile for Thsd1 was provided by 
examining the gene in developing zebrafish larvae by whole-mount in situ hybridisation: 
expression of the Thsd1 zebrafish orthologue was detected in the main axial vessels - dorsal 
aorta and posterior cardinal vein - and head vessels at 26 hours post-fertilisation (hpf). In 
addition, Thsd1 expression was also detected in the caudal and midcerebral veins (MCeV), 
and in the somites (Figure 1B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(B) Whole-mount in situ hybridisation comparison of endothelial specific Kdrl (upper panel) with Thsd1 (lower 
panel) in zebrafish at 26 hours post-fertilisation (hpf), lateral view, anterior is to the left. Like Kdrl, Thsd1 
transcripts were localised in the developing vascular network, including the main axial vessels - dorsal aorta and 
posterior cardinal vein - and cerebral vasculature (black arrow), as well as in the caudal and midcerebral veins 
(MCeV). In addition, expression of Thsd1 in the somites was observed. Right hand panel shows high 
magnification images of the head region. 
 
 
Knockdown of Thsd1 in zebrafish induces haemorrhaging of cerebral vessels 
For functional evaluation of Thsd1 in vivo, the gene was silenced in developing zebrafish 
larvae of the transgenic zebrafish lines Tg(Fli1:eGFP)y1 and Tg(Kdrl:eGFP x 
Gata1:dsRed)y1, using morpholino (MO)-knockdown technology. Adequate targeting of 
Thsd1 was verified by qPCR analysis (Supplemental figure 1, online). Silencing of Thsd1 
had no effect on vascular growth, and macroscopic evaluation showed no obvious defects 
in the general vasculature (Figure 1C). However, time-lapse studies carried out during the 
first 48 hpf identified severe and frequent haemorrhaging in the cranial region - a known 
predilection site for vascular haemorrhaging in zebrafish13, 17-21 - that was observed in 24% 
of the injected embryos (n = 195). Haemorrhaging occurred as a sudden rupture of blood 
vessels, implying intrinsic weakness and lack of integrity of the neovascular barrier (Figure 
1D, E). Cerebral haemorrhaging was further confirmed by an o-Dianisidine staining of 
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iron/haem in red blood cells in Thsd1-silenced wild-type zebrafish. Thsd1 silencing 
resulted in large areas of accumulated blood in the head of the zebrafish larvae compared 
with uninjected controls (Figure 1F). This phenotype was consistently observed in the 
Thsd1-silenced zebrafish after injections of different MO concentrations (Figure 1G). 
 
Morpholino-induced knockdown of Thsd1 in zebrafish results in acute cerebral haemorrhages without 
affecting vascular growth. (C) Tg(Fli1:eGFP)y1 embryos at 26 hpf, lateral view, anterior is to the left. No 
apparent morphological abnormalities in the trunk or cerebral vasculature were observed between the Thsd1 
targeting morpholino-injected (Thsd1-KD) embryos and the uninjected control (UIC) embryos. Right hand panel 
shows high magnification images of intersegmental outgrowth in the trunk region. (D, E) Tg(Kdrl:eGFP x 
Gata1:dsRed)y1 Thsd1-KD embryos around (D) 28 hpf and (E) 2 dpf, lateral view, anterior is to the left. 
Endothelial cells (Kdrl:eGFP-positive, green) and erythrocytes (Gata1:dsRed-positive, red). Right hand panel 
shows high magnification images of the head region. Extensive and frequent haemorrhages were detected in the 
head region (white arrow). 
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(F) o-Dianisidine stained embryos around 26-28 hpf, top view (left) lateral view (right), anterior is to the left. 
Areas of accumulated blood (red asterisk) in the head region were observed in Thsd1-KD embryos. (G) 
Morpholino dose-response increase in the percentage of zebrafish with the cerebral haemorrhage phenotype (red 
bar) compared with the wild-type phenotype (no cerebral haemorrhaging, blue bar). 
 
 
Thsd1 knockdown in the developing retinal vasculature of neonatal mice promotes 
vascular haemorrhages 
To further validate the findings in the zebrafish, Thsd1 function was studied during the 
development of the retinal vasculature of neonatal mice. To determine the optimal moment 
of Thsd1 knockdown, Thsd1 mRNA expression in the murine retina was evaluated during 
postnatal development by qPCR analysis. Thsd1 mRNA levels were adjusted to CD31 
mRNA levels to compensate for changes in percentage of ECs. High expression levels of 
Thsd1 were observed from 3 to 9 days post-partum, which corresponds with the period of 
plexus formation and vascular remodelling (Figure 2A). Based on these findings, Thsd1 
knockdown was induced in the first week of retinal vascular development by intra-ocular 
injection of a siRNA pool composed of four different Thsd1 targeting siRNA sequences in 
two-day old wild-type C57BL/6J mouse pups and compared with controls injected with a 
scrambled non-targeting siRNA pool. Efficient knockdown of Thsd1 was observed two 
days after intra-ocular injection (Supplemental figure 2, online). Assessment and 
quantification of the number of vascular branches, the total number of vessels and the total 
tubule length after visualisation of the vasculature by isolectin GS-IB4 staining, showed no 
difference between si-Thsd1 and si-sham injected eyes five days after intra-ocular injection 
(Figure 2B-E, whole retina image provided in Supplemental figure 3A, online). 
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Figure 2. Thsd1 depletion during murine retinal vascular development results in vascular haemorrhaging 
without affecting vascular growth. (A) Endogenous expression level of Thsd1 in the developing retinal 
vasculature of neonatal mice from 3 to 15 days after birth compared with CD31 expression in the retina (n = 3; 
mean ± SEM). Thsd1 is highly expressed from day 3 to 9, which coincides with the period of plexus formation and 
remodelling. (B) Retinas stained with isolectin GS-IB4. Left hand image shows black and white micrograph, right 
hand image shows the inverse image. (C-E) Quantification by means of the dimensions of the vascular network 
showed no morphological defects after Thsd1 knockdown (Thsd1-KD): (C) number of junctions, (D) number of 
tubules and (E) total tubule length. 
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However, double-staining of retinas with isolectin GS-IB4 (ECs, green) and TER-119 
antibody (erythrocytes, red) showed a significant higher frequency of haemorrhaging and 
larger areas of bleeding in the si-Thsd1 injected eyes, whereas retinal haemorrhaging was 
hardly observed in si-sham injected controls (Figure 2F, G, whole retina image provided in 
Supplemental figure 3B, online). Thus, like in the developing zebrafish, loss of Thsd1 
expression had no effect on vascular growth, but had resulted in a vasculature highly 
susceptible to vascular haemorrhaging. Combined, these data has identified a role for Thsd1 
in establishing vascular integrity during blood vessel development. 
 
In contrast, double-staining of retinas with isolectin GS-IB4 (endothelial cells, green) and TER-119 (erythrocytes, 
red) demonstrated severe and frequent vascular haemorrhaging in the Thsd1-KD group: (F) Thsd1-KD induced 
significantly larger areas of extravascular TER-119 erythrocytes accumulation. Upper panel shows low 
magnification and lower panel shows high magnification micrographs. (G) Quantification of retinal haemorrhage 
with the bleeding area expressed as percentage of the total retinal area showed a 600% increase in Thsd1-KD 
versus sham retinas (n = 10; mean ± SEM). 
 
 
Thsd1 controls endothelial barrier function in vitro 
To clarify the molecular mechanism underlying the impaired endothelial integrity, we 
moved to in vitro assays to define Thsd1 function in vascular cells. The expression level of 
Thsd1 was evaluated in different cell types. On comparing HUVECs, vSMCs, HeLa and 
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sarcoma cells, the highest mRNA expression level of Thsd1 was observed in HUVECs 
(Figure 3A). In line with previous in vivo findings, siRNA-mediated knockdown of Thsd1 
in HUVECs did not affect network-formation in a standard 2D matrigel network-formation 
assay (as indicated by the number of junctions, capillary tubules or total tubule length) 
when compared with cultures transfected with equimolar of si-sham or untransfected 
controls (Figure 3B-E). Adequate knockdown of the target gene was validated on both 
mRNA and protein level, and did not affect the expression of the family member 
Thrombospondin 1 (Supplemental figure 4A-C, online). 
 
 
Figure 3. Thsd1 knockdown in cultured endothelial cells impairs endothelial integrity. (A) Thsd1 was highly 
expressed in HUVEC compared with vSMC, HeLa and sarcoma cells, as demonstrated by qPCR analysis. (B) 
Assessment of network-formation capacity for Thsd1-silenced ECs (Thsd1-KD) in a 2D matrigel experiment. 
Tubules were stained by Calcein-AM uptake. (C-E) Quantification of the vascular network showed no 
morphological changes in Thsd1-KD HUVECs: (C) number of junctions, (D) number of tubules and (E) total 
tubule length (n = 3; mean ± SEM). 
 
 
A Transwell permeability assay - measuring HRP passage - was carried out to 
determine the effect of Thsd1 on the endothelial barrier function in HUVECs. Like the in 
vivo findings, endothelial barrier function was significantly decreased in Thsd1-depleted 
HUVECs as suggested by increased permeability for HRP (Figure 3F). Further evaluation 
of endothelial barrier function by ECIS measurements showed that Thsd1 silencing in 
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HUVEC monolayers severely impeded the build-up of endothelial electric resistance 
compared with sham treated groups, thus verifying a decline in effective cell junction 
formation (Figure 3G). 
 
 
 
 
 
 
 
 
 
 
 
 
(F) Measurement of endothelial barrier function in vitro. Passage of horseradish peroxidase (HRP) over a 
confluent monolayer of HUVECs during thrombin (1 U/ml) stimulation for the different conditions showed 
significant increased HRP permeability after Thsd1 silencing (n = 3; mean ± SEM). (G) ECIS measurement of 
sham or Thsd1-KD HUVEC monolayers showed a delay in electric resistance build-up as a result of Thsd1 
inhibition (n = 3; mean ± SEM). 
 
 
Thsd1 mediates cell-cell interaction via CRT-LRP1 downstream signalling regulation 
of Rac1 
Previous reports indicated that Thrombospondin 1 mediates EC apoptosis via CD36 
binding and signalling.22-24 To evaluate if Thsd1, like its family member, may mediate 
vascular barrier function via this apoptosis pathway, co-immunoprecipitation analysis was 
carried out to identify the binding partners of Thsd1. No binding between Thsd1 and CD36 
was detected in HUVECs (Supplemental figure 5A, online). In addition, no effect was 
observed on early or late apoptosis in si-Thsd1 transfected cells compared with si-sham 
transfected and untransfected controls (Supplemental figure 5B-D, online). Thus, these data 
indicate that Thsd1 operates via a separate, CD36-independent pathway. 
Based on the homology in protein domains between Thsd1 and Thrombospondin 1, the 
CRT-LRP1 complex may provide a potential binding target for Thsd1. Co-
immunoprecipitation analysis confirmed that Thsd1 and CRT could indeed form a protein 
complex. Likewise, CRT binding to LRP1 was verified (Figure 4A, B, additional controls 
in Supplemental figure 6, online). In addition, separation of the cytosolic and cell-
membrane fraction demonstrated that Thsd1 was present in both compartments (Figure 
4D). Co-immunoprecipitation analysis of the different fractions clearly showed that cell-
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membrane bound Thsd1 could directly bind to CRT located in the same compartment, 
although Thsd1 binding to CRT in the cytosol also takes place (Figure 4D). 
 
 
Figure 4. Thsd1 binds the CRT-LRP1 complex and induces actin cytoskeleton modulation via Rac1 
activation. (A) Immunoprecipitation of Thsd1 in HUVECs showed an effective pull down of Thsd1 (upper panel) 
and co-immunoprecipitation of CRT (lower panel). Immunoprecipitation using a mouse IgG isotype control 
showed no effective pull down of Thsd1 or CRT. (B) Immunoprecipitation of CRT in HUVECs showed an 
effective pull down of CRT (upper panel) and co-immunoprecipitation of LRP1 (lower panel). 
Immunoprecipitation using a mouse IgG isotype control showed no effective pull down of CRT or LRP1. (C) 
Western blot analysis of Thsd1 level in HUVECs transfected with Thsd1 targeting siRNA (Thsd1-KD) or 
HUVECs infected with an adenovirus expressing human Thsd1 (Thsd1-OE). (D) Co-immunoprecipitation of 
Thsd1 using IgG capture antibody directed against Thsd1 compared with IgG isotype control on the isolation 
beads in the membrane and cytosol fraction showed that Thsd1 binding to CRT takes place in the cell membrane 
fraction and cytosol fraction (shown are representative results of n = 2). 
 
 
Western blot analysis further demonstrated that the downstream signalling cascade of CRT-
LRP1 was regulated by Thsd1 (Figure 4C-K): knockdown of Thsd1 (Figure 4C, Thsd1 
overexpression validation is shown in Supplemental figure 3D, E, online) decreased signal 
transduction via FAK by downregulation of FAK protein and FAK phosphorylation (Figure 
4E, H), while PI3K phosphorylation was diminished (Figure 4F, I). Further downstream, 
Thsd1 silencing inhibited PI3K-mediated Rac1 activation, demonstrated by a decline in 
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Rac1-GTP levels, while total Rac1 protein levels remained unaffected (Figure 4G, J). These 
findings are further strengthened by the effect of Thsd1 overexpression: HUVECs infected 
with an adenovirus expressing human Thsd1, showed opposite effects with increased FAK 
phosphorylation and Rac1 activation compared with sham virus treated controls (Figure 
4C-K). A LRP1 blocking study with RAP (Receptor Associated Protein) was carried out to 
verify direct Thsd1 involvement in CRT-LPR1 signalling. Indeed, RAP treatment blocked 
Rac1 activation in Thsd1 overexpressing HUVECs, indicating that LRP1 activation via 
Thsd1-CRT complex formation is relevant for Thsd1 signalling via Rac1 (Figure 4L). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(E-K) Western blot analysis of CRT-LRP1 downstream targets in Thsd1-KD or Thsd1-OE conditions: Thsd1-KD 
downregulated (E) FAK, (H) FAK-P and (I) PI3K-P, whereas (F) PI3K and (G) Rac1 were not affected. Thsd1-
OE enhanced (H) FAK-P and (G) Rac1, whereas (E) FAK, (F) PI3K and (I) PI3K-P remained unaffected. (J) 
Thsd1-KD in HUVECs showed a decline in Rac1-GTP levels measured by GEF-assays, while Thsd1-OE resulted 
in an increase in Rac1-GTP levels. (L) Pre-incubation with 50 µg/ml RAP (Receptor Associated Protein) before 
Rac1 activation with high serum medium limited the effect of Thsd1-OE on Rac1 activation (n = 4; mean ± SEM). 
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Rac1 is an important mediator of endothelial barrier function as it enforces cell-cell 
and cell-matrix interaction via regulation of the actin cytoskeleton.7-9 To study the Rac1-
mediated function of Thsd1 in actin dynamics, si-Thsd1, si-sham and control ECs were 
evaluated in an adhesion assay in which cells were seeded on a collagen-coated surface. 
Cell spreading and actin filaments distribution was evaluated at different time points after 
cell seeding (Figure 4M, Supplemental figure 7A, online). Quantification and stratification 
of cell size showed that Thsd1 knockdown induced a trend towards a decrease in the 
number of large cells (>1500 nm2) compared with si-sham transfected controls (Figure 4N). 
 
 
Rac1 activity affects actin cytoskeleton dynamics during cell spreading. Actin mobility was assessed in a cell 
spreading assay. (M) 30 minutes after cell seeding, Thsd1-KD showed a delay in actin cytoskeleton spreading 
compared with scrambled non-targeting siRNA (sham) transfected and untransfected controls (contr). F-actin 
fibres (red) and nuclei (blue). (N) Quantification of the cell/actin surface area showed a decrease in the number of 
large cells (>1500 nm2) in Thsd1-KD HUVECs (KD) compared with scrambled non-targeting siRNA (sh) 
transfected and untransfected controls (co) (n = 3; mean ± SEM). 
 
 
This decline in cell size and thus spreading efficiency was associated with a defect in cell-
extracellular matrix interaction: paxillin and vinculin visualisation of focal adhesion sites 
showed a significant decline of focal adhesion capping at stress fibre ends in Thsd1-
silenced cells compared with control conditions at different time points after cell seeding 
(Supplemental figure 7B, online). Loss of association between VE-cadherin and the actin 
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cytoskeleton at cell-cell junction sites promotes endothelial and vascular permeability.6 
Therefore, the effect of Thsd1 knockdown was assessed on VE-cadherin/actin cytoskeleton 
association in a confluent HUVEC monolayer. Knockdown of Thsd1 in HUVECs reduced 
co-localisation of VE-cadherin with the actin cytoskeleton compared with sham transfected 
and untransfected controls (Figure 4O). Taken together, these data indicate that Thsd1 
modulates cell-cell interaction via a signalling mechanism that involves CRT-LRP1, FAK, 
PI3K and Rac1-mediated regulation of the endothelial actin cytoskeleton. 
 
 
(O) Thsd1-KD reduced co-localisation of VE-cadherin with the actin cytoskeleton at the cell-cell junctions, as 
demonstrated by intracellular immunofluorescent staining. VE-cadherin (green), F-actin (red), co-localised area 
(yellow) and nuclei (blue). Quantification of the percentage of actin filaments that are co-localised with VE-
cadherin are shown in the lower graph (n = 3; mean ± SEM). 
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Rac1 activation prevents loss of endothelial barrier function induced by Thsd1 
knockdown 
Our experiments points toward a Rac1-mediated loss of endothelial integrity in response to 
Thsd1 silencing. To validate whether this Thsd1-induced modulation of Rac1 activity is 
crucial for this process, si-Thsd1 transfected HUVECs were treated with a pharmaceutical 
activator for Rac1 in the Transwell permeability assay in vitro. Rac1 stimulation rescued 
endothelial permeability after Thsd1 knockdown (Figure 4P), thus confirming that Thsd1-
induced loss of endothelial permeability in cultured cells was indeed mediated via Rac1 
inhibition. To further validate these in vitro findings, a phenotype rescue experiment was 
carried out in the murine retina model: Thsd1 was silenced in combination with treatment 
with the Rac1 activator and compared with controls that had been treated with intra-ocular 
injection of si-Thsd1 only. In line with our in vitro findings, Rac1 activation reversed the 
effects of Thsd1 silencing with a significant reduction in the extend of vascular 
haemorrhaging (Figure 4Q). Combined, these data provide evidence that Thsd1 regulates 
endothelial permeability via Rac1 activation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rac1 stimulation rescues impaired endothelial integrity in Thsd1-depleted cells. (P) Measurement of 
endothelial barrier function in vitro. Differences in HRP passage in Rac1-stimulated HUVEC monolayers 
compared with no Rac1 activation after 120 minutes of HRP passage are shown. Control, sham and Thsd1-KD 
conditions without Rac1 activation were set to zero. Graphs indicate changes in HRP passage in response to Rac1 
activation in the different groups (n = 3; mean ± SEM). (Q) Representative pictures of double-stained retinas with 
isolectin GS-IB4 (endothelial cells, green) and TER-119 (erythrocytes, red). Rac1 stimulation reduced area size of 
extravascular TER-119 erythrocytes accumulation (dotted area marked by an asterisk) after Thsd1-KD (n = 5). 
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Thsd1 correlates with neovascular intraplaque haemorrhaging and increased plaque 
vulnerability 
Intimal neovascular growth of highly permeable vessels with compromised vascular 
integrity is an important contributor to atherosclerotic lesion progression and plaque 
destabilisation. Previous reports demonstrated an association between changes in 
expression levels of VE-cadherin and loss of endothelial cell-cell contacts in plaque 
neovessels with intimal extravasation of blood-derived cells25, while increased Rac1 
activation was correlated to lesion advancement26, suggesting an involvement of these 
molecular regulators of cell-cell barrier function. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Thsd1 correlates with neovascular intraplaque haemorrhaging and increased plaque 
vulnerability. Representative sections of carotid endarteriectomy specimens stained for (A) CD31 and (B) Thsd1. 
Specimens were divided in stable plaque (upper row) and advanced vulnerable plaque lesions with intraplaque 
haemorrhage (lower row). (C) Quantification of CD31 expression in stable plaque (stable) and vulnerable plaque 
(vul) with intraplaque haemorrhage. No significant difference in CD31 expression between the two groups was 
observed. (D) Quantification of Thsd1:CD31 ratio in stable plaque and vulnerable plaque with intraplaque 
haemorrhage. Thsd1:CD31 ratio was significantly increased in vulnerable plaque specimens with intraplaque 
haemorrhage (n = 5; mean ± SEM). 
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Next, we investigated the possible role of Thsd1 in the pathobiology of the compromised 
neovasculature in advanced atherosclerotic lesions. A correlation study was carried out in 
human atherosclerotic plaques that were obtained from patients with symptomatic carotid 
artery disease. Plaques were divided into stable plaques and advanced plaques vulnerable to 
rupture with pathological evidence of intraplaque haemorrhage. Thsd1 and CD31 
expression was determined by immunohistological staining (Figure 5A, B). The ratio of 
CD31-positive ECs expressing Thsd1 was significantly increased in vulnerable plaques 
with intraplaque haemorrhage compared with stable plaques, 0.34 ± 0.04% versus 0.20 ± 
0.03% of the total intimal area (Figure 5D). This was independent of the degree of 
vascularisation, as there was no difference in CD31 expression between stable plaques and 
vulnerable plaques with intraplaque haemorrhage, 4.8 ± 1.1% versus 4.4 ± 0.9% of the total 
intimal area (Figure 5C). These results points toward a possible role for Thsd1 in 
endothelial barrier dysfunction in advanced atherosclerotic lesions that are vulnerable to 
rupture. 
 
Thsd1 attenuates intraplaque haemorrhage and plaque destabilisation without 
affecting neovascular growth 
Our previous in vivo and in vitro findings indicate that Thsd1 is a beneficial factor for 
maintaining endothelial barrier function. Here, we hypothesised that Thsd1 overexpression 
may reduce vascular bleeding in vulnerable plaque. The effect of Thsd1 overexpression was 
assessed in our ApoE-knockout mice vulnerable plaque model. Peri-adventitial infection of 
an adenovirus expressing murine Thsd1 in the carotid artery resulted in a significant 
increase in Thsd1 mRNA expression compared with infection with a sham virus 
(Supplemental figure 8, online). Endogenous Thsd1 expression in the carotid arteries of 
non-treated ApoE-knockout mice was significantly increased in response to 1 week of 
feeding of a high cholesterol, high fat diet (Supplemental figure 8, online). Overexpression 
of Thsd1 induced clear attenuation of the plaque phenotype at 9 weeks after flow-alteration 
and atherosclerosis induction, indicated by a significant 75% decrease in neovascular 
leakage, as measured by Dextran-FITC extravasation in pAd-Thsd1 treated murine carotid 
arteries compared with pAd-sham treated controls (Figure 6A, B). This observation was 
also validated by TER-119 immunohistological staining of perivascular accumulation of 
erythrocytes (Figure 6A, C). A reduction in vascular leakage was also detected in the 
plaque adventitial area, where Thsd1 reduced Dextran-FITC leakage with 75% as observed 
by whole-mount visualisation by confocal microscopy (Figure 6D). These effects were 
independent of intimal neovascular growth, as no changes in numbers of CD31-positive 
cells were observed (Figure 6E, F). Coincided with improved neovascular integrity, a 40% 
reduction in intraplaque macrophages accumulation in the Thsd1 overexpression group was 
observed (Figure 6G, H), whereas intraplaque lipid accumulation remained unaffected 
(Figure 6I, J). This reduction in percentage of intraplaque macrophages did not affect lesion 
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size as measured by intima:media ratio (Figure 6K, L). However, necrotic core area was 
significantly decreased (Figure 6M). Together, these data clearly demonstrate that Thsd1 
overexpression is capable to restore compromised endothelial barrier function in vulnerable 
plaque. 
 
 
Figure 6. Overexpression of Thsd1 attenuates intraplaque haemorrhaging and stabilises plaque phenotype 
in an ApoE-knockout mice vulnerable plaque model. (A) Representative sections of pAd-sham and pAd-Thsd1 
treated advanced murine lesions stained for TER-119. Quantification of (B) the percentage Dextran-FITC-positive 
area and (C) the percentage TER-119-positive area. (D) Whole-mount immunostaining of the adventitial 
vasculature with isolectin GS-IB4 (endothelial cells, red) with detection of Dextran-FITC perivascular leakage 
(green, indicated by arrows) in the upstream (atherosclerotic) carotid region from the flow device. Dotted lines 
indicate vessel boundaries (n = 6). (E) Representative sections of pAd-sham and pAd-Thsd1 treated advanced 
murine lesions stained for CD31. (F) Quantification of the percentage CD31-positive area. 
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(G) Representative sections of pAd-sham and pAd-Thsd1 treated advanced murine lesions stained for CD68. (H) 
Quantification of the percentage CD68-positive area. (I) Representative sections of pAd-sham and pAd-Thsd1 
treated advanced murine lesions stained for lipids. (J) Quantification of the percentage Oilred O-positive area. (K) 
Representative haematoxylin and eosin staining of pAd-sham and pAd-Thsd1 treated advanced murine lesions. (L) 
Quantification of the intima:media (I:M) ratio and (M) the percentage necrotic core area. For all micrographs, 
lumen areas are indicated by dotted lines (white) marked by an asterisk. Necrotic core areas are indicated by dotted 
lines in blue. For A, E and G: elastin fibres (green), DAPI (blue), Ter119, CD31 and CD68 (red) (n = 10; mean ± 
SEM). 
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siRNA-mediated silencing of Thsd1 aggravates vascular leakage in murine vulnerable 
plaque 
The protective function of Thsd1 in the vasculature of vulnerable plaque is also validated 
by a Thsd1 knockdown experiment in the same ApoE-knockout mice vulnerable plaque 
model: Thsd1 knockdown of the atherosclerotic carotid arteries was achieved by siRNA-
mediated silencing as shown by qPCR analysis (Supplemental figure 8, online). In line with 
previous results, Thsd1 knockdown in the ApoE-knockout mice vulnerable plaque model 
severely aggravated vascular leakage, shown by a 2000% increase in Dextran-FITC 
perivascular leakage (Figure 7A, B) and a 500% increase in intimal extravascular 
accumulation of TER-119-positive erythrocytes (Figure 7C). Like in the Thsd1 
overexpression condition, no effect of Thsd1 knockdown on intimal neovascular growth 
was observed, as no difference in CD31-positive cells was detected (Figure 7D, E). 
However, Thsd1 knockdown did not affect intraplaque macrophage or lipid accumulation 
(Figure 7F, G). Lesion and necrotic core size also remained unaffected (Figure 7H, I). 
 
Figure 7. Thsd1 knockdown severely aggravates intraplaque haemorrhaging in murine vulnerable plaque. 
(A) Representative sections of si-sham and si-Thsd1 treated advanced murine lesions stained for TER-119. (B) 
Quantification of the percentage Dextran-FITC-positive area and (C) the percentage TER-119-positive area. (D) 
Representative sections of si-sham and si-Thsd1 treated advanced murine lesions stained for CD31. (E) 
Quantification of the percentage CD31-positive area. 
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Quantification of (F) the percentage CD68-positive area and (G) the percentage Oilred O-positive area. (H) 
Representative haematoxylin and eosin staining of si-sham and si-Thsd1 treated advanced murine lesions. (I) 
Quantification of the intima:media (I:M) ratio. For all micrographs, lumen areas are indicated by dotted lines 
(white) marked by an asterisk. Necrotic core areas are indicated by dotted lines in blue. For A and D: elastin fibres 
(green), DAPI (blue), TER-119 and CD31 (red) (n = 10; mean ± SEM). 
 
 
Pro-atherogenic and anti-atherogenic stimuli determine Thsd1 mRNA expression in 
HUVECs 
Combined, the results of our ApoE-knockout mice vulnerable plaque model clearly 
demonstrate that Thsd1 attenuates vascular haemorrhaging and plaque destabilisation by 
enhancing intimal neovascular integrity. To further characterise the influence of 
atherogenic triggers on Thsd1 expression in atherosclerosis, we assessed the effect of two 
well-known pro-atherogenic stimuli - low oxygen and the pro-inflammatory cytokine TNFα 
- and one anti-atherogenic stimulus - the anti-inflammatory cytokine IL-10 - on Thsd1 
expression in HUVECs. 
HUVECs were exposed to low oxygen (3% O2) conditions for 4 days and compared 
with normal oxygen (20% O2) cultures. From day 1, a steady decrease in Thsd1 mRNA 
level was observed compared with normal oxygen controls. On day 3 and 4, Thsd1 mRNA 
expression was significantly decreased in HUVECs exposed to low oxygen (Figure 7J). 
Likewise, stimulation with different concentrations of the pro-atherogenic cytokine TNFα 
also decreased Thsd1 mRNA expression in HUVECs (Figure 7K). 
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In contrast, the anti-atherogenic cytokine IL-10 triggered a rise in Thsd1 mRNA expression 
(Figure 7L). Thus, the anti-atherogenic and pro-atherogenic factors that are abundant in the 
micro-environment of advanced atherosclerotic lesions determine the expression level of 
cell-cell barrier function protective Thsd1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pro-atherogenic and anti-atherogenic stimuli determine Thsd1 mRNA expression. Response of endogenous 
Thsd1 mRNA expression levels in HUVECs to pro-atherogenic stimuli, including: (J) low (3% O2) and normal 
(20% O2) oxygen conditions over time, and (K) different concentrations of TNFα. Response of endogenous Thsd1 
mRNA expression levels in HUVECs to an anti-atherogenic stimulus, concerning: (L) IL-10. Thsd1 mRNA 
expression in endothelial cells was diminished by pro-atherogenic stimuli, while an anti-atherogenic stimulus 
increased Thsd1 mRNA expression (n = 4; mean ± SEM). 
 
 
 
Discussion 
 
In this study we identified Thsd1 as a potent angiogenic regulator during embryonic and 
postnatal vascular development. We showed that Thsd1 was upregulated in the developing 
murine embryo in Flk1-positive angioblasts compared with Flk1-negative cells, while 
whole-mount in situ hybridisation in developing zebrafish larvae validated the predominant 
vascular expression of Thsd1. The thrombospondin type I domain (TSP1) in the Thsd1 
protein shares a high homology (98%) with the TSP1 domain of Thrombospondin 1, a gene 
known for its anti-angiogenic properties.23,27 Reports indicate that upregulation of the 
zebrafish Thrombospondin 1 orthologue by mRNA injection of Eleven-Nineteen Lysine-
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rich Leukaemia (ELL) - a transcription factor of Thrombospondin 1 - resulted in multiple 
vascular haemorrhaging.28 Unlike Thrombospondin 1, the basic function of Thsd1 in 
vascular development was until now, still largely unknown. Based on the specific 
expression of Thsd1 in the EC subset, we hypothesised that Thsd1 may play a functional 
role in angiogenesis. Indeed, knockdown of Thsd1 in the developing zebrafish with MO 
injections resulted in frequent and severe haemorrhaging in the head region. 
Coinciding with this finding, the cranial region was also the location of high Thsd1 
expression in the cerebral vasculature during early development. In addition, multiple 
previous studies have suggested that the cranial vasculature may be a predilection site for 
vascular rupture in the zebrafish model.13,17,21 Several zebrafish mutants have been 
identified that display a very similar vascular haemorrhaging phenotype, including heg1, 
ccm1, ccm2 and ccm3.17,29,30 Like Thsd1, these genes appear to be involved directly or 
indirectly in Rac1 activation and RhoA degradation.31 Little is known about the 
biochemical and physical properties of Thsd1. Previously, it has been demonstrated that the 
Thsd1 gene is located between FLJ11712 and C13orf9 within 13q14.3 and has three 
transcripts (splice variants) of which isoform 1 and 2 are single-pass type I membrane 
proteins, while isoform 3 is secreted extracellular into the blood plasma. Thsd1 is a 
glycoprotein of 852 amino acids (94,584 Da) synthesised by many cells and contains a 
TSP1 domain, which has been found in a number of proteins involved in the complement 
pathway, as well as in extracellular matrix proteins.32-34 
Our studies indicate that whereas the vascular integrity seemed to be affected by Thsd1 
silencing, the vascular cerebral network appeared to remain intact. This distinct phenotype 
was once again observed when Thsd1 was silenced in a murine retina model for 
angiogenesis35, in which Thsd1 knockdown with siRNA resulted in vascular haemorrhages, 
independent of changes in vascular macrostructures such as outgrowth of the vasculature 
towards the border and total number of vessels. To obtain more insight in the molecular 
mechanisms by which Thsd1 affect vascular integrity without affecting vascular growth, we 
studied the function of Thsd1 in HUVEC in a number of in vitro assays. Cultured 
monolayers of Thsd1-silenced HUVECs reacted in line with the observed phenotype in 
vivo, demonstrating that cell-cell barrier function was diminished in a Transwell 
permeability assay. On the other hand, network-formation remained unaffected as shown by 
a 2D matrigel network-formation assay. Further evaluation of the binding partners and 
downstream pathways of Thsd1 identified CRT of the CRT-LRP1 complex as a direct 
downstream effector of Thsd1, and clarified that Thsd1 modulates cell-cell barrier function 
via a Rac1-actin cytoskeleton-mediated pathway in which FAK-PI3K signalling is 
involved. It has to be noted that LRP1 immunoblotting of Thsd1 pull down lysates shows 
only a very weak LRP1 band (data not shown), as LRP1 can be detected as a clear band in 
CRT pull down samples. These findings imply that LRP1 is not directly associated to 
Thsd1, but forms a complex with Thsd1 via the intermediate adaptor function of CRT. 
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Rac1 activity is crucial for the process of cell spreading, as it decreases cell 
contractility via actomyosin suppression and counteracts RhoA-induced actin stress fibre 
formation.35 In addition, activation of Rac1 has been reported to preserve cell-cell junction 
formation and thereby endothelial barrier function.36,37 Here, our data clearly show that 
Thsd1 is involved in Rac1 activation and that Thsd1 knockdown diminished adaptation of 
the actin cytoskeleton of ECs during cell adhesion. 
It was previously reported that cells with impaired interaction between the actin 
cytoskeleton and cell-cell junction sites were able to proceed through the early phase of in 
vitro network-formation, while in the later phases of angiogenesis increased rigidity of the 
actin cytoskeleton resulted in loss of endothelial barrier function.38 In the later phase of 
vascular development, the maturation of newly formed vessels in response to biological and 
biomechanical cues - such as pericyte stimulation and blood flow - are characterised by the 
transition of ‘pro-angiogenic’ ECs into the quiescent phalanx cell phenotype. Acquisition of 
this phalanx cell phenotype includes strengthening of the cell-cell junctions mediated by 
VE-cadherin, and involves modulation in junction complex assembly, restriction of 
VEGFR-2 signalling and actin cytoskeleton reorganisation.39 In the light of the findings 
reported in this study, Thsd1 silencing may therefore compromise vascular integrity by 
inhibiting Rac1 modulation of the actin cytoskeleton in late angiogenesis during this 
transition into the quiescent phalanx cell phase. Indeed, qPCR evaluation of co-cultures of 
HUVECs with human brain-derived pericytes in a duo-chamber system that enables direct 
reciprocal contact, showed that Thsd1 expression was significantly induced by pericyte 
stimulation (preliminary data, not shown). However, further evaluation of typical neovessel 
stabilising or mural cell - pericytes or vSMCs - recruitment factors, including Ang1 and 2, 
Tie2, PDGF-β, PDGFR-2, VEGF-A and VEGFR-2, showed no changes in response to 
Thsd1 silencing (preliminary data, now shown). Additional studies are needed to clarify the 
potential role of Thsd1 in neovessel stabilisation. Rac1 activation is regulated by FAK.40 
Previously, it has been demonstrated that Thrombospondin 1 binds to CRT, leading to 
stabilisation of the CRT-LRP1 complex at the cell surface resulting in downstream 
activation of FAK.41 As Thsd1 shares a similar domain with Thrombospondin 1, we 
hypothesised that Thsd1 could likewise bind to CRT. Our data confirmed complex 
formation of Thsd1 and CRT. In addition, the downstream activation of the CRT-
LRP1/FAK signalling cascade was verified in vitro and in vivo. We further demonstrated 
that PI3K activation, downstream of FAK, was inhibited by Thsd1 knockdown. Previously, 
it was demonstrated that PI3K is involved in the regulation of vessel integrity during 
embryonic development and tumour neovascularisation. Loss of PI3K led to depolarisation 
or junction disassembly, which resulted in weak cell-cell junctions, leakage and structural 
failure.42 Overexpression of PI3K promotes Rac1 activity.43 In line with these findings, our 
data demonstrate that loss of Thsd1 inhibited FAK-PI3K signalling, which was associated 
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with a decrease in Rac1 activity. These findings provide further proof that Thsd1 regulates 
vessel integrity by a Rac1-mediated pathway (Figure 8). 
 
 
Figure 8. Molecular pathway of Thsd1 during angiogenesis. Thsd1 maintains vascular integrity by its 
interaction with CRT at the cell surface, stabilising the CRT-LRP1 complex. Complex stabilisation results in 
downstream activation of FAK and PI3K, which increases Rac1-GTP levels. Rac1 regulates cell spreading by 
actin cytoskeleton modulation and maintains endothelial integrity by strengthening VE-cadherin/actin bonds. 
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As endothelial cell-cell barrier function and neovascular integrity play important roles in 
progression and destabilisation of rupture prone atherosclerotic lesions, we aimed to 
evaluate the function of Thsd1 in this widespread vascular-related disease. Advanced 
atherosclerotic lesions in humans are characterised by intimal growth of a neovasculature 
with apparent compromised integrity. Immunopathological assessment of human carotid 
endarterectomy specimens demonstrated that Thsd1 expression was significantly increased 
in advanced vulnerable lesions with intraplaque haemorrhaging compared with stable 
plaques, suggesting a compensatory upregulation of Thsd1 to maintain vascular integrity in 
the intimal neovascular endothelium. This idea of a Thsd1-involved feedback mechanism in 
order to preserve cell-cell barrier function was validated by our Thsd1 gain- and loss-of-
function studies in the ApoE-knockout mice vulnerable plaque model: Thsd1 
overexpression led to less intraplaque haemorrhaging as measured by a lower percentage of 
intraplaque erythrocytes and a decrease in intraplaque Dextran-FITC leakage. 
Methia et al previously showed that ApoE-knockout mice on a high cholesterol diet 
exhibited dramatic blood-brain barrier defects. ApoE consists of three isoforms, ApoE2, 
ApoE3 and ApoE4. It was further demonstrated that ApoE4 is a major risk factor for 
Alzheimer’s disease.43 Interestingly, Nishitsuji et al44 could proof that the effect of ApoE 
on blood-brain barrier leakage was isoform dependant as ApoE4-knockin mice showed a 
more severely compromised blood-brain barrier function than ApoE3-knockin mice. Later, 
Bell et al45 showed that ApoE, ApoE3 and ApoE4 regulate blood-brain barrier permeability 
via the CypA-NFκB-MMP9 pathway. ApoE and ApoE3 are both known to suppress CypA-
NFκB-MMP9 activation via LRP1. In contrast, the working mechanism of ApoE4 is LRP1-
independent of MMP9. 
Potentially, the LRP1-mediated inhibition of CypA-NFκB-MMP9 signalling could 
represent a second mechanism via which Thsd1 regulates vascular permeability: Thsd1 may 
activate LRP1 leading to decreased CypA levels and subsequently less nuclear NFκB 
translocation and MMP9 activation, thus contributing to endothelial integrity. Although it 
has been shown that Thrombospondin 1 influences MMP9 activity, it has not yet been 
shown that this pathway also acts via LRP1. Additional studies are needed to further 
elucidate the contribution of Thsd1 function to vascular integrity via MMP9 activation. 
There is emerging evidence that intraplaque haemorrhaging plays an important role in 
plaque progression towards a vulnerable plaque.46,47 Furthermore, intraplaque 
haemorrhaging is correlated with plaque rupture and predicted future cardiovascular events 
and outcome in cardiovascular patients.48,49 Intraplaque haemorrhage is the result from 
extravasation of erythrocytes from newly formed vessels. Neovascularisation - driven by 
intraplaque hypoxia50 - results in the formation of immature and fragile vessels under 
influence of VEGF-A. These immature and fragile vessels have a greater vascular 
permeability resulting in the extravasation of leucocytes and erythrocytes, leading to an 
increase in inflammatory response, expansion of the necrotic core and intraplaque 
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haemorrhaging. Stabilisation of these so-called leaky vessels might prevent plaque 
destabilisation and formation of a vulnerable plaque.10 Remarkably, macrophage 
accumulation and necrotic core size were in decline after Thsd1 was overexpressed in our 
ApoE-knockout mice vulnerable plaque model. This indicates that as Thsd1 attenuates 
endothelial dysfunction in atherosclerosis, the beneficial effects of improved neovascular 
integrity in the lesion also slowdown plaque progression. Overall, Thsd1 overexpression led 
to a more stable plaque phenotype compared with sham treated animals, an effect that was 
independent of neovascular growth as there was no difference in percentage of adventitial 
or intimal endothelial structures. A limitation of these overexpression studies is that pAd-
Thsd1 virus infection could not be achieved selectively and overexpression of Thsd1 in 
non-ECs may contribute to the observed findings. However, by carrying out Thsd1 loss-of-
function studies in the same ApoE-knockout mice vulnerable plaque model, the essential 
role of Thsd1 in the regulation of vascular integrity and attenuation of atherosclerosis 
progression could be confirmed: in contrast to Thsd1 overexpression, Thsd1 knockdown 
led to a significant increase in intraplaque erythrocyte and Dextran-FITC perivascular 
leakage without affecting neovascular growth. 
In conclusion, here we have identified Thsd1 as a new regulator of vascular integrity in 
vascular development and advanced vascular disease. To our knowledge, this study is the 
first report of the biological function of Thsd1 in ECs during normal embryonic and 
postnatal blood vessel formation. In advanced atherosclerotic lesions, Thsd1 is involved in 
maintaining cell-cell barrier function in the intraplaque neovasculature and protects the 
plaque from extensive haemorrhaging and further disease progression. In the light of our 
findings of the basic and pathobiological function of Thsd1, the gene may be considered an 
interesting research target for the development of new diagnostics and therapeutics in the 
treatment of atherosclerosis and other vascular-related diseases in which the 
pathophysiology entails loss of blood vessel integrity. 
 
 
References 
 
1. Klaassen I, van Noorden CJ, Schlingemann RO. Molecular basis of the inner blood-
retinal barrier and its breakdown in diabetic macular oedema and other pathological 
conditions. Prog Retin Eye Res. 2013;34:19-48. 
2. Vandenbroucke E, Mehta D, Minshall R, Malik AB. Regulation of endothelial 
junctional permeability. Ann N Y Acad Sci. 2008;1123:134-145. 
3. Tian X, Tian Y, Sarich N, Wu T, Birukova AA. Novel role of stathmin in microtubule-
dependent control of endothelial permeability. FASEB J. 2012;26(9):3862-3874. 
Thsd1 and vascular integrity 
 
 147
4. Spindler V, Schlegel N, Waschke J. Role of GTPases in control of microvascular 
permeability. Cardiovasc Res. 2010;87(2):243-253. 
5. Broman MT, Mehta D, Malik AB. Cdc42 regulates the restoration of endothelial 
adherens junctions and permeability. Trends Cardiovasc Med. 2007;17(5):151-156. 
6. Kim SH, Cho YR, Kim HJ, Oh JS, Ahn EK, Ko HJ, Hwang BJ, Lee SJ, Cho Y, Kim 
YK, Stetler-Stevenson WG, Seo DW. Antagonism of VEGF-A-induced increase in 
vascular permeability by an integrin α3β1-Shp-1-cAMP/PKA pathway. Blood. 
2012;120(24):4892-4902. 
7. Huveneers S, Oldenburg J, Spanjaard E, van der Krogt G, Grigoriev I, Akhmanova A, 
Rehmann H, de Rooij J. Vinculin associates with endothelial VE-cadherin junctions to 
control force-dependent remodelling. J Cell Biol. 2012;196(5):641-652. 
8. Hoang MV, Nagy JA, Senger DR. Active Rac1 improves pathologic VEGF neovessel 
architecture and reduces vascular leak: mechanistic similarities with angiopoietin 1. 
Blood. 2011;117(5):1751-1760. 
9. Kraemer A, Goodwin M, Verma S, Yap AS, Ali RG. Rac is a dominant regulator of 
cadherin-directed actin assembly that is activated by adhesive ligation independently of 
Tiam1. Am J Physiol Cell Physiol. 2007;292(3):C1061-C1069. 
10. Jain RK, Finn AV, Kolodgie FD, Gold HK, Virmani R. Anti-angiogenic therapy for 
normalisation of atherosclerotic plaque vasculature: a potential strategy for plaque 
stabilisation. Nat Clin Pract Cardiovasc Med. 2007;4(9):491-502. 
11. Sluimer JC, Daemen MJ. Novel concepts in atherogenesis: angiogenesis and hypoxia 
in atherosclerosis. J Pathol. 2009;218(1):7-29. 
12. Takayanagi S, Hiroyama T, Yamazaki S, Nakajima T, Morita Y, Usui J, Eto K, 
Motohashi T, Shiomi K, Keino-Masu K, Masu M, Oike Y, Mori S, Yoshida N, Iwama 
A, Nakauchi H. Genetic marking of haematopoietic stem and endothelial cells: 
identification of the Tmtsp gene encoding a novel cell surface protein with the 
thrombospondin 1 domain. Blood. 2006;107(11):4317-4325. 
13. Gjini E, Hekking LH, Küchler A, Saharinen P, Wienholds E, Post JA, Alitalo K, 
Schulte-Merker S. Zebrafish Tie2 shares a redundant role with Tie1 in heart 
development and regulates vessel integrity. Dis Model Mech. 2011;4(1):57-66. 
14. van der Heijden M, van Nieuw Amerongen GP, van Bezu J, Paul MA, Groeneveld AB, 
van Hinsbergh VW. Opposing effects of the angiopoietins on the thrombin-induced 
permeability of human pulmonary microvascular endothelial cells. PLoS One. 
2011;6(8):e23448. 
15. van Nieuw Amerongen GP, Vermeer MA, Nègre-Aminou P, Lankelma J, Emeis JJ, 
van Hinsbergh VW. Simvastatin improves disturbed endothelial barrier function. 
Circulation. 2000;102(23):2803-2809. 
Chapter 5 
 
 148 
16. Aman J, van Bezu J, Damanafshan A, Huveneers S, Eringa EC, Vogel SM, Groeneveld 
AB, Vonk Noordegraaf A, van Hinsbergh VW, van Nieuw Amerongen GP. Effective 
treatment of oedema and endothelial barrier dysfunction with imatinib. Circulation. 
2012;126(23):2728-2738. 
17. Kleaveland B, Zheng X, Liu JJ, Blum Y, Tung JJ, Zou Z, Sweeney SM, Chen M, Guo 
L, Lu MM, Zhou D, Kitajewski J, Affolter M, Ginsberg MH, Kahn ML. Regulation of 
cardiovascular development and integrity by the heart of glass-cerebral cavernous 
malformation protein pathway. Nat Med. 2009;15(2):169-176. 
18. Montero-Balaguer M, Swirsding K, Orsenigo F, Cotelli F, Mione M, Dejana E. Stable 
vascular connections and remodelling require full expression of VE-cadherin in 
zebrafish embryos. PLoS One. 2009;4(6):e5772. 
19. Gore AV, Lampugnani MG, Dye L, Dejana E, Weinstein BM. Combinatorial 
interaction between CCM pathway genes precipitates haemorrhagic stroke. Dis Model 
Mech. 2008;1(4-5):275-281. 
20. Liu J, Fraser SD, Faloon PW, Rollins EL, Vom Berg J, Starovic-Subota O, Laliberte 
AL, Chen JN, Serluca FC, Childs SJ. A betaPix Pak2a signalling pathway regulates 
cerebral vascular stability in zebrafish. Proc Natl Acad Sci U S A. 2007;104(35):13990-
13995. 
21. Buchner DA, Su F, Yamaoka JS, Kamei M, Shavit JA, Barthel LK, McGee B, Amigo 
JD, Kim S, Hanosh AW, Jagadeeswaran P, Goldman D, Lawson ND, Raymond PA, 
Weinstein BM, Ginsburg D, Lyons SE. Pak2a mutations cause cerebral haemorrhage in 
redhead zebrafish. Proc Natl Acad Sci U S A. 2007;104(35):13996-14001. 
22. Kwon HB, Choi YK, Lim JJ, Kwon SH, Her S, Kim HJ, Lim KJ, Ahn JC, Kim YM, 
Bae MK, Park JA, Jeong CH, Mochizuki N, Kim KW. AKAP12 regulates vascular 
integrity in zebrafish. Exp Mol Med. 2012;44(3):225-235. 
23. Armstrong LC, Bornstein P. Thrombospondins 1 and 2 function as inhibitors of 
angiogenesis. Matrix Biol. 2003;22(1):63-71. 
24. Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, Bouck NP. CD36 
mediates the in vitro inhibitory effects of thrombospondin 1 on endothelial cells. J Cell 
Biol. 1997;138(3):707-717. 
25. Bobryshev YV, Cherian SM, Inder SJ, Lord RS. Neovascular expression of VE-
cadherin in human atherosclerotic arteries and its relation to intimal inflammation. 
Cardiovasc Res. 1999;43(4):1003-1017. 
26. Ohkawara H, Ishibashi T, Shiomi M, Sugimoto K, Uekita H, Kamioka M, Takuwa Y, 
Teramoto T, Maruyama Y, Takeishi Y. RhoA and Rac1 changes in the atherosclerotic 
lesions of WHHLMI rabbits. J Atheroscler Thromb. 2009;16(6):846-856. 
Thsd1 and vascular integrity 
 
 149
27. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, Bouck 
NP. A tumour suppressor-dependent inhibitor of angiogenesis is immunologically and 
functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci 
U S A. 1990;87(17):6624-6628. 
28. Zhou J, Feng X, Ban B, Liu J, Wang Z, Xiao W. Elongation factor ELL (Eleven-
Nineteen Lysine-rich Leukaemia) acts as a transcription factor for direct 
thrombospondin 1 regulation. J Biol Chem. 2009;284(28):19142-19152. 
29. Voss K, Stahl S, Hogan BM, Reinders J, Schleider E, Schulte-Merker S, Felbor U. 
Functional analyses of human and zebrafish 18-amino acid in-frame deletion pave the 
way for domain mapping of the cerebral cavernous malformation 3 protein. Hum 
Mutat. 2009;30(6):1003-1011. 
30. Stainier DY, Fouquet B, Chen JN, Warren KS, Weinstein BM, Meiler SE, Mohideen 
MA, Neuhauss SC, Solnica-Krezel L, Schier AF, Zwartkruis F, Stemple DL, Malicki J, 
Driever W, Fishman MC. Mutations affecting the formation and function of the 
cardiovascular system in the zebrafish embryo. Development. 1996;123:285-292. 
31. Faurobert E, Albiges-Rizo C. Recent insights into cerebral cavernous malformations: a 
complex jigsaw puzzle under construction. FEBS J. 2010;277(5):1084-1096. 
32. Ko JM, Chan PL, Yau WL, Chan HK, Chan KC, Yu ZY, Kwong FM, Miller LD, Liu 
ET, Yang LC, Lo PH, Stanbridge EJ, Tang JC, Srivastava G, Tsao SW, Law S, Lung 
ML. Monochromosome transfer and microarray analysis identify a critical tumour-
suppressive region mapping to chromosome 13q14 and Thsd1 in oesophageal 
carcinoma. Mol Cancer Res. 2008;6(4):592-603. 
33. Dunham A, Matthews LH, Burton J, Ashurst JL, Howe KL, Ashcroft KJ, Beare BM, 
Burford DC, Hunt SE, Griffiths-Jones S, Jones MC, Keenan SJ, Oliver K, Scott CE, 
Ainscough R, Almeida JP, Ambrose KD, Andrews DT, Ashwell RI, Babbage AK, 
Bagguley CL, Bailey J, Bannerjee R, Barlow KF, Bates K, Beasley H, Bird CP, Bray-
Allen S, Brown AJ, Brown JY, Burrill W, Carder C, Carter NP, Chapman JC, Clamp 
ME, Clark SY, Clarke G, Clee CM, Clegg SC, Cobley V, Collins JE, Corby N, Coville 
GJ, Deloukas P, Dhami P, Dunham I, Dunn M, Earthrowl ME, Ellington AG, Faulkner 
L, Frankish AG, Frankland J, French L, Garner P, Garnett J, Gilbert JG, Gilson CJ, 
Ghori J, Grafham DV, Gribble SM, Griffiths C, Hall RE, Hammond S, Harley JL, Hart 
EA, Heath PD, Howden PJ, Huckle EJ, Hunt PJ, Hunt AR, Johnson C, Johnson D, Kay 
M, Kimberley AM, King A, Laird GK, Langford CJ, Lawlor S, Leongamornlert DA, 
Lloyd DM, Lloyd C, Loveland JE, Lovell J, Martin S, Mashreghi-Mohammadi M, 
McLaren SJ, McMurray A, Milne S, Moore MJ, Nickerson T, Palmer SA, Pearce AV, 
Peck AI, Pelan S, Phillimore B, Porter KM, Rice CM, Searle S, Sehra HK, Shownkeen 
R, Skuce CD, Smith M, Steward CA, Sycamore N, Tester J, Thomas DW, Tracey A, 
Tromans A, Tubby B, Wall M, Wallis JM, West AP, Whitehead SL, Willey DL, 
Wilming L, Wray PW, Wright MW, Young L, Coulson A, Durbin R, Hubbard T, 
Chapter 5 
 
 150 
Sulston JE, Beck S, Bentley DR, Rogers J, Ross MT. The DNA sequence and analysis 
of human chromosome 13. Nature. 2004;428(6982):522-528. 
34. Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi 
K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara 
T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari 
K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri 
T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, 
Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa 
M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, 
Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, 
Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, 
Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, 
Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, 
Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, 
Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, 
Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, 
Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, 
Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki 
K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, 
Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, 
Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, 
Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi 
Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita 
R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S. Complete sequencing 
and characterisation of 21,243 full-length human cDNAs. Nat Genet. 2004;36(1):40-
45. 
35. Stahl A, Connor KM, Sapieha P, Chen J, Dennison RJ, Krah NM, Seaward MR, 
Willett KL, Aderman CM, Guerin KI, Hua J, Löfqvist C, Hellström A, Smith LE. The 
mouse retina as an angiogenesis model. Invest Ophthalmol Vis Sci. 2010;51(6):2813-
2826. 
36. Waschke J, Burger S, Curry FR, Drenckhahn D, Adamson RH. Activation of Rac1 and 
Cdc42 stabilises the microvascular endothelial barrier. Histochem Cell Biol. 
2006;125(4):397-406. 
37. Wójciak-Stothard B, Potempa S, Eichholtz T, Ridley AJ. Rho and Rac but not Cdc42 
regulate endothelial cell permeability. J Cell Sci. 2001;114(Pt 7):1343-1355. 
38. Chervin-Pétinot A, Courçon M, Almagro S, Nicolas A, Grichine A, Grunwald D, 
Prandini MH, Huber P, Gulino-Debrac D. Epithelial protein lost in neoplasm (EPLIN) 
interacts with α-catenin and actin filaments in endothelial cells and stabilises vascular 
capillary network in vitro. J Biol Chem. 2012;287(10):7556-7572. 
Thsd1 and vascular integrity 
 
 151
39. Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. 
Cell. 2011;146(6):873-887. 
40. Tomar A, Schlaepfer DD. Focal adhesion kinase: switching between GAPs and GEFs 
in the regulation of cell motility. Curr Opin Cell Biol. 2009;21(5):676-683. 
41. Orr AW, Pallero MA, Xiong WC, Murphy-Ullrich JE. Thrombospondin induces RhoA 
inactivation through FAK-dependent signalling to stimulate focal adhesion 
disassembly. J Biol Chem. 2004;279(47):48983-48992. 
42. Yuan TL, Choi HS, Matsui A, Benes C, Lifshits E, Luo J, Frangioni JV, Cantley LC. 
Class 1A PI3K regulates vessel integrity during development and tumourigenesis. Proc 
Natl Acad Sci U S A. 2008;105(28):9739-9744. 
43. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, 
Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele 
and the risk of Alzheimer’s disease in late onset families. Science. 
1993;261(5123):921-923. 
44. Nishitsuji K, Hosono T, Nakamura T, Bu G, Michikawa M. Apolipoprotein E regulates 
the integrity of tight junctions in an isoform-dependent manner in an in vitro blood-
brain barrier model. J Biol Chem. 2011;286(20):17536-17542. 
45. Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z, Holtzman DM, Betsholtz 
C, Armulik A, Sallstrom J, Berk BC, Zlokovic BV. Apolipoprotein E controls 
cerebrovascular integrity via cyclophilin A. Nature. 2012;485(7399):512-516. 
46. Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, Farb A, 
Guerrero LJ, Hayase M, Kutys R, Narula J, Finn AV, Virmani R. Intraplaque 
haemorrhage and progression of coronary atheroma. N Engl J Med. 
2003;349(24):2316-2325. 
47. Michel JB, Virmani R, Arbustini E, Pasterkamp G. Intraplaque haemorrhages as the 
trigger of plaque vulnerability. Eur Heart J. 2011;32(16):1977-1985, 1985a, 1985b, 
1985c. 
48. Altaf N, MacSweeney ST, Gladman J, Auer DP. Carotid intraplaque haemorrhage 
predicts recurrent symptoms in patients with high-grade carotid stenosis. Stroke. 
2007;38(5):1633-1635. 
49. Hellings WE, Peeters W, Moll FL, Piers SR, van Setten J, van der Spek PJ, de Vries 
JP, Seldenrijk KA, de Bruin PC, Vink A, Velema E, de Kleijn DP, Pasterkamp G. 
Composition of carotid atherosclerotic plaque is associated with cardiovascular 
outcome: a prognostic study. Circulation. 2010;121(17):1941-1950. 
50. Moreno PR, Purushothaman KR, Sirol M, Levy AP, Fuster V. Neovascularisation in 
human atherosclerosis. Circulation. 2006;113(18):2245-2252. 
 
 
 152 
 
  
 
 
 
Chapter 6 
 
 
 
 
Cerebral cavernous malformations: 
from molecular pathogenesis 
to genetic counselling 
and clinical management 
 
 
 
 
 
 
 
 
 
 
 
European Journal of Human Genetics 2012; 20 (2): 134-140 
doi: 10.1038/ejhg.2011.155 
 
R.A. Haasdijk, C. Cheng, A.J. Maat-Kievit, H.J. Duckers 
 
 
 
 
 
Chapter 6 
 
 154 
Abstract 
 
Cerebral cavernous (or capillary-venous) malformations (CCM) have a prevalence of about 
0.1-0.5% in the general population. Genes mutated in CCM encode proteins that modulate 
junction formation between vascular endothelial cells. Mutations lead to the development 
of abnormal vascular structures. In this article, we review the clinical features, molecular 
and genetic basis of the disease, and management. 
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Introduction 
 
Cerebral cavernous (or capillary-venous) malformations (CCM; OMIM no. 116860) are 
vascular malformations with a prevalence of 0.1-0.5% in the general population, with a 
familial incidence close to 20%.1-3 CCM may occur sporadically, but most of the time it has 
an autosomal dominant inheritance pattern with variable expression and incomplete 
penetrance.2-6 At least three genes have been associated with CCM: k-rev interaction 
trapped protein 1 (KRIT1) (CCM1; OMIM *604214), MGC4607 (CCM2; OMIM 
#603284), and programmed cell death 10 (PDCD10) (CCM3; OMIM #603285). These 
genes encode proteins that are involved in junction formation between vascular endothelial 
cells. Mutations in the CCM genes, which are in general loss-of-function mutations, lead to 
the development of abnormal vascular structures characterised by thin-walled, dilated blood 
vessels with gaps between the endothelial cells.1,7 
The underlying genetic mechanism in CCM is partially understood. Second-site 
genetic mutations have been proposed as one of the possible molecular mechanisms.1,8 
A total of 9% of individuals were symptomatic before age 10 years, 62-72% between 
10 and 40 years, and 19% after age 40 years.9,10 Up to 25% of individuals with CCM 
remain symptom free throughout their lives.11 This percentage may be an underestimate 
because many asymptomatic persons go unrecognised. Otten et al12 reported an absence of 
symptoms in 90% of individuals with CCM ascertained in autopsy. Approximately 50-75% 
of persons with CCM become symptomatic. Affected individuals most often present with 
seizures (40-70%), focal neurologic deficits (35-50%), non-specific headaches (10-30%) 
and cerebral haemorrhage (41%).9,11,13,14 In the most recent study, Denier et al15 found 
seizures in 55%, focal neurological deficits in 9%, non-specific headaches in 4% and 
cerebral haemorrhage in 32%. 
In most cases, cavernous malformations (or cavernomas) are located within the brain, 
but in a small proportion of patients with familial CCM, cavernomas may also be observed 
in the spinal cord, retina, skin or liver.2,3,16 Retinal cavernomas occur in about 5% of 
patients with familial CCM. They are unilateral, generally stable and asymptomatic, and 
can be diagnosed by routine fundoscopy.2,17 Cutaneous vascular malformations are seen in 
9% of familial CCM patients. Three distinct major phenotypes were identified: 
hyperkeratotic cutaneous capillary-venous malformations (39%), strongly associated with a 
KRIT1 mutation. Second, capillary malformations (34%) and finally, venous 
malformations (21%) mostly seen in patients with a PDCD10 mutation. Patients with a 
Malcavernin mutation are possibly less prone for cutaneous vascular malformations.2,16,18 
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Molecular and genetic basis of CCMs 
 
Mutated genes and new loci 
To date, three genes have been associated with the pathogenesis of CCM, including KRIT1 
- also known as CCM1 - located on chromosome 7q11.2-21,19,20 Malcavernin, murine 
OSM-osmosensing scaffold for MEKK3 (MGC4607) - also known as CCM2 - on 
chromosome 7p1319,21 and PDCD10 - also known as CCM3 -, originally identified as TF-1 
cell apoptosis-related gene-15 (TFAR15) on chromosome 3q26.1 (Table 1).19,22,23 In 
addition, there is at least one further - as yet unspecified - gene that can cause CCM, which 
has been mapped to chromosome 3q26.3-27.2. Gianfrancesco et al25 reported the zona 
pellucida-like domain containing 1 gene as possible candidate. This gene is also located on 
the long arm of chromosome three centromeric of PDCD10.3,24-26 
 
Table 1. CCM protein interactions. 
 
Ligand Interacted protein Possible function 
 
KRIT1 (CCM1) 
 
Rap1a 
ICAP1α 
Malcavernin 
HEG1 receptor 
Junctional proteins 
(plus end of ) Microtubules 
 
 
Tumour suppressor gene 
Cell adhesion 
Cell spreading 
Direction of endothelial cell 
migration 
 
Malcavernin (CCM2) 
 
KRIT1 
PDCD10 
Rac1 
Kinases involved in the p38 
MAPK signalling cascade 
 
 
Sequester KRIT1 to the cytosol 
Lumen formation 
Vascular permeability 
Migration 
 
PDCD10 (CCM3) 
 
Malcavernin 
STK24 
STK25 
Mst4 
 
 
Apoptosis 
Direction of endothelial cell 
migration 
 
CCM: cerebral cavernous (or capillary-venous) malformations, HEG1: heart of glass 1 receptor, ICAP1α: α 
isoform of the β1-integrin regulator integrin cytoplasmic adaptor protein 1, KRIT1: k-rev interaction trapped 
protein 1, PDCD10: programmed cell death 10, STK24/25: serine/threonine protein kinase. 
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Distribution and frequency of gene mutations 
Close to 100 mutations (88 germline mutations) have been identified in the KRIT1 gene, 
representing about 40-53% of the CCM families. Mutations in the MGC4607 gene may 
account for 15-20% of familial CCM cases.3,7,26-28 The only missense mutation in the 
MGC4607 gene reported so far, is a leucine to arginine substitution at amino acid 198 
(L198R), located in the phosphotyrosine-binding domain (PTB) of Malcavernin.29 
Approximately 10-40% of CCM families have been linked to the PDCD10 gene.26,28 With a 
single exception, mutations in the PDCD10 gene are either truncating or large genomic 
deletions of the entire gene. The only known in-frame deletion of PDCD10 is located in 
exon 5, encompassing amino acids L33-K50, encoding the serine/threonine kinase binding 
and phosphorylation domain.22,23,30 In about 22% of CCM cases with multiple lesions no 
mutation is detected in the three CCM genes.26 Although de novo mutations have been 
reported for all three CCM genes, they appear to be more common in the PDCD10 gene.2,31 
The proportion of familial cases has been estimated approximately at 20% in the 
general population, and estimated to be as high as 50% in Hispanic-American patients of 
Mexican descent. These families are all apparently related to the same founder mutation 
(Q455X) in the KRIT1 gene.2,3,5 
 
Genotype-phenotype relationship 
CCM is an autosomal dominant disorder with a clinical penetrance of 88% in CCM1 
families, 100% in CCM2 and 63% in CCM3 families.2,32 
Different explanations have been provided for the molecular pathogenesis of lesion 
formation in CCM. First, a Knudsonian two-hit mechanism might be involved. According 
to this mechanism, CCM formation would require a complete loss of the two alleles of a 
given CCM gene within affected cells. Loss of one of the alleles (first hit) would be the 
result of a germline mutation, whereas loss of the second allele (or second hit) will occur 
somatically. In this view, familial CCM exhibits an autosomal dominant mode of 
inheritance, but is likely recessive at the cellular level.2,27,33 On the basis of animal, as well 
as human studies, evidence grows for the two-hit mechanism. For example, in Ccm 
heterozygous mice, homozygous knockout for Msh2, penetrance of CCM lesions has been 
increased. Even so, in surgically resected mature lesions from CCM patients, mutations 
have been found in both alleles.34 Second, haploinsufficiency may also be an explanation in 
CCM pathophysiology. In this case, the patient has only a single functional copy of one of 
the CCM genes, due to mutational inactivation of the other. The single functional copy of 
the gene, however, does not result in sufficient protein for, for example, an adequate 
functional junction formation between endothelial cells, which in turn leads to the 
development of abnormal vascular structures. Third, paradominant inheritance might 
explain several CCM features. In paradominant inheritance, heterozygous individuals 
carrying a ‘paradominant’ mutation are phenotypically normal, but the trait only becomes 
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manifest when a somatic mutation occurs during embryogenesis, giving rise to loss of 
heterozygosity and formation of a mutant cell population that is homozygous for the 
mutation. In addition, a second hit may be caused by environmental factors. The exposure 
of CCM mutated, presensitised microvascular regions to oxidative stress generated by 
endothelial nitric oxide synthase uncoupling and reactive oxygen species formation could 
lead to perivascular astrocytosis.35-37 The localised nature and the number of lesions 
(usually a single one in sporadic cases versus multiple lesions in familial cases), as well as 
the age of first presentation of the phenotype being earlier in familial cases and fits in this 
type of inheritance. Finally, trans-heterozygosity - in which a patient has synergistic 
mutations in different genes of the CCM pathway (for example a germline mutation in the 
KRIT1 gene with an additional somatic mutation in the MGC4607 or PDCD10 gene) - 
might also explain intrafamilial clinical variability. Indeed, it has been shown that a 
decrease in the KRIT1, MGC4607 or PDCD10 gene alone caused little or no effect 
independently, but when combined, resulted in very high incidence of intracranial 
haemorrhage.1,3,27,38 
 
 
Biology of CCMs 
 
Protein function and expression pattern 
The KRIT1 gene contains 20 exons of which 16 encode a 736 amino acid protein 
containing three NPxY/F motifs and three ankyrin repeat domains at the N-terminus, and 
one C-terminal band 4.1 ezrin radixin moesin domain (FERM) found in exons 14-20 
(Figure 1).1,2,27,39-41 The NPxY/F motifs may be involved in dimerisation either 
intramolecular folding of the KRIT1 protein, resulting in a closed and open conformation of 
KRIT1.41 After that, the first NPxY/F motif interacts with the α-isoform of the β1-integrin 
regulator integrin cytoplasmic adaptor protein 1 (ICAP1α). ICAP1α is a 200 amino acid 
protein containing a PTB domain and even as KRIT1 a nuclear localisation signal motif in 
the N-terminus. There is evidence that both KRIT1 and ICAP1α can translocate into the 
nucleus, where they could cooperate in regulating gene expression. In particular, an 
open/closed conformation switch regulates KRIT1 nucleocytoplasmic shuttling and 
molecular interactions.40,41 The ankyrin repeats in KRIT1 are thought to be involved in 
protein-protein interaction and have been found in many proteins. No partner interacting 
with KRIT1 ankyrin repeats has yet been found.27,39,41 The FERM domain in KRIT1 is 
composed of three subdomains, F1-F3, arranged in cloverleaf shape. The F3 subdomain has 
a PTB-like domain, which recognises the NPxY/F motif on the cytoplasmic tail of 
transmembrane receptors. Rap1a is also bind by the FERM domain, suggesting that KRIT1 
may function as a scaffold for transmembrane receptors and Rap1a.27,29,39,41 
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The MGC4607 gene contains 10 exons encoding Malcavernin, a 444 amino acid 
protein containing a PTB domain similar to that of ICAP1α. Malcavernin binds KRIT1 by 
the PTB domain and inhibits in this way nuclear translocation of the KRIT1-ICAP1α 
complex.2,7,21,41 
The PDCD10 gene contains seven exons encoding a 212 amino acid protein containing 
a dimerisation domain at the N-terminus and a C-terminal focal adhesion targeting-
homology domain with a highly conserved HP1 surface.42 Previous studies suggested also 
the presence of an N-terminal serine/threonine kinase binding and phosphorylation domain, 
which binds proteins of the germinal centre kinase III family (STK24, STK25 and 
Mst4).2,30,43-46 The dimerisation domain mediates dimerisation of PDCD10. The Fat-
homology domain is important for stabilisation of the expressed PDCD10 protein and 
interacts with the PTB domain of Malcavernin and paxillin LD motifs.42 PDCD10 also 
binds Ptdlns(3,4,5)P3 and functions in this way in the (PI3k-)PIP3-PDPK1-Akt signalling 
pathway.23,47 He et al suggested that the C-terminus of PDCD10 could be important in the 
stabilisation of VEGFR-2 signalling, which is crucial for vascular development.23,48 
 
 
Figure 1. Functional domains of CCM proteins. Ankyrin: protein-protein interaction domain, FERM: four-point 
one ezrin radixin moesin domain, NLS: nuclear localisation signal, NPxY/F: ICAP1α - Malcavernin binding site, 
PTB: phosphotyrosine-binding domain, S/T-KBP: serine/threonine kinase binding and phosphorylation domain. 
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Despite the vascular nature of CCM, in situ hybridisation studies have shown KRIT1 
mRNA and protein expression in astrocytes, neurons and various epithelial cells. KRIT1 
protein was also detected in vascular endothelial cells during early angiogenesis, localised 
in the cell-cell junctions.3,49 Guzeloglu-Kayisli et al50 demonstrate that KRIT1 is also 
present in endothelial cells and cells involved in the formation of the blood-brain barrier, 
which implicates an important role for KRIT1 in intercellular communication and 
adherence. MGC4607 mRNA expression has been detected in neurons and astrocytes, as 
well as in cerebral vessels. PDCD10 mRNA is expressed in neuronal cells at adult stages, 
but also during embryogenesis.3,51 
Additional, neural expression of KRIT1, MGC4607 and PDCD10 imply that vascular 
malformations in CCM could also result from a defect in signalling between endothelial 
and neural cells, but it is still unclear whether the primary defect is of vascular or neuronal 
origin.3 In spite of this, most research has been focused on endothelial cells. 
 
Histology 
The vessel wall in CCM is characterised by less and abnormal junction formation between 
endothelial cells. After that, the expression of intercellular junction proteins is increased to 
compensate for the loose of cell contacts. Another characteristic of CCM is the lack of 
subendothelial support in the vessel wall of CCM made visible by decline in the presence of 
perivascular supporting cells (pericytes) and deposition of a basal lamina with disorganised 
collagen bundles. In addition, the formation of microgaps at the interendothelial junction 
sites was observed using scanning electron microscopy.52,53 Zhao et al54 suggested that 
CCM may develop as a result of irregular organisation of endothelial cells, as a 
consequence of an increased proliferation and migration potential of these cells. In line with 
this hypothesis, increased migratory and proliferatory endothelial cell function would 
indeed require reduced cell-cell contact and reduced presence of pericytes. 
 
 
Molecular pathogenesis of CCMs 
 
At the molecular level CCM proteins regulate cell-cell adhesion (Figure 2A), cell polarity 
and most likely cell adhesion to the extracellular matrix (Figure 2B).1,46,55 
 
Cell-cell adhesion 
Initiation and maintenance of cell-cell adhesion require the assembly of adherens junctions. 
The formation of these adherens junctions is stimulated by Rap1a, which forms a complex 
with KRIT1. Rap1a recruits KRIT1 to the plasma membrane, where it binds to the heart of 
glass 1 (HEG1) receptor to form a ternary complex of HEG1, KRIT1 and 
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Malcavernin.19,41,56 HEG1 is a transmembrane protein, expressed specifically in the 
endothelium and endocardium. No binding ligand for HEG1 is currently known, although it 
has been suggested in previous studies that HEG1 may be involved in the Wnt/β-catenin 
signalling, possibly by binding KRIT1.41,57-59 KRIT1 binds β-catenin and stimulate the 
association of β-catenin with vascular endothelial-cadherin, required for adherens junction 
formation.60 KRIT1 may also function as a tumour suppressor gene; KRIT1-β-catenin 
binding prevents β-catenin translocation to the nucleus where displacement of the 
transcriptional repressor Groucho from T-cell factor proteins by β-catenin would activate 
Wnt target gene expression.55,61,62 However, β-catenin activity in the nucleus is also vital 
for the blood-brain barrier, as many regulatory proteins involved in its development are 
under Wnt/β-catenin control.41,62 
 
Cell polarity 
Adherens junctions also promote tight junction assembly. This takes place by the formation 
of a ternary complex of KRIT1, AF6/afadin and claudin 5.55,63 Tight junctions may function 
as a physical barrier along the cell surface. As a consequence of asymmetrical distribution 
of proteins and lipids across this barrier, cell polarisation takes place.41,64 Cell polarity is 
important in the process of lumen formation.41 Except tight junction formation, cell polarity 
is also established through a reshaping of the intracellular cytoskeleton organisation. This is 
regulated by ROCK, a RhoA effector. Crose et al65 showed that Malcavernin regulates 
RhoA protein level. Malcavernin binding of Smurf1 increases Smurf1-mediated 
degradation of RhoA. After that, Borikova et al66 also showed that KRIT1 and PDCD10 in 
addition to Malcavernin are required for the regulation of RhoA protein levels. KRIT1 is a 
negative regulator of RhoA activity. The functional mechanism of KRIT1 is not yet totally 
known. In contrast, some aspects of PDCD10 inhibition of RhoA activation has been 
elucidated, as PDCD10 acts by stabilisation of germinal centre kinase III proteins and 
subsequent activation of moesin, a RhoA inhibitor.67-69 Loss of the CCM proteins results in 
an increase of RhoA activity and changes in regulation of ROCK and the cytoskeleton 
rigidity. 
 
Cell adhesion to the extracellular matrix 
β1-integrin, essential for the control of the intracellular cytoskeleton organisation, regulates 
endothelial cell adhesion to the extracellular matrix.39,70 It is proposed that β1-integrin 
signal to Cdc42 and Rac1.41,71,72 Both are required for the induction of vacuole and lumen 
formation in vascular endothelial cells.39,43,73,74 In addition, β1-integrin also promotes blood 
vessel maturation by stimulating the adhesion of mural cells to endothelial cells.41 β1-
integrin function is inhibited by binding of ICAP1α. KRIT1 competes with β1-integrin for 
binding to ICAP1α, suggesting that KRIT1 may regulate the ICAP1α inhibitory effect on 
β1-integrin.7,27-29,39,41 
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Figure 2. Integrin signalling pathway. (A) Cell-cell adhesion. HEG1 receptor: heart of glass type 1 receptor, 
KRIT1: k-rev interaction trapped protein 1, PDCD10: programmed cell death 10, STK24/25: serine/threonine 
protein kinase, TCF: T-cell factor protein. (           ) inhibition, (           ) stimulation, (           ) interaction. 
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(B) Cell-extracellular matrix adhesion. ICAP1α: α isoform of the β1-integrin regulator integrin cytoplasmic 
adaptor protein 1, KRIT1: k-rev interaction trapped protein 1, PDCD10: programmed cell death 10, PTB: 
phosphotyrosine-binding domain. (           ) inhibition, (           ) stimulation, (           ) interaction. 
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Cell adhesion to the extracellular matrix induces formation of focal adhesion sites in 
which plaque proteins - such as vinculin and paxillin - provide a bridge between β-integrins 
and the actin cytoskeleton. Subsequent activation of signalling cascades, regulated by focal 
adhesion kinase, promote actin cytoskeleton plasticity.75 Malcavernin has been shown to be 
capable to regulate actin cytoskeleton plasticity. In response to hyperosmotic shock, 
restoration of cell volume and cell shape is regulated by the p38 MAPK signalling cascade, 
controlled by Malcavernin. Malcavernin acts as a scaffold protein for Rac1 and the 
upstream kinases MEKK3 and MKK3. The p38 MAPK signalling pathway leads to the 
activation of heat shock protein 27, which in turn activates actin polymerisation and 
stabilisation.29,41,55,73,76 
 
 
Clinical management of CCMs 
 
Genetic counselling and molecular diagnosis 
To estimate the genetic risk of CCM, three key points are essential (Figure 3)3: 
 
 a detailed three-generation family tree with specific enquiry about seizures, cerebral 
haemorrhages, focal neurological deficits and (recurrent) headaches 
 MRI of the brain to differentiate between solitary or multiple CCM lesions 
 age of onset 
 
Genetic testing for KRIT1, MGC4607 and PDCD10 can confirm the clinical diagnosis in 
patients, and enables predictive and prenatal testing. 
The yield of mutation screening in CCM depends on family history. If only a single 
lesion can be detected, familial transmission is extremely rare. In contrast, sporadic cases 
with multiple cerebral lesions are most likely to have a genetic cause and need to be 
considered as familial cases. In these cases, genetic screening of all three CCM genes is 
indicated. The sensitivity of this screen is estimated to be 57%; therefore, the patient should 
be aware that a negative test does not exclude a genetic cause.2,3 The explanation for a 
negative test may be a somatic mosaicism of a de novo mutation during gestation, which is 
not always detectable in DNA extracted from peripheral mononuclear blood cells. Also 
additional mutations outside the CCM coding exons may account for altered transcription 
of CCM associated proteins and fail to be detected by conventional gene mapping 
techniques.2 
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In familial cases, sensitivity of genetic screening of all three CCM genes in a CCM 
proband with an affected relative is 96%. Once the mutation has been identified in a 
proband, sensitivity of screening of the relatives of this particular patient is 100%.2 Genetic 
counselling is important to help patients and relatives to come to an informed choice. 
When mutation screening is negative, predictive testing of relatives is not an option, 
which precludes the need for a magnetic resonance imaging (MRI). When mutation 
screening is positive, an additional MRI would be recommended. Although the sensitivity 
of MRI is very high, MRI as an initial screening test does not exclude a predisposition for 
CCM, as the disease may be in its latent phase, devoid of CNS lesions.2,27 
Predictive testing of minors should not be performed, given the possible psychological 
and socio-economic consequences of genetic testing, late onset, and reduced penetrance.2 
 
 
Figure 3. Scheme for work-up of CCM patients at clinical presentation. Most patients (50-80%) with CCM 
are sporadic without a known family history of CCM. Solitary CCM lesions may be found in 8-19% of familial 
cases and roughly 75% of sporadic cases. Multiple lesions are indicative of familial forms of CCM.27 
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Prenatal diagnosis and pregnancy 
Prenatal diagnosis or pre-implantation genetic diagnosis is technically feasible in known 
familial mutations. Decisions about termination of pregnancy in case of familial mutation 
detection in a foetus might be difficult, because of reduced penetrance and late onset of 
symptoms. There is no contra-indication for pregnancy and normal delivery in patients with 
identified small lesions, without recent clinical signs of haemorrhage. Large lesions or 
recent symptomatic haemorrhages are a relative contra-indication for pregnancy. In case of 
pregnancy, caesarean section should then be considered.2,27 
 
Clinical management of CCMs 
Clinical monitoring of CCM depends on the presence of clinical manifestations. In 
asymptomatic individuals with an increased risk of CCM, a MRI analysis every 1 or 2 years 
should be considered. In our hospital MRI will be performed in carriers or at-risk persons. 
Only if neurological problems arise or increase, MRI will be repeated. The indication for 
surgery should be discussed individually with the patient in an experienced neurosurgical 
centre. Thereby, patients clinical course in combination with MRI characteristics of the 
CCM lesion, such as localisation, size or new haemorrhage, are important factors for the 
decision of surgery. In case of deep-seated or brainstem lesions, surgery is associated with a 
morbidity rate of 30-70% and a mortality rate of 2%. Stereotactic radiosurgery for these 
lesions remains controversial.77-79 
Medical treatment consists of inhibition of RhoA by simvastatin, or its effector protein 
ROCK by fasudil. Also cyclic adenosine monophosphate-elevating drugs should be 
considered. All of them stabilise CCM lesions by improving vascular integrity.66,79-82 
Preventing progression of CCM lesions could be reached by sorafenib - an anti-angiogenic 
drug - targeting VEGF receptors and ERK signalling, which is enhanced in the endothelium 
of CCM lesions.83,84 Treatment with antiplatelet drugs should be avoided, whereas 
anticoagulation with coumadin derivatives is contra-indicated.2,19,53 
 
Prognosis of CCMs 
The long-term prognosis of familial CCM is not well known, but the available data suggest 
that it is quite favourable after (surgical) treatment. 
MRI identified new lesions appear at a rate of 0.2-0.4 lesions per patient year. The new 
onset seizure rate is 2.4% per patient year and the haemorrhage rate is 3.1%.2,3,10,27,85 
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Conclusion 
 
The pathogenesis of CCM remains to date incompletely clarified. One theory is a perturbed 
relationship between adhesion and migration of endothelial precursor cells during the 
formation of the primary vascular plexus. Initiation, guidance and termination of migration 
are precisely regulated by interaction with the extracellular matrix and neighbouring cells. 
Adhesion and migration are linked by the CCM pathway proteins. CCM complex 
components function as bridging molecules between junctional and cytoplasmic proteins. 
Loss-of-function of one of the CCM proteins leads to a decrease in adhesion. This theory is 
mainly based on research carried out in endothelial cells. Additional studies to the effect of 
interaction between neural and endothelial cells are necessary, as it remains unclear 
whether the primary defect of CCM is of vascular or neuronal origin. 
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Abstract 
 
Objective - New vessel formation contributes to organ development during embryogenesis 
and tissue repair in response to mechanical damage, inflammation, and ischemia in adult 
organisms. Early angiogenesis includes formation of an excessive primitive network that 
needs to be reorganised into a secondary vascular network with higher hierarchical 
structure. Vascular pruning - the removal of aberrant neovessels by apoptosis - is a vital 
step in this process. Although multiple molecular pathways for early angiogenesis have 
been identified, little is known about the genetic regulators of secondary network 
development. 
Methods and Results - Using a transcriptomics approach, we identified a new endothelial 
specific gene named FYVE, RhoGEF, and PH domain-containing 5 (Fgd5) that plays a 
crucial role in vascular pruning. Gain- and loss-of-function studies demonstrate that Fgd5 
inhibits neovascularisation, indicated by in vitro network-formation, aortic-ring, and 
coated-bead assays, and by in vivo coated-bead plug assays and studies in the murine retina 
model. Fgd5 promotes apoptosis-induced vaso-obliteration via induction of the Hey1-p53 
pathway by direct binding and activation of Cdc42. Indeed, Fgd5 correlates with apoptosis 
in endothelial cells during vascular remodelling and was linked to rising p21Cip1 levels in 
aging mice. 
Conclusion - Here, we have identified Fgd5 as a new genetic regulator of vascular pruning 
by activation of endothelial cell-targeted apoptosis. 
Fgd5 regulates vascular pruning 
 
 179
Introduction 
 
Vascularisation during development and regeneration plays a vital role in adult disease 
progression, including tumour growth and metastasis, arthritis, diabetic retinopathy, and 
cardiovascular disease. Vascular growth in both development and disease consists of a 
strictly orchestrated, multi-step process that requires integrated activation of several 
molecular pathways. During early vascular growth, a dense primary vascular network 
without functional arterial and venous distinction is formed in response to low-oxygen 
conditions. This primitive system, consisting of small capillaries, is relatively unstable, 
with tip and stalk cell vessel structures expanding and collapsing at a high rate. Transition 
of this primary network into a stable secondary vasculature with a defined arterial/venous 
hierarchy of larger vessels that branch into a restricted capillary field requires intensive 
vascular remodelling, a late angiogenic process that includes neovessel stabilisation and 
pruning of redundant vessel structures.1,2 
The molecular regulation by angiogenic factors such as vascular endothelial growth 
factor (VEGF)-A and fibroblast growth factor (FGF) that promote growth of the primary 
vasculature has been studied extensively. In contrast, the key molecular pathways that 
regulate the reorganisation of this early network into the more mature secondary vascular 
structure are still largely undefined. For the process of vascular pruning, vaso-obliteration 
by apoptosis induced by hyperoxia has been described3, but little is known about the 
molecular regulation of this important aspect in vascular remodelling that determines the 
fate of the neovasculature. Here, we define the function of an endothelial cell (EC) specific 
gene that plays a crucial role in apoptosis during vascular pruning. 
Previously, we carried out a genome-wide expression profile analysis to identify 
potential trivial regulators in angiogenesis. A new gene named FYVE, RhoGEF, and PH 
domain-containing 5 (Fgd5) was discovered that showed specific expression in endothelial 
precursor cells in developing murine embryos and vasculature of zebrafish larvae and 
mature mice. The Fgd family members of Rho guanine-nucleotide exchange factors (GEF) 
include Fgd1 through Fgd6, as well as the Fgd1-related Cdc42-GEF4-8, all sharing the Dbl 
homology, FYVE, and pleckstrin homology (PH) domains. Fgd1, Fgd4 and FRG have been 
shown to control Cdc42 activity via their Dbl homology domain by converting inactive 
GDP-bound Cdc42 into active GTP-bound Cdc42, resulting in altered capacities in actin 
cytoskeleton assembly, filopodia formation, and Jun N-terminal kinase pathway 
activation.9-13 To date, the basic function of Fgd5 remains unknown. 
Our studies, which incorporate gain- and loss-of-function of the Fgd5 gene, 
demonstrated in vitro and in vivo that Fgd5 induces vascular regression by pruning of 
redundant neovessels during neovascularisation. Fgd5 functions as a RhoGEF that binds 
and activates its direct target - Cdc42 - and therefore promotes Hey1-dependent p53-
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mediated apoptosis in ECs. The Fgd5 mRNA level also correlates with rising p21Cip1 levels 
in aging C57BL/6J wild-type mice, which coincides with a decline in CD31 expression. 
These findings identify Fgd5 as a new, critical regulator of neovasculature fate during late 
phase angiogenesis and demonstrate that Fgd5 may act as a defining factor for vascular 
regression in later adult life. 
 
 
Methods 
 
A more detailed description of materials and methods is available in the Data Supplement 
(online). Summarised descriptions of the different techniques used in this study are supplied 
below. 
 
This study was carried out in accordance with the Council of Europe Convention 
(ETS123)/Directive (86/609/EEC) for the protection of vertebrate animals used for 
experimental and other scientific purposes and with the approval of the National and Local 
Animal Care Committee. 
 
Isolation of Flk1-positive and Flk1-negative cells from mouse embryos 
First, 10.5 to 15.5 days post-fertilisation (dpf) FVB/N mouse embryos were harvested and 
digested to obtain single cell suspensions in 0.12% collagenase type I/phosphate-buffered 
saline (PBS) in 10% foetal calf serum (FCS) (Lonza, Breda, The Netherlands). Single cell 
suspensions were labelled with PE-conjugated anti-mouse Flk1 antibody 1:50 and Hoechst 
1:100 (BD, Breda, The Netherlands), and sorted to > 90% purity for Flk1-positive/Hoechst-
negative cells, using a BD FACSCantoTM cell-sorter (Breda, The Netherlands). Cells were 
dissolved in RLT-buffer and processed for qPCR analysis. 
 
qPCR and Western blot 
RNA was isolated using the RNeasy Mini Kit from Qiagen (Venlo, The Netherlands), 
checked for quality and quantity by capillary electrophoresis (Agilent 2100 Bioanalyser; 
Agilent Technologies, Amstelveen, The Netherlands), and reversed transcribed into cDNA. 
qPCR reactions were carried out by real-time fluorescence assessment of the SYBR® Green 
signal with the iCycler iQTM Detection System (Bio-Rad, Veenendaal, The Netherlands). 
qPCR analysis was carried out for transcripts of mouse FRG, Fgd1 through Fgd6, eNOS, 
p21Cip1 and CD31, as well as for human VEGFR-1 and 2, Notch 1 and 4, Dll4, jagged 1, 
ephrin B2 and B4, neuropilin 1 and 2, p53, and Hey1. Target mRNA expression levels are 
reported relative to the housekeeping genes - HPRT1 in murine samples and beta-actin in 
the human samples - as previously described (Supplemental table 1 and 2, online).14 
Fgd5 regulates vascular pruning 
 
 181
For Western blot analysis, samples were lysed in NP40 Cell Lysis Buffer (Invitrogen, 
Bleiswijk, The Netherlands) and analysed on a 12.5% SDS-PAGE gel, followed by 
Western blotting using antibodies against p21Cip1 and p53 1:1,000 (Abcam, Cambridge, 
UK), Rac1, RhoA and Cdc42 1:500 (Abcam, Cambridge, UK), and Fgd5 1:500 (BD, 
Breda, The Netherlands) for protein detection. Protein bands were visualised by the LI-
COR Detection System (LI-COR Biotechnology, Cambridge, UK) as previously 
described.15-17 
 
Immunohistology of ventricle, aorta and carotid arteries 
Mouse ventricle, aorta and carotid arteries were embedded in OCT (Sakura Finetek, Hoge 
Rijndijk, The Netherlands) and snap-frozen in liquid nitrogen. Then, 5 μm cryosections 
were double-stained with Alexa Fluor®-conjugated isolectin GS-IB4 1:500 (Invitrogen, 
Bleiswijk, The Netherlands) and Fgd5 antibody 1:100 (BD, Breda, The Netherlands), 
followed by rhodamin-FITC-labelled anti-mouse IgG 1:500 (Invitrogen, Bleiswijk, The 
Netherlands) and goat FAB against mouse IgG (H+L) for blocking (Jackson 
ImmunoResearch Labs, West Grove, USA) as previously described.18,19 
 
In vivo coated-bead assay 
Mature SCID mice (age 10-15 weeks) were injected subcutaneously with 700 beads in 300 
l Matrigel (400 primary human umbilical vein endothelial cells (HUVEC) per bead; BD, 
Breda, The Netherlands) supplemented with 2.5 ng/ml rat fibrinogen and 20 ng/ml human 
FGF. For each animal, an adenovirus (pAd)-sham and pAd-Fgd5 expressing HUVEC-
coated-bead plug was implanted in each flank. At day 8, solidified Matrigel plugs were 
retrieved, washed, fixed in 4% PFA/PBS, and imbedded in OCT (Sakura Finetek, Hoge 
Rijndijk, The Netherlands). For validation of transgene expression, qPCR analysis were 
carried out on isolated plugs obtained at different time points. Then, 5 m cryosections 
were stained by haematoxylin and eosin staining, or using CD31 antibody 1:500 and 
rhodamin-labelled anti-rat IgG secondary antibody 1:500 (R&D systems, Abingdon, UK). 
For quantification of the percentage nuclei and percentage CD31-positive cells, data 
analysis was carried out using a commercial image analysis system (Clemex Technologies, 
Longueuil, Canada). 
 
Mouse model of retinal vascularisation 
Three-day old C57BL/6J pups were anesthetised by placement on ice. Then, 0.5 μl pAd-
Fgd5 (5x107 pfu) was injected into the left eye and 0.5 μl pAd-sham (5x107 pfu) was 
injected into the right eye using a 33-Gauge needle (World Precision Instruments, Berlin, 
Germany). For Fgd5 silencing experiments, 100 nmol Accell Fgd5 targeting siRNA (si-
Fgd5) was injected into the left eye and 100 nmol Accell scrambled non-targeting siRNA 
(si-sham) was injected into the right eye (Dharmacon, Etten-Leur, The Netherlands). For 
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rescue experiments with VEGFR-1, an active soluble form of VEGFR-1 was co-injected 
with 100 nmol Accell si-Fgd5. Depending on the assay, mice pups were killed at post-natal 
day 4, 6, 8, 11, 16 and 21, and retinas were stained with rhodamin-FITC-labelled isolectin 
GS-IB4 or collagen IV antibody 1:200 (Millipore, Amsterdam, The Netherlands), followed 
by Alexa Fluor®-conjugated anti-rabbit/mouse secondary antibodies 1:500 (Invitrogen, 
Bleiswijk, The Netherlands). Whole-mount retinas were visualised by confocal microscopy 
(LSM510-NLO/FCS; Carl Zeiss, Sliedrecht, The Netherlands) using a 10x lens to obtain 
high-resolution micrographs of the topical vascular layer. Post-processing was needed to 
reassembly the individual micrographs into an overview of the entire retina. Processed 
retina images were analysed using Angiosys Image Analysis Software 1.0 (TCS CellWorks, 
Buckingham, UK). At least 3 individual retinal flaps per mouse retina were assessed. 
Adequate transgene expression and gene silencing were validated by qPCR analysis. 
For flow cytometric assessment of the retinal ECs, the retina was homogenised in 0.12% 
collagenase type I/PBS/10% FCS for 15 minutes, filtered through a 3 μm mesh (BD, Breda, 
The Netherlands), and stained with PE-conjugated anti-mouse Flk1 antibody 1:50, followed 
by Annexin V and propidium iodide (PI) staining (BD, Breda, The Netherlands). The 
percentage of apoptotic cells in the Flk1-positive population was quantified by flow 
cytometry on a BD FACSCantoTM (Breda, The Netherlands). For detection of cleaved 
caspase 3 and Fgd5, retinal cells were fixed and permeabilised using the Cytofix/Cytoperm 
System (BD, Breda, The Netherlands), followed by Fgd5 (Sigma-Aldrich, Zwijndrecht, The 
Netherlands) and secondary antibody staining with an allophycocyanin-labelled mouse anti-
rabbit antibody, followed by FITC-labelled rabbit anti-cleaved caspase 3 and PE-labelled 
mouse anti-Flk1 antibody staining and subsequent quantification by flow cytometry on a 
BD FACSCantoTM (Breda, The Netherlands). 
 
Cell cultures 
HUVECs were cultured on gelatin-coated plates at 37°C in 5% CO2 in EBM®-2 medium 
supplemented with a commercial BulletKit, 10% FCS and 1% penicillin/streptomycin 
(Lonza, Breda, The Netherlands). Only cell cultures of passages three to six were used 
throughout the study. 
For immunohistological staining, HUVECs were grown on cover slips and fixed in ice-
cold acetone for 5 minutes, followed by permeabilisation in 0.1% Triton X/PBS, incubation 
with Fgd5 antibody 1:100 (BD, Breda, The Netherlands), and subsequent TSA-
amplification of the signal (Roche, Woerden, The Netherlands). This was followed by 
incubation with Cdc42 or zyxin antibody 1:500 (Abcam, Cambridge, UK) and detection 
with 1:500 FITC-labelled anti-rabbit/rat IgG antibody (Invitrogen, Bleiswijk, The 
Netherlands). Cover slips were mounted with 4,6-diamidino-2-phenylindole (DAPI) in 
Vectashield® mounting medium (H-1200; Vector Laboratories, Burlingame, USA) and 
imaged by fluorescence microscopy (Carl Zeiss, Sliedrecht, The Netherlands). 
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Cell proliferation, cell cycle and apoptosis assay 
Transfected HUVECs were synchronised in the G0/G1-phase by serum deprivation in 
EBM®-2 medium supplemented with a commercial BulletKit and 0.2% FCS for 12 hours. 
For cell growth assessment, cells were harvested and quantified using a haematocytometer 
(trypan blue negative) at different time points. We carried out 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrasodium bromide (MTT) uptake experiments for cell metabolism 
assessment according to the instruction manual (ATCC, Manassas, USA). 
For cell cycle analysis, cells were harvested at 0, 4 and 12 hours after activation, fixed 
in 70% ethanol/PBS for 15 minutes on ice, stained with PI 1:300, and analysed by flow 
cytometry on a BD FACSCantoTM (Breda, The Netherlands). 
For apoptosis analysis, cells were harvested at 0, 4 and 12 hours after activation, and 
stained for Annexin V and PI signals using an Annexin V Apoptosis Detection Kit (BD, 
Breda, The Netherlands), followed by analysis of the samples by flow cytometry on a BD 
FACSCantoTM (Breda, The Netherlands). 
 
Small G-protein activation assay and Fgd5 protein complex co-immunoprecipitation 
Rac1, RhoA and Cdc42 activation levels were measured using the G-LISA Detection 
System (Tebu-Bio, Heerhugowaard, The Netherlands). 
For Fgd5 protein complex co-immunoprecipitation, magnetic beads (Dynabeads®; 
Invitrogen, Bleiswijk, The Netherlands) were coated and cross-linked with 2.5 μg Fgd5 
antibody (BD, Breda, The Netherlands) before immunoprecipitation overnight at 4°C with 
protein cell lysates of transfected HUVECs (50 μg total protein in 100 μl incubation buffer 
supplied by the G-LISA Detection System). Beads were washed and protein samples were 
eluted with elution buffer (Invitrogen, Bleiswijk, The Netherlands) before analysis by 
Western blot on a 12.5% SDS-PAGE gel. 
 
Statistical analysis 
Data were reported as mean ± standard error of the mean (SEM). Statistical significance 
was evaluated by one-way ANOVA, as appropriate, followed by individual unpaired 
Student’s t-test. In specific assays, repeated measurement analysis was applied. 
Significance was accepted at P < 0.05 (* P < 0.05, ** P < 0.01 in the figures). 
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Results 
 
Fgd5 is specifically expressed in endothelial precursor cells during murine and 
zebrafish development and in fully differentiated endothelial cells 
Fgd5 was specifically expressed in the Flk1-positive cell population during embryonic 
development in mice as shown by microarray and qPCR analysis. Fgd5 mRNA was 
predominantly expressed from 8.5 to 16.5 dpf Flk1-positive endothelial precursor cells, 
when the majority of the vascular structures were established (Figure 1A). Selection of 
endothelial precursor cells - based on the Flk1 cell surface marker - was further validated 
by microarray analysis, which showed a significant rise in the expression levels of well-
known angiogenic genes such as angiopoietin 2, neuropilin 1 and 2, Tie1, Flt1, and Ets1 in 
the Flk1-positive compared with the Flk1-negative pool (data not shown). 
 
 
Figure 1. Fgd5 is specifically expressed in endothelial cells. (A) Endogenous expression level of Fgd5 in Flk1-
positive angioblasts during murine embryonic development from 8.5 to 16.5 days post-fertilisation (dpf) compared 
with Flk1-negative cells as analysed by qPCR. The expression level of Fgd5 in Flk1-negative cells was arbitrarily 
set to one (n = 6; mean  SEM). Fgd5 was upregulated at all time points. (B) Whole-mount in situ hybridisation of 
Fgd5 in zebrafish larvae at 26 hours post-fertilisation (hpf), lateral view, anterior is to the left. Fgd5 transcripts 
were localised in the developing vascular network, including main axial vessels - dorsal aorta and posterior 
cardinal vein - and intersegmental vessels (ISV). (C) qPCR analysis of Fgd5 expression in various tissues of 
mature C57BL/6J mice (n = 6; mean  SEM). 
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Specific vascular expression of Fgd5 in the developing vascular tree was validated in 
zebrafish larvae by whole-mount in situ hybridisation (Figure 1B). Fgd5 mRNA in mature 
C57BL/6J mice was predominantly expressed in the aorta and carotid arteries compared 
with heart, skeletal muscle, kidney, liver, eye and brain tissue (Figure 1C), mimicking the 
expression profile of endothelial-specific markers including eNOS and CD31. The other 
Fgd family members showed a ubiquitous expression pattern (Figure 1D). In vitro, Fgd5 
was specifically expressed in primary human arterial endothelial cells (HAEC) and 
HUVECs compared with non-relevant cells (HeLa and sarcoma cells) (Figure 1E), 
underlining endothelial-specific expression throughout different species and developmental 
stages. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(D) qPCR analysis of the expression of the Fgd family members FRG, Fgd1, Fgd2, Fgd3, Fgd4 and Fgd6, and the 
expression pattern of vascular specific CD31 and eNOS (n = 4; mean  SEM). (E) qPCR analysis of primary cell 
lines, including HUVECs and HAECs compared with non-relevant cell types - HeLa and sarcoma cells (n = 3; 
mean  SEM). 
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Immunohistological analysis demonstrated selective Fgd5 expression in ECs in the 
microvasculature of the myocardium and in the endothelial lining of large blood vessels, 
including the aorta (Figure 1F, G). These findings were further confirmed by analysis of 
public gene expression databases (NCBI, Gene Expression Omnibus) (Supplemental figure 
1, online). From these results, we conclude that Fgd5 is the predominant member of the Fgd 
family expressed in ECs during embryonic vascular development and in adult vasculature. 
 
(F) Immunohistological staining of myocardium of mature C57BL/6J mice detected co-localisation of the Fgd5 
protein (green) with the endothelial cell marker isolectin GS-IB4 (red). (G) Immunohistological staining of aortas 
of mature C57BL/6J mice detected Fgd5 protein (green) in the endothelium and adventitia. Luminal area marked 
by an asterisk. 
 
 
Fgd5 diminishes angiogenesis in vitro and in vivo 
Fgd5 function in HUVECs was assessed by gain- and loss-of-function studies by infection 
of adenovirus expressing murine or human Fgd5, or by transfection of Fgd5 targeting 
siRNA (Supplemental figure 2A-E, online). In a 2D matrigel network-formation assay, 
siRNA-mediated silencing of Fgd5 promoted network-formation (Supplemental figure 2F-I, 
online), whereas Fgd5 overexpression attenuated network-formation (Supplemental figure 
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2J-M, online). Similarly, in an ex vivo murine aortic-ring assay, adenovirus-mediated 
overexpression of murine Fgd5 significantly reduced vascular outgrowth (Supplemental 
figure 2N, O, online). In an established angiogenesis model using HUVECs-coated 
Cytodex® beads, Fgd5 overexpression also diminished capillary sprouting and lumen 
formation (Supplemental figure 2P-U, online). DAPI staining verified comparable numbers 
of cells attached to the beads at the initiation of the experiment (Supplemental figure 2V, 
online). 
To assess the role of Fgd5 in angiogenesis in vivo, beads - coated with pAd-sham or 
pAd-Fgd5 infected HUVECs - were suspended in Matrigel and injected subcutaneously in 
immunodeficient SCID mice. Matrigel Fgd5 plugs harvested at day 8 after transplantation 
revealed reduced plug vascularisation, whereas the sham plugs showed an extensive 
neocapillary network (Figure 2A-D) and increased outgrowth of CD31-positive cells 
(Figure 2E, F). Human Fgd5 transgene expression in the plugs was validated at different 
time points by qPCR analysis and showed significantly higher levels of human Fgd5 
mRNA in plugs with pAd-Fgd5 versus pAd-sham treated HUVECs (Figure 2G). 
 
Figure 2. Fgd5 inhibits angiogenesis in an in vivo coated-bead assay. (A) Representative macroscopic pictures 
of subcutaneously injected matrigel plugs containing HUVEC-coated Cytodex® beads in SCID mice at day 8. 
HUVECs were infected with either pAd-Fgd5 or sham virus. (B) Representative macroscopic pictures of the 
matrigel plugs containing HUVEC-coated Cytodex® beads infected with pAd-Fgd5 or sham virus. Lack of 
vascularisation and accumulation of erythrocytes within the plugs is visible in the pAd-Fgd5 group compared with 
the sham virus infected control group. (C) Histological haematoxylin and eosin staining shows a decline in the 
accumulation of HUVECs on beads coated with pAd-Fgd5 infected HUVECs compared with the sham virus 
infected control group. White arrows point to perinuclear outgrowth. (D) Quantitative analysis of micrographs 
show the effect of Fgd5 on the percentage of cell covered plug area (mm2 per bead) in the pAd-Fgd5 infected 
versus sham virus infected and non-infected controls (n = 8). 
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(E) Immunohistological staining reveals accumulation of CD31-positive endothelial cells (red) surrounding the 
Cytodex® beads (left hand panel), which co-localised with the DAPI-positive nuclei (blue) (right hand panel). The 
contours of the Cytodex® beads are visible by autofluorescence. (F) Quantitative analysis of the coated-bead assay 
show the effect of Fgd5 on the percentage CD31-positive surface area per bead (mm2) in the pAd-Fgd5 group 
compared with the sham virus infected and non-infected control groups (n = 8; mean  SEM). (G) Validation of 
human Fgd5 expression in the coated-beads as assessed by qPCR at different time points (n = 4; mean  SEM). 
 
 
Fgd5 function in angiogenesis was further assessed using an adenovirus expressing 
murine Fgd5 in murine postnatal vascular development (Figure 3A-C). Murine pAd-Fgd5 
overexpression after intra-ocular injection at post-natal day 3 (5x107 pfu) reduced the 
vascular retinal network in the developing murine eye mainly at post-natal day 8 and 11 
(Figure 3A) and is characterised by truncations in the superficial vasculature resulting in a 
decrease in total vascular tubule length, number of junctions and neocapillaries, whereas 
mean tubule length was increased at the earliest time point (Figure 3B, C). 
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Figure 3. Fgd5 inhibits angiogenesis the murine retina model. (A) Effect of murine Fgd5 overexpression 
during retinal vascular development. Representative micrographs of the retinal vasculature visualised by whole-
mount isolectin GS-IB4 staining from 8 to 21days after birth. Whole-mount en-face staining of the retina (left hand 
panels) and high magnification examples of individual flaps (right hand panels) are shown. pAd-Fgd5 injection 
three days after birth severely impeded vascular development compared with sham virus controls. High 
magnification micrographs show disruption of vessels and shortened sprouts. (B) Representative examples of 
retinal flaps after processing by quantitative software (Angiosys Image Analysis Software 1.0): junctions (yellow 
dots) and vessels (blue lines) are shown. (C) Quantification of this experiment showed that Fgd5 overexpression 
induced a decrease in the number of junctions, number of tubules and total tubule length, whereas the mean tubule 
length was increased (n = 6; mean  SEM). (D) Effect of murine siRNA-mediated silencing of endogenous Fgd5 
during retinal vascular development. Representative micrographs of the retinal vasculature visualised by whole-
mount isolectin GS-IB4 staining from 8 to 21 days after birth. Whole-mount en-face staining of the retina (left 
hand panels) and high magnification examples of individual flaps (right hand panels) are shown. si-Fgd5 injection 
three days after birth supported a more excessive vascular network compared with scrambled non-targeting siRNA 
controls. High magnification micrographs show persistence of excessive sprouts and poor differentiation of veins 
and arteries by lack of pruning of the junctional vessels. (E) Representative examples of retinal flaps after 
processing by quantitative software (Angiosys Image Analysis Software 1.0): junctions (yellow dots) and vessels 
(blue lines) are shown. (F) Quantification of this experiment showed that Fgd5 silencing induced an increase in the 
number of junctions, number of tubules and total tubule length, whereas the mean tubule length was decreased (n 
= 5; mean  SEM). (G) Validation of transfection efficiency by qPCR analysis: murine Fgd5 mRNA levels in the 
retina after infection with pAd-Fgd5 or sham virus (upper panel), and murine Fgd5 mRNA levels in the retina after 
treatment with siRNA targeting Fgd5 or scrambled non-targeting siRNA (lower panel) as assessed on different 
time points (n = 4; mean  SEM). (H) Double-stained retinas 8 days after birth for isolectin GS-IB4 (green, upper 
panel) and collagen IV (red, middle panel) shows exposed collagen IV basement membrane sheets due to vessel 
retraction in pAd-Fgd5 or sham virus treated retinas (indicated by white circles in the overlay, bottom panel). 
Quantification of exposed collagen IV sites shows that Fgd5 overexpression in the retina significantly increases 
neovessel retraction (n = 6; mean  SEM). 
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siRNA-mediated Fgd5 knockdown substantiates these findings, because Fgd5 knockdown 
at post-natal day 3 resulted visa versa in an extended retinal vascular bed with persistence 
of excessive branches and tubule structures that failed to be removed during the vascular 
remodelling process (Figure 3D-F). qPCR analysis validated that murine Fgd5 mRNA 
expression in the pAd-Fgd5 treated retinas was significantly increased compared with 
treatment with pAd-sham up to post-natal day 6. Similarly, si-Fgd5 treated retinas showed a 
significant reduction in levels of endogenous Fgd5 at similar time points (post-natal day 4 
and 6) compared with transfection with scrambled non-targeting siRNA treated retinas 
(Figure 3G). High-resolution representative retina examples of the Fgd5 gain- and loss-of-
function are provided in the supplemental data (Supplemental figure 2W, online). 
Alteration in Fgd5 expression levels during retinal vascularisation did not affect the 
expansion rate of the vascular bed, as evidenced by the fact that the front of the network 
reached the border zone of the retina in all of the assessed conditions by post-natal day 8 
(Figure 3A, D). This points toward a role in active pruning of pre-established neovessels 
rather than an inhibitory function in neovessel formation for Fgd5. To evaluate this further, 
pAd-Fgd5 treated retinas were assessed for neovessel retraction as visualised by whole-
mount isolectin GS-IB4/collagen IV staining. The number of exposed collagen IV basement 
membrane sheets at post-natal day 8 was significantly increased in Fgd5-overexpressed 
conditions compared with pAd-sham treated controls (Figure 3H). Further evidence was 
provided by FACS analysis, demonstrating that Fgd5 overexpression in the retinal bed 
decreased the percentage of Flk1-positive or CD31-positive (endothelial) cells (Figure 4A, 
B) at post-natal day 6 as a result of increased apoptosis, as revealed by Annexin V/PI 
analysis (Figure 4C, D). Combined, these data indicate that Fgd5 plays a significant role in 
the regression of the retinal vascular network. 
 
Fgd5 induces apoptosis in endothelial cells via a Hey1-p53 regulatory pathway 
The observed anti-angiogenic effects of Fgd5 may be attributed to changes in EC 
proliferation and survival. Fgd5 expressing HUVECs showed a reduced growth rate 
compared with pAd-sham infected controls (Supplemental figure 3A, B, online). In 
contrast, siRNA-mediated Fgd5 knockdown in HUVECs increased cell proliferation 
compared with si-sham controls (Supplemental figure 3C, online). Annexin V/PI FACS 
analysis demonstrated that Fgd5 overexpression promoted apoptosis, whereas siRNA-
mediated Fgd5 silencing diminished apoptosis (Supplemental figure 3D, E, online). The 
increase in cell death coincided with rising p21Cip1 and p53 protein levels (Supplemental 
figure 3F, G, online). These data imply that Fgd5 could be involved in p21Cip1-associated 
cell cycle arrest and p53-dependent apoptosis, resulting in vascular regression. To elucidate 
the downstream signalling cascade involved in Fgd5-mediated vascular pruning, the gene 
expression for well-defined angiogenic modulators was determined by qPCR. Fgd5 
knockdown inhibited VEGFR-1 and Flt1 mRNA expression, but promoted VEGFR-2, Kdr 
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and Flk1 mRNA expression, whereas Fgd5 overexpression decreased VEGFR-2 in favour 
of VEGFR-1 mRNA levels, thus promoting an anti-angiogenic state in the ECs 
(Supplemental figure 3H, online). In addition, Fgd5 knockdown was associated with the 
downregulation of Notch pathway genes, including Notch 1 and 4, and Dll4. Hey1, one of 
the key downstream transcriptional regulators of the Notch signalling pathway20, was 
markedly downregulated by Fgd5 knockdown (Supplemental figure 3H, online). In 
contrast, Fgd5 overexpression induced reversed effects. Fgd5 knockdown or overexpression 
in HUVECs did not change mRNA expression of VEGF-A, jagged 1, ephrin B2 and B4, 
neuropilin 1 and 2 (Supplemental figure 3I, online). To investigate whether the process of 
Fgd5-mediated vascular pruning could be mediated by changes in the VEGFR-1:VEGFR-2 
ratio, a soluble active form of VEGFR-1 was provided in si-Fgd5 treated retinas. Indeed, 
the restoration of VEGFR-1 bio-availability diminished the formation of excessive vascular 
structures that was associated with Fgd5 silencing (Supplemental figure 3J, online). Thus, 
Fgd5 could regulate the vascular pruning process by promoting VEGFR-1 versus VEGFR-
2 bio-availability. 
 
 
Figure 4. Fgd5 expression affects retinal vascular development and correlates with apoptosis. (A) Flow 
cytometric analysis of the percentage of Flk1-positive cells in the retina - infected with pAd-Fgd5 or sham virus - 
three days after injection. Red histograph represents the isotype control, blue histograph represents the Flk1-
positive signal. (B) Bar graphs show the percentage of Flk1-positive cells and CD31-postive cells in the alive cell 
population. (C) Dot plot graphs of the percentage of dead cells, apoptotic cells and alive cells in the Flk1-positive 
population. (D) Quantification of the percentage of apoptotic cells in the Flk1-positive population (left graph) and 
the CD31-positive population (right graph) (Flk1 analysis: n = 6 and CD31 analysis: n = 4). 
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Hey1 was previously associated with p53-mediated apoptosis21, suggesting that Hey1 
could mediate Fgd5-induced apoptosis in ECs. Here, we assessed the function of Hey1 in 
Fgd5-mediated apoptosis. Hey1 knockdown in Fgd5 expressing HUVECs could rescue 
growth inhibition induced by Fgd5 (Figure 5A). It also diminished p21Cip1 and p53 protein 
levels (Figure 5B, C) and reversed ECs from Fgd5-induced apoptosis (Figure 5D, E). PI-
aided cell cycle analysis suggested that Fgd5 enhanced the sub-G1 apoptotic fraction, 
whereas the percentage of alive and proliferating cells decreased, i.e. decrease in G1 and S–
G2 fraction in the pAd-Fgd5 group compared with the pAd-sham treated group (Figure 5F, 
G). This cytostatic effect was rescued by Hey1 knockdown in Fgd5 overexpressing ECs. 
Likewise, in an in vitro coated-bead assay, Fgd5-mediated inhibition of capillary outgrowth 
was reversed by concomitant Hey1 silencing (Figure 5H, I). 
 
 
Figure 5. Fgd5 induces apoptosis in endothelial cells via Hey1 activation. (A) Number of HUVECs three days 
after infection with sham virus, pAd-Fgd5, pAd-Fgd5 with si-Hey1, pAd-Fgd5 with si-sham, or sham virus with 
si-sham. Representative immunoblots with corresponding graphs that show quantification of (B) p53 and (C) 
p21Cip1 band densities in the examined groups (n = 4; mean  SEM). 
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(D) Representative flow cytometric analysis of non-infected control HUVECs and HUVECs infected with sham 
virus, pAd-Fgd5 or pAd-Fgd5 with si-Hey1. (E) Quantification of the percentage of Annexin V-positive cells (n = 
4; mean  SEM). (F) Representative flow cytometric analysis of non-infected control HUVECs and HUVECs 
infected with sham virus, pAd-Fgd5 or pAd-Fgd5 with si-Hey1. (G) Quantification of the percentages of cells in 
the subG1, G1 and S–G2-fractions in the different experimental groups (n = 4; mean  SEM). 
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(H) Representative micrographs show phalloidin stained microvascular sprouting (red) of HUVECs coated on 
Cytodex® beads in matrigel. HUVECs were infected with sham virus, pAd-Fgd5 or pAd-Fgd5 with si-Hey1. (I) 
Quantitative analysis of the effect of Hey1 knockdown in Fgd5 overexpressing cells on the relative sprout area per 
bead (n = 3; mean  SEM). 
 
 
Further studies demonstrate that Fgd5-induced cell death was indeed mediated via 
p21Cip1 and p53, because co-transfection of pAd-Fgd5 in HUVECs with p21Cip1 or p53 
targeting siRNA rescued these cells from apoptosis (Figure 6A, B) and reduced the sub-G1 
apoptotic fraction while promoting the percentage of alive and proliferative cells as 
demonstrated by cell cycle analysis (Figure 6C, D). In addition, p53 silencing reversed the 
growth inhibitory effects of Fgd5 overexpression in the coated-bead assay (Figure 6E, F). 
These data support the pro-apoptotic function of Fgd5 in ECs during late neo-angiogenesis 
and demonstrate involvement of the Hey1-p21Cip1-p53 signalling cascade in the induction 
of Fgd5-mediated apoptosis in ECs. 
Fgd5 regulates vascular pruning 
 
 197
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Fgd5-mediated endothelial cell death depends on p21Cip1 and p53 signalling. (A) Representative 
flow cytometric analysis of HUVECs infected with sham virus, pAd-Fgd5, pAd-Fgd5 with si-p21Cip1, or pAd-Fgd5 
with si-p53. (B) Quantification of the percentage of Annexin V-positive cells (n = 4; mean  SEM). (C) 
Representative flow cytometric analysis of non-infected control HUVECs and HUVECs infected with sham virus, 
pAd-Fgd5, pAd-Fgd5 with si-p21Cip1, or pAd-Fgd5 with si-p53. 
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(D) Quantification of the percentages of cells in the subG1, G1 and S–G2-fractions in the different experimental 
groups (n = 4; mean  SEM). (E) Representative micrographs show microvascular sprouting of HUVECs coated 
on Cytodex® beads in matrigel. HUVECs were infected with sham virus, pAd-Fgd5 or pAd-Fgd5 with si-p53. (F) 
Quantitative analysis of the effect of p53 knockdown in Fgd5 overexpressing cells on the relative sprout area per 
bead (n = 3; mean  SEM). 
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Fgd5 binds and activates Cdc42 small G-protein 
To determine the direct protein target of Fgd5, we assessed whether Fgd5 could bind and 
activate small G-proteins like its better-known family members. Fgd5 transgene expression 
in HUVECs did not alter total Cdc42, decreased Rac1 and increased RhoA protein levels 
(Figure 7A). However, co-immunoprecipitation using an antibody against Fgd5 identified 
Cdc42 as the selective binding partner of Fgd5 (Figure 7B), leading to specific activation of 
Cdc42 in a GEF-activity assay (Figure 7C-E). In addition, fluorescence microscopy showed 
co-localisation of endogenous Fgd5 with Cdc42 at the perinuclear site in the cytoplasm of 
ECs (Figure 7F, G). In contrast, Rac1 and RhoA activity was significantly reduced in 
response to Fgd5 overexpression. Because no direct binding of Fgd5 to Rac1 or RhoA was 
observed in the co-immunoprecipitation studies, these data suggest that the inhibition of 
Rac1 and RhoA activity is an indirect downstream effect of Fgd5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Fgd5 binds and activates Cdc42 small G-protein. (A) Western blot analysis of Rac1, RhoA and 
Cdc42 levels in HUVECs overexpressing Fgd5. (B) Immunoprecipitation of Fgd5 in HUVECs overexpressing 
Fgd5 showed co-immunoprecipitation of Cdc42, but not of Rac1 or RhoA. Immunoprecipitation using an IgG 
isotype control showed no effective pull down of Fgd5 or Cdc42 (shown are representative results of n = 3). 
Chemiluminescence measurement of the GTP-bound small G-proteins in HUVECs infected with sham virus or 
pAd-Fgd5, showing the levels of (C) RhoA-GTP, (D) Rac1-GTP and (E) Cdc42-GTP in response to serum 
activation (n = 4; mean  SEM). 
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(F) Fgd5 was mainly located perinuclear in the cytoplasm and co-localises with Cdc42, as demonstrated by 
immunofluorescent staining. Fgd5 (red), Cdc42 (green), co-localised area (yellow) and nuclei (blue) (n = 3). (G) 
Fgd5 does not co-localise with zyxin - a focal adhesion marker - as demonstrated by immunofluorescent staining. 
Fgd5 (red), zyxin (green) and nuclei (blue) (n = 3). 
 
 
Fgd5 level correlates with vascular regression in aging 
Transgenic mice with constitutively activated Cdc42 show premature aging with failing 
DNA repair, accelerated cell senescence and increased p53-dependent apoptosis.22 
Similarly, Cdc42 activation in cell culture was previously associated with cell senescence23 
and apoptosis24, whereas Cdc42 deletion in haematopoietic stem cells promoted 
proliferation by loss of p21Cip1 regulation during cell cycle progression.25 To assess the role 
of Fgd5 in aging-related vascular regression we carried out qPCR analysis of aging wild-
type C57BL/6J mice ranging from early fully mature (37-41 weeks) to old (80-92 weeks) 
specimens. A significant increase in Fgd5 levels was observed in the oldest group of 
animals, which coincided with rising p21Cip1 expression, whereas CD31 levels were 
diminished in the oldest group (Supplemental figure 4, online). 
 
 
Discussion 
 
This study has several findings. First, Fgd5 is specifically expressed in both progenitor and 
mature ECs, in contrast to its family members FRG, Fgd1, Fgd2, Fgd3, Fgd4 and Fgd6, 
which show an ubiquitous expression in different cell types. In addition, this EC-specific 
expression is preserved throughout the evolution in different species. Second, Fgd5 inhibits 
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neovascularisation, as indicated by the results obtained in vitro from network-formation, 
aortic-ring and coated-bead assays. These findings were validated in vivo by results 
obtained from the coated-bead plug assay and the murine retina model. Third, Fgd5 binds 
and activates its direct downstream target - Cdc42. Fourth, Fgd5 inhibits neovascularisation 
by apoptosis-induced vaso-obliteration via induction of the Hey1-p53 pathway. Finally, 
Fgd5 indeed correlates with apoptotic marker expression in Flk1-positive ECs during 
vascular remodelling in the mouse retina, whereas high levels of Fgd5 expression were 
linked to rising p21Cip1 mRNA levels in aging C57BL/6J wild-type mice. 
Here, we define, for the first time to the best of our knowledge, the function of Fgd5 as 
an EC-specific GEF that plays a crucial role in apoptosis-induced vascular pruning during 
vascular remodelling. 
Vascular growth and remodelling during development and disease are tightly regulated 
by stimulatory and inhibitory signals that determine the complexity of the vascular tree 
hierarchy. Here, we describe the inhibitory role of Fgd5 in vascular development, a member 
of the Fgd family of RhoGEF from which thus far no biological function was allocated. 
Fgd1 was the first Fgd member to be identified and mutations in the gene were proven to be 
responsible for Faciogenital Dysplasia or Aarskog-Scott syndrome.8 Further studies 
indicated that Fgd1 functioned as a Cdc42-specific GEF, thereby activating Cdc42 
signalling by exchanging bound GDP with GTP.7 Fgd2, Fgd3, Fgd4 and FRG were 
identified by genetic searches as Fgd1 homologues4-6, and were all subsequently associated 
with a specific role in Cdc42 activation with downstream effects on cell migration and 
morphology9-13, whereas the function of Fgd5 and Fgd6 remained to be elucidated. 
Although the preserved Cdc42-GEF activity of the different Fgd members seemed to imply 
a redundancy in the protein family by overlapping function, the specific expression of Fgd5 
in ECs points toward a unique role for this particular Fgd member in EC regulation. Similar 
to the other family members, Fgd5 comprises (in order) a Dbl homology adjacent to a PH 
domain, followed by a FYVE-finger domain and a second C-terminal PH domain. 
Although the Dbl homology domain is responsible for catalytic activity, the PH domain 
appears to be vital for localisation and full activation of this group of RhoGEFs.6,12,13 Here, 
we show specific direct binding of Fgd5 to Cdc42 and demonstrate Fgd5-mediated 
activation of Cdc42. In addition, similar to recent findings that indicated co-localisation of 
Fgd1 with Cdc42 in the Golgi complex in HeLa cells26, Fgd5 intracellular distribution in 
ECs was primarily co-localised with Cdc42 in the perinuclear region. Together, these data 
identify Cdc42 as the direct downstream target of Fgd5 and assign an EC-specific RhoGEF 
function to this gene. 
Our data also demonstrated that the effect of Fgd5 could be attributed to p21Cip1-
mediated G1/S–G2 cell cycle arrest, followed by p53-mediated apoptosis. Transgenic 
overexpression of Fgd5 coincided with the upregulation of the Notch signalling pathway, 
including Notch 1 and 4, Dll4, and the downstream transcription factor Hey1. Genetic 
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regulation of these Notch genes could be induced after Fgd5-mediated Cdc42 activation via 
the p38-MAPK signalling pathway that regulates transcriptional activation.27 More 
downstream of Cdc42 towards the process of apoptosis, recent studies have indicated that 
Hey1 triggered p53 activation through repression of HDMD2 transcription, indentifying a 
new direct link between Hey1 and p53.21 Our experiments further showed that siRNA 
targeting of Hey1 in Fgd5 transgenic ECs inhibited Fgd5-induced G1/S–G2 cell cycle arrest 
and cell death by reverting protein levels of p21Cip1 and p53 back to baseline. In addition, 
Hey1 knockdown of Fgd5 transgenic HUVECs restored the sprouting capacity of these 
cells in the in vitro coated-bead assay, whereas siRNA targeting of p21Cip1 or p53 in Fgd5 
transgenic ECs obtained similar effects on apoptosis and sprout-formation. Together, our 
data clearly indicate Fgd5-mediated cell death in ECs involves the Hey1-p21Cip1-p53 
pathway. 
In our studies, we demonstrated that rising endogenous Fgd5 levels in the Flk1-positive 
ECs in the developing retinal vasculature were associated with the expression of the 
apoptosis marker cleaved caspase 3. Surprisingly, a large population of Flk1-
postive/caspase 3-positive/Fgd5-negative cells was also observed next to the Flk1-
positive/caspase 3-positive/Fgd5-positive subpopulation, which suggests that Fgd5-induced 
apoptosis is not the only regulatory mechanism of vascular pruning. Indeed, Ishida et al3 
have previously published that vascular regression in the murine retina was also regulated 
by infiltration of leukocytes. These cells induce apoptosis of the redundant vascular 
structure via a FasL-mediated process. In light of these findings, our data demonstrate that 
Fgd5 activation provides an additional mechanism that is partially responsible for the 
observed cell death of Flk1-positive ECs in the natural vascular pruning process. 
Wang et al22 demonstrated that during natural aging, Cdc42 activity in different organs 
was increased in wild-type mice. By targeting of Cdc42-GAP - which reverses Cdc42 from 
its active GTP-bound to its inactive GDP-bound state - they successfully created a murine 
strain with constitutively elevated Cdc42-GTP levels. These Cdc42-GAP-knockout animals 
had a prematurely aged phenotype with a failing DNA repair system and a considerably 
shortened average lifespan from 27 weeks to 12 months. In addition, increased apoptosis 
was observed in various cell types during organ development and aging, which was 
dependent on p21Cip1 and p53 activation. Cdc42-GAP-null cells also showed early 
proliferative senescence compared with wild-type cells.22 Cdc42 activation was previously 
associated with cell senescence23 and apoptosis24, whereas Cdc42 deletion in 
haematopoietic stem cells promoted cell proliferation by deregulating p21Cip1 levels during 
cell cycle progression.25 These studies suggested a direct link between Cdc42 activity and 
p53-mediated apoptosis, which was further affirmed in our findings in which GEF activity 
of Fgd5 elevated the level of Cdc42-GTP in ECs and coincided with Hey1-p53-induced cell 
death. Fgd5-induced apoptosis could be further confirmed in vivo because high endogenous 
levels of Fgd5 during retinal vascular development were linked to a rise in cleaved caspase 
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3 levels in ECs. More important, transgenic overexpression of Fgd5 in the developing 
murine retinal vasculature induced EC apoptosis and vascular regression, whereas Fgd5 
silencing promoted survival of excessive vascular structures. 
Thus far, we have established an important role for Fgd5 in vascular remodelling as an 
inducer of vascular pruning of redundant neovessels. In aging, an imbalance between 
Cdc42 deactivation and activation could result in elevated Cdc42 activity, which has severe 
effects on the proliferative and stress-responsive capacities of aging cells.22 Thus, it would 
be interesting to study the level of Fgd5 expression not only in diseases with pronounced 
apoptosis-induced vascular regression, but also in the aging vasculature. In this study, we 
found a correlation between Fgd5 levels and increasing levels of p21Cip1 expression in the 
highly vascularised hind limb tissue of aging wild-type mice, which coincided with a 
decline in CD31 EC marker expression. Currently, we are carried out further studies to 
elucidate the role of this EC-specific GEF in vascular regression in the natural aging 
process. 
In conclusion, we have identified Fgd5 as a new genetic regulator of vascular pruning 
of redundant neovessels by activation of targeted apoptosis. In addition, Fgd5 function 
could prove to be a decisive factor in the survival and stability of aging vasculature. 
 
 
References 
 
1. Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodelling is 
defined by pericyte coverage of the preformed endothelial network and is regulated by 
PDGFβ and VEGF. Development. 1998;125(9):1591-1598. 
2. Jain RK. Molecular regulation of vessel maturation. Nat Med. 2003;9(6):685-693. 
3. Ishida S, Yamashiro K, Usui T, Kaji Y, Ogura Y, Hida T, Honda Y, Oguchi Y, Adamis 
AP. Leukocytes mediate retinal vascular remodelling during development and vaso-
obliteration in disease. Nat Med. 2003;9(6):781-788. 
4. Obaishi H, Nakanishi H, Mandai K, Satoh K, Satoh A, Takahashi K, Miyahara M, 
Nishioka H, Takaishi K, Takai Y. Fabrin, a novel Fgd1-related actin filament-binding 
protein capable of changing cell shape and activating c-Jun N-terminal kinase. J Biol 
Chem. 1998;273(30):18697-18700. 
5. Pasteris NG, Nagata K, Hall A, Gorski JL. Isolation, characterisation and mapping of 
the mouse Fgd3 gene, a new Faciogenital Dysplasia (Fgd1; Aarskog syndrome) gene 
homologue. Gene. 2000;242(1-2):237-247. 
6. Pasteris NG, Gorski JL. Isolation, characterisation and mapping of the mouse and 
human Fgd2 genes, Faciogenital Dysplasia (Fgd1; Aarskog syndrome) gene 
homologues. Genomics. 1999;60(1):57-66. 
Chapter 7 
 
 204 
7. Zheng Y, Fischer DJ, Santos MF, Tigyi G, Pasteris NG, Gorski JL, Xu Y. The 
Faciogenital Dysplasia gene product Fgd1 functions as a Cdc42 Hs-specific guanine-
nucleotide exchange factor. J Biol Chem. 1996;271(52):33169-33172. 
8. Pasteris NG, Cadle A, Logie LJ, Porteous ME, Schwartz CE, Stevenson RE, Glover 
TW, Wilroy RS, Gorski JL. Isolation and characterisation of the Faciogenital Dysplasia 
(Aarskog-Scott syndrome) gene: a putative Rho/Rac guanine nucleotide exchange 
factor. Cell. 1994;79(4):669-678. 
9. Miyamoto Y, Yamauchi J, Itoh H. Src kinase regulates the activation of a novel Fgd1-
related Cdc42 guanine nucleotide exchange factor in the signalling pathway from the 
endothelin A receptor to JNK. J Biol Chem. 2003;278(32):29890-29900. 
10. Hayakawa M, Matsushima M, Hagiwara H, Oshima T, Fujino T, Ando K, Kikugawa 
K, Tanaka H, Miyazawa K, Kitagawa M. Novel insights into Fgd3, a putative GEF for 
Cdc42, that undergoes SCF(FWD1/beta-TrCP)-mediated proteasomal degradation 
analogous to that of its homologue Fgd1 but regulates cell morphology and motility 
differently from Fgd1. Genes Cells. 2008;13(4):329-342. 
11. Huber C, Mårtensson A, Bokoch GM, Nemazee D, Gavin AL. Fgd2, a Cdc42-specific 
exchange factor expressed by antigen-presenting cells, localises to early endosomes 
and active membrane ruffles. J Biol Chem. 2008;283(49):34002-34012. 
12. Umikawa M, Obaishi H, Nakanishi H, Satoh-Horikawa K, Takahashi K, Hotta I, 
Matsuura Y, Takai Y. Association of frabin with the actin cytoskeleton is essential for 
microspike formation through activation of Cdc42 small G-protein. J Biol Chem. 
1999;274(36):25197-25200. 
13. Ono Y, Nakanishi H, Nishimura M, Kakizaki M, Takahashi K, Miyahara M, Satoh-
Horikawa K, Mandai K, Takai Y. Two actions of frabin: direct activation of Cdc42 and 
indirect activation of Rac. Oncogene. 2000;19(27):3050-3058. 
14. Cheng C, Tempel D, Oostlander A, Helderman F, Gijsen F, Wentzel J, van Haperen R, 
Haitsma DB, Serruys PW, van der Steen AF, de Crom R, Krams R. Rapamycin 
modulates the eNOS versus shear stress relationship. Cardiovasc Res. 2008;78(1):123-
129. 
15. Cheng C, Tempel D, den Dekker WK, Haasdijk RA, Chrifi I, Bos FL, Wagtmans K, 
van de Kamp EH, Blonden L, Biessen EA, Moll F, Pasterkamp G, Serruys PW, 
Schulte-Merker S, Duckers HJ. Ets2 determines the inflammatory state of endothelial 
cells in advanced atherosclerotic lesions. Circ Res. 2011;109(4):382-395. 
16. Cheng C, Noordeloos AM, Jeney V, Soares MP, Moll F, Pasterkamp G, Serruys PW, 
Duckers HJ. Haem oxygenase-1 determines atherosclerotic lesion progression into a 
vulnerable plaque. Circulation. 2009:119(23):3017-3027. 
Fgd5 regulates vascular pruning 
 
 205
17. Cheng C, Noordeloos AM, van Deel ED, Tempel D, den Dekker WK, Wagtmans K, 
Duncker DJ, Soares MP, Laman JD, Duckers HJ. Dendritic cell function in 
transplantation arteriosclerosis is regulated by haem oxygenase-1. Circ Res. 
2010;106(10):1656-1666. 
18. Cheng C, Tempel D, van Haperen R, van Damme LC, Algür M, Krams R, de Crom R. 
Activation of MMP8 and MMP13 by angiotensin II correlates to severe intra-plaque 
haemorrhages and collagen breakdown in atherosclerotic lesions with a vulnerable 
phenotype. Atherosclerosis. 2009;204(1):26-33. 
19. Segers D, Helderman F, Cheng C, van Damme LC, Tempel D, Boersma E, Serruys 
PW, de Crom R, van der Steen AF, Holvoet P, Krams R. Gelatinolytic activity in 
atherosclerotic plaques is highly localised and is associated with both macrophages and 
smooth muscle cells in vivo. Circulation. 2007;115(5):609-616. 
20. Fischer A, Schumacher N, Maier M, Sendtner M, Gessler M. The Notch target genes 
Hey1 and Hey2 are required for embryonic vascular development. Genes Dev. 
2004;18(8):901-911. 
21. Huang Q, Raya A, DeJesus P, Chao SH, Quon KC, Caldwell JS, Chanda SK, Izpisua-
Belmonte JC, Schultz PG. Identification of p53 regulators by genome-wide functional 
analysis. Proc Natl Acad Sci U S A. 2004;101(10):3456-3461. 
22. Wang L, Yang L, Debidda M, Witte D, Zheng Y. Cdc42 GTPase-activating protein 
deficiency promotes genomic instability and premature aging-like phenotypes. Proc 
Natl Acad Sci U S A. 2007;104(4):1248-1253. 
23. Cho KA, Ryu SJ, Oh YS, Park JH, Lee JW, Kim HP, Kim KT, Jang IS, Park SC. 
Morphological adjustment of senescent cells by modulating caveolin-1 status. J Biol 
Chem. 2004;279(40):42270-42278. 
24. Maillet M, Lynch JM, Sanna B, York AJ, Zheng Y, Molkentin JD. Cdc42 is an 
antihypertrophic molecular switch in the mouse heart. J Clin Invest. 
2009;119(10):3079-3088. 
25. Yang L, Wang L, Geiger H, Cancelas JA, Mo J, Zheng Y. Rho-GTPase Cdc42 
coordinates haematopoietic stem cell quiescence and niche interaction in the bone 
marrow. Proc Natl Acad Sci U S A. 2007;104(12):5091-5096. 
26. Egorov MV, Capestrano M, Vorontsova OA, Di Pentima A, Egorova AV, Mariggiò S, 
Ayala MI, Tetè S, Gorski JL, Luini A, Buccione R, Polishchuk RS. Faciogenital 
Dysplasia protein (Fgd1) regulates export of cargo proteins from the Golgi complex via 
Cdc42 activation. Mol Biol Cell. 2009;20(9):2413-2427. 
27. Kang JS, Bae GU, Yi MJ, Yang YJ, Oh JE, Takaesu G, Zhou YT, Low BC, Krauss RS. 
A Cdo-Bnip-2-Cdc42 signalling pathway regulates p38alpha/beta-MAPK activity and 
myogenic differentiation. J Cell Biol. 2008;182(3):497-507. 
 
 
 206 
 
 
 
 
 
Chapter 8 
 
 
 
 
Tnfaip8l1 
promotes angiogenesis 
by inhibition of 
endothelial cell apoptosis 
 
 
 
 
 
 
 
 
 
 
 
Submitted 
 
 
D. Tempel, R.A. Haasdijk, F.L. Bos, D.M.A. Hermkens 
P.E. Bürgisser, J.C. Sluimer, L. Bosman, E.A.L. Biessen 
C. Cheng, S. Schulte-Merker, H.J. Duckers 
 
 
 
Chapter 8 
 
 208 
Abstract 
 
Objective - During the initial phase of angiogenesis, proliferating endothelial cells (EC) are 
highly susceptible to apoptosis and need rescuing by biological anti-apoptotic cues to 
ensure neovasculature survival. Although the molecular mechanisms that govern the 
formation of a vascular network have been studied intensively, specific angiogenic factors 
that regulate EC apoptosis still need to be further identified. 
Methods and Results - Using a transcriptomics approach to identify new regulators of 
angiogenesis, we identified Tumour necrosis factor alpha inducible protein like 1 
(Tnfaip8l1), a gene of hitherto unknown function that was highly expressed in ECs. 
Vascular Tnfaip8l1 expression was predominantly restricted to angioblasts and adult ECs in 
mice and developing zebrafish. Gain- and loss-of-function assays in vitro and in vivo 
indicated that Tnfaip8l1 is involved in vascular development by inhibition of death effector 
domain-containing receptor-mediated apoptosis in ECs. Tnfaip8l1 proved to quench the 
activation of caspase 3 by inhibition of caspase 8 activity, leading to enhanced EC survival 
and vascular growth. EC and vasculature survival is crucial for safeguarding cardiac 
function after an ischemic insult. We demonstrate that the endothelial expression of 
Tnfaip8l1 was strongly increased after a myocardial infarction (MI), which suggests a role 
for Tnfaip8l1 in the neovascularisation response after MI. 
Conclusion - Here, we present Tnfaip8l1 as a new regulator of EC survival during vascular 
growth-associated apoptosis and ischemic disease. 
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Introduction 
 
Survival of a newly formed or a fully established vascular network is highly dependent on 
external biological stimuli, which include secreted growth and chemotactic factors and the 
composition of microenvironment components that make up the supporting extracellular 
matrix. Cell apoptosis is commonly observed in fast expanding cell populations and during 
embryonic development. The dynamics of biological cues alternate from those that promote 
growth and expansion - such as VEGF-A and FGF - to those that promote vascular waning 
by active induction of apoptosis - such as FASL and TNFα.1 A delicate balance between 
these pro-angiogenic and anti-angiogenic factors generally protects endothelial cells (EC) 
against apoptosis during vascular development, and ensures survival of selective neovessels 
for further maturation into a functional vascular network.2 In addition, increasing evidence 
suggests that EC apoptosis may actively counteract neovascular growth.3,4 In vascular-
related pathology, EC apoptosis often contributes to disease progression. For example, in 
atherosclerosis, loss of the endothelium in the cap region of atherosclerotic lesions triggers 
atherothrombosis5, while in early myocardial infarction (MI) response, active protection of 
ECs against apoptosis is crucial for fast recovery of the myocardium.6,7 In contrast, disease 
progression in cancer may be held back by an effective decline in blood flow due to EC 
apoptosis and subsequent vascular degradation. Although the importance of EC apoptosis is 
clearly demonstrated by earlier reports, the molecular regulators that orchestrate EC and 
thus vascular network survival remain to be determined. Here, we describe the function of a 
new gene with specific endothelial expression and potent anti-apoptotic activity. 
Previously, we studied the expression profile of Flk1-positive angioblasts in embryos 
during different days of murine embryonic development.8 We found that Tumour necrosis 
factor alpha inducible protein like 1 (Tnfaip8l1) is one of the ~2,000 genes that were > 1.90 
fold upregulated in Flk1-positive angioblasts compared with Flk1-negative cells. Tnfaip8l1 
is a member of the Tnfaip8 subfamily, which includes Tnfaip8l1, Tnfaip8l2, Tnfaip8l3 and 
Tnfaip8.9 All family members contain a death effector domain (DED)-like domain 
homologous to DED II of Fas-associated death domain-like interleukin-1b-converting 
enzyme (FLICE/caspase 8)-inhibitory proteins (FLIP). DEDs are commonly found in 
proteins that regulate or mediate the process of apoptosis.10 FLIPs block death domain-
containing receptor-DEDs, thereby interfering with the activation of caspase 8.11,12 Unlike 
FLIPs, Tnfaip8 inhibits apoptosis by inhibiting caspase 8 activity and caspase 3 activation 
in cells in vitro.13,14 Tnfaip8l2 has been shown to bind to caspase 8 and influence its activity 
in immune cells.15 However, the function of Tnfaip8l1, and more specifically its role in 
ECs, is currently unknown. Given the specific expression of Tnfaip8l1 in Flk1-positive 
angioblasts during vascular development, we sought to define the potential role of 
Tnfaip8l1 within the process of vascularisation. 
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Here, we demonstrate that Tnfaip8l1 is specifically expressed in the zebrafish and 
mouse vasculature during embryonic development, but also in adult ECs. Tnfaip8l1 
overexpression reduced endothelial apoptosis and promoted vascular network formation in 
vitro and in vivo. Vice Versa, knockdown of Tnfaip8l1 by short hairpin RNA (shRNA) 
lentivirus infection resulted in enhanced endothelial apoptosis and diminished network 
formation in vitro and in vivo. Further studies in vitro showed that Tnfaip8l1 inhibited 
TNFα and FasL-induced endothelial apoptosis, by inhibiting the activation of caspase 3 by 
reducing the activity of cleaved caspase 8 in vitro. Furthermore, after a MI - a condition in 
which EC survival and high levels of TNFα play a crucial role in cardiac protection - the 
endothelial expression of Tnfaip8l1 strongly increased, suggesting a role for Tnfaip8l1 in 
the repair mechanism after MI. 
Taken together, these data indicate that Tnfaip8l1 functions as a pro-angiogenic factor 
by enhancing EC survival during vascular development and after an ischemic event. 
Considering its potent anti-apoptotic nature, Tnfaip8l1 might be an interesting target for the 
development of therapeutic agents for the protection of the degradation sensitive 
(neo)vasculature in vascular disease or during the treatment of cancer. 
 
 
Methods 
 
A more detailed description of materials and methods is available in the Data Supplement 
(online). Summarised descriptions of the different techniques used in this study are supplied 
below. 
 
Animals 
All experiments were carried out in accordance with the Council of Europe Convention 
(ETS123)/Directive (86/609/EEC) for the protection of vertebrate animals used for 
experimental and other scientific purposes and with the approval of the National and Local 
Animal Care Committee. C57BL/6J mice were obtained from The Jackson Laboratory (Bar 
Harbor, USA), and maintained and bred under standard laboratory conditions. Wild-type 
zebrafish and the transgenic zebrafish line Tg(Fli1:eGFP)y1 were kept and bred under 
standard laboratory conditions. 
 
Isolation of Flk1-positive angioblasts from murine embryos 
Developing mouse embryos were collected at different days during development. After 
proteolytic dissociation of the embryos, the single cell suspensions were incubated with PE-
conjugated anti-mouse Flk1 antibody 1:50 (555308; BD, Breda, The Netherlands) and 
Hoechst (Sigma-Aldrich, Zwijndrecht, The Netherlands). Cell suspensions were sorted for 
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> 90% purity for Flk1-positive/Hoechst-negative cells using a BD FACSCantoTM cell-sorter 
(Breda, The Netherlands). Flk1-negative/Hoechst-negative cells served as a control. 
 
Zebrafish whole-mount in situ hybridisation and morpholino injection 
Template DNA for in situ probe generation was obtained by direct amplification of target 
genes from genomic DNA. Primers for probe generation were designed to span exons of at 
least 250 base pairs in size to ensure probe specificity. Reverse primers were tagged with a 
T3 RNA polymerase promotor tail to allow direct in vitro transcription and generation of 
antisense probes after PCR purification. Primer sequences used were: 5’-CTC TAG TTT 
GGA GGG CAA TAG-3’ (forward) and 5’-AAT AAG GCA CGA GAT CTT CC-3’ 
(reverse) (Biolegio, Nijmegen, The Netherlands). Antisense RNA probes were labelled with 
a digoxigenin RNA Labeling Mix from Roche (Woerden, The Netherlands). Whole-mount 
in situ hybridisation was carried out as previously described.16 Coarse in situ transcript 
detection was automated using the Intavis AG in situ robot followed by manual in situ 
transcript detection to increase the signal to noise ratio. 
Morpholinos (MO) (Gene Tools, Philomath, USA) were diluted in Milli-Q water 
containing 0.2% phenol red. One cell stage embryos were injected with different dosages of 
MO as described previously.17 MO sequences used were: 5’-TGG TGC TGA ACG AGT 
CCA TGA TGG TC-3’ for the MO Tnfaip8l1-ATG, 5’-CTT GTA TCC GGT TCA AAT 
GGG G-3’ for the MO Tnfaip8l1-UTR and 5’-CTC TTA CCT CAG TTA CAA TTT ATA-
3’ for the MO control. 
Zebrafish embryos were mounted in 1% low melting point agarose in a culture dish 
with a cover slip replacing the bottom. Imaging was carried out with a Leica Microsystems 
SP5 confocal microscope using a 10x, 20x or 40x objective with digital zoom. Angiography 
was carried out as previously described.18 
 
Mouse model of retina vascularisation 
Two-day old C57BL/6J mice pups were anesthetised by placement on ice. Either 1 μl of 
adenovirus expressing murine Tnfaip8l1 (5x107 pfu) or 1 μl Tnfaip8l1 targeting siRNA 
(1.33 μg/μl) (Thermo Fisher Scientific, Breda, The Netherlands) was injected into the left 
eye using a 33-Gauge needle (World Precision Instruments, Berlin, Germany). As a control 
either 1 μl of sham virus (5x107 pfu) or 1 μl scrambled non-targeting siRNA (1.33 μg/μl) 
(Thermo Fisher Scientific, Breda, The Netherlands) was injected into the right eye. Mice 
pups were killed five days after intra-ocular injection and eyes were enucleated. Retinas 
were stained with Alexa Fluor® 488-conjugated isolectin GS-IB4 1:200 (I21411; Invitrogen, 
Bleiswijk, The Netherlands) before microscopic assessment. Four different regions per 
retina were used to analyse the newly formed vasculature. Adequate transgene-expression 
was validated by qPCR analysis. 
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For the TUNEL assay, retinas were briefly fixed in 4% PFA, embedded in paraffin and 
cut longitudinally into 5 μm sections. Sections were dehydrated and labelled using a 
TUNEL staining kit (CardioTACS In Situ Apoptosis Detection Kit, R&D systems, 
Abingdon, UK) according to the instruction manual, followed by counterstaining with 
nuclear fast red. TUNEL positive cells were quantified using a commercial image analysis 
system (Clemex Technologies, Longueuil, Canada). 
 
In vitro analysis of Tnfaip8l1 in HUVEC 
Primary cultures of human umbilical vein endothelial cells (HUVEC) were cultured in 
EBM®-2 medium supplemented with a commercial BulletKit (Lonza, Breda, The 
Netherlands) under normoxic conditions (21% O2). Passages three and five were used 
throughout the study. HUVECs were infected using either a lentivirus encoding shRNA 
targeting human Tnfaip8l1, a lentivirus expressing human Tnfaip8l1 or a sham lentivirus in 
culture medium supplemented with 10 μg/ml diethylaminoethyl (DEAE)-dextran at 37oC. 
After 72 hours gene and protein expressions were verified by qPCR and Western blot 
analysis as described below. To induce apoptosis HUVECs were stimulated with TNFα (10 
ng/ml) (BD, Breda, The Netherlands) or FasL (1 ng/ml) (Sigma-Aldrich, Zwijndrecht, The 
Netherlands) for 8 hours. 
 
2D matrigel network-formation assay 
In vitro network-formation was studied on BioCoat Matrigel tissue culture plates (BD, 
Breda, The Netherlands). 72 hours after lentiviral infection, HUVECs were plated at 30,000 
cells/well in 96-well plates pre-coated with a solution of Matrigel basement membrane 
matrix. After 18 hours of incubation at 37°C, cells were visualised by Calcein-AM uptake 
(BD, Breda, The Netherlands). Network-formation was examined using an inverted 
fluorescence microscope and the photographs were subsequently analysed using Angiosys 
Image Analysis Software 1.0 (TCS CellWorks, Buckingham, UK). 4,6-diamidino-2-
phenylindole (DAPI) in Vectashield® mounting medium (H-1200; Vector Laboratories, 
Burlingame, USA) was added to assess the cell number after 18 hours. 
 
Apoptosis and cell cycle assay 
For the apoptosis analysis, cells were harvested 72 hours after infection, stained for 
Annexin V and propidium iodide (PI) signals using an Annexin V Apoptosis Detection Kit 
(BD, Breda, The Netherlands), followed by analysis of the samples by flow cytometry on a 
BD FACSCantoTM (Breda, The Netherlands). 
For the cell cycle analysis, HUVECs were harvested and fixed in 70% 
ethanol/phosphate-buffered saline (PBS) for 24 hours at 4oC, stained with PI and analysed 
by flow cytometry on a BD FACSCantoTM (Breda, The Netherlands). 
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Caspase 8 activity assay 
Caspase 8 activity in infected HUVECs was assessed with a commercial Caspase 8 
(Colorimetric) Assay Kit (Abcam, Cambridge, UK), according to the instruction manual. 
Briefly, HUVECs were harvested and lysed with the supplied lysis buffer. Protein 
concentration was determined by a colorimetric protein assay, followed by optical 
spectroscopy (Bio-Rad, Veenendaal, The Netherlands). After addition of DTT and IETD-
pNA substrate, 200 μg of protein was incubated at 37oC for 2 hours. Samples were 
spectrophotometrically read at 405 nm. 
 
Immunohistology of embryos and heart samples 
Murine embryos at embryonic day (E)12.5 and murine heart samples - with or without MI - 
were embedded in paraffin and cut longitudinally into 5 μm sections. The sections were 
rehydrated and incubated with FITC-conjugated lectin GS (Sigma-Aldrich, Zwijndrecht, 
The Netherlands) and Tnfaip8l1 (Santa Cruz Biotechnology, Heidelberg, Germany) in 5% 
bovine serum albumin (BSA)/PBS for 90 minutes at room temperature. Sections were 
washed in PBS and incubated for 30 minutes with an Alexa Fluor® 546-conjugated donkey 
anti-goat IgG (Invitrogen, Bleiswijk, The Netherlands). After washing, sections were cover 
slipped with DAPI in Vectashield® mounting medium (H-1200; Vector Laboratories, 
Burlingame, USA). Data analysis was carried out using a commercial image analysis 
system (Clemex Technologies, Longueuil, Canada). 
Human heart samples - with or without MI - were collected and processed by the 
Experimental Vascular Pathology group (Maastricht UMC+, The Netherlands). The 
paraffin sections were rehydrated and incubated with goat anti-human Tnfaip8l1 (Santa 
Cruz Biotechnology, Heidelberg, Germany) in 5% BSA/PBS o/n at 4oC. Sections were 
washed in PBS and incubated for 90 minutes with Alexa Fluor® 546 donkey anti-goat IgG 
(Invitrogen, Bleiswijk, The Netherlands). After washing, sections were mounted with 
Vectashield® hard-set mounting media (Vector Laboratories, Burlingame, USA). 
 
Statistical analysis 
Data were analysed by one-way ANOVA, as appropriate, followed by individual unpaired 
Student’s t-test. Significance was accepted at P < 0.05 (* P < 0.05, ** P < 0.01 in the 
figures). All data are presented as mean ± standard error of the mean (SEM), unless 
otherwise stated. 
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Results 
 
Tnfaip8l1 expression during development in mice and zebrafish and in the adult 
murine vasculature 
To evaluate the expression of Tnfaip8l1, we compared Flk1-positive angioblasts to the 
Flk1-negative background during embryonic murine development by qPCR analysis. 
Tnfaip8l1 was higher expressed in Flk1-positive angioblasts compared with the Flk1-
negative background from 8 to 16 days post-fertilisation (dpf) (Figure 1A). Vascular 
expression of Tnfaip8l1 was also validated in developing zebrafish larvae by whole-mount 
in situ hybridisation. Tnfaip8l1 was detected in the dorsal aorta, intersegmental vessels 
(ISV) and the pro-nephric duct (Figure 1B). 
 
 
Figure 1. Tnfaip8l1 expression during development in mice and zebrafish and in the adult murine 
vasculature. (A) Tnfaip8l1 mRNA expression in Flk1-positive cells during mouse development. (B) Global 
whole-mount in situ expression profiles for Tnfaip8l1 shows apparent vascular expression patterns at 24-28 hours 
post-fertilisation. 
 
 
The endothelial expression was further confirmed by immunohistological analysis of a 12.5 
dpf murine embryo. Tnfaip8l1 protein expression was identified in the vasculature of a 
developing embryo (Figure 1C). Tnfaip8l1 protein expression was also observed in the 
blood vessels in the heart of a adult mouse (Figure 1D). This finding was further supported 
by different primary cells isolated by laser dissection from adult murine hearts. Tnfaip8l1 
expression in ECs was at least 1.75 higher compared with other vascular cell types, 
including smooth muscle cells (SMC), cardiomyocytes and fibroblasts (Supplemental 
figure 1A, online). Strikingly, RNA analysis of other Tnfaip8 family members - Tnfaip8 
and Tnfaip8l2 - did not show a similar endothelial expression pattern as observed for 
Tnfaip8l1 (Supplemental figure 1B, C, online). These data demonstrate that Tnfaip8l1 is 
predominantly expressed in vascular ECs in zebrafish and mice. 
Tnfaip8l1 inhibits endothelial cell apoptosis 
 
 215
 
(C) Immunohistological example of a 12.5 dpf mouse embryo, showing co-localisation between lectin (green) and 
Tnfaip8l1 (red). (D) Immunohistological example of an adult mouse heart, showing endothelial specific 
expression of Tnfaip8l1 by a double staining of lectin and Tnfaip8l1. 
 
 
Tnfaip8l1 enhances network-formation in vitro 
The angiogenic effect of Tnfaip8l1 was assessed in vitro, using the well established 
network-formation assay in Matrigel. Using a lentivirus - encoding a shRNA targeting 
human Tnfaip8l1 - we were able to inhibit gene and protein expression in HUVECs by 48% 
and 61%, respectively, compared with a sham lentivirus (Figure 2A-C). Overexpression of 
Tnfaip8l1 was studied by infection with a lentivirus - containing the full-length cDNA of 
human Tnfaip8l1. Lentiviral infection of the Tnfaip8l1 cDNA construct increased the gene 
and protein expression of Tnfaip8l1 by 121% and 68%, respectively, compared with a sham 
lentivirus (Figure 2A-C). In contrast, neither knockdown, nor overexpression of Tnfaip8l1 
in HUVECs affected the gene expression of its family members - Tnfaip8 and Tnfaip8l2 
(Figure 2D, E). Interestingly, also neither knockdown, nor overexpression of Tnfaip8l1 in 
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HUVECs affected the expression of VEGFR-2, which was previously reported for its 
family member Tnfaip8 (Figure 2F). 
 
 
Figure 2. Tnfaip8l1 enhances network-formation in vitro. Tnfaip8l1 (A) mRNA and (B, C) protein expression 
in HUVECs was reduced after infection with a lentivirus encoding a Tnfaip8l1 targeting shRNA construct, without 
affecting the mRNA expression of its genetic family members: (D) Tnfaip8, (E) Tnfaip8l2 and (F) VEGFR-2. 
Tnfaip8l1 overexpression in HUVECs with a lentivirus containing the full-length cDNA of human Tnfaip8l1 
resulted in an increase of Tnfaip8l1 (A) mRNA and (B, C) protein, without changes in mRNA expression levels of 
its direct family members: (D) Tnfaip8, (E) Tnfaip8l2, and (F) VEGFR-2. 
 
 
In the 2D matrigel network-formation assay, knockdown of Tnfaip8l1 diminished the 
number of tubules and junctions of sprouting cells by 43% and 41%, respectively, 
compared with sham transfected HUVECs (Figure 2G-I). In addition, overexpression of 
Tnfaip8l1 enhanced the number of tubules and junctions by 1.46 and 1.41 fold, 
respectively, compared with sham infected HUVECs (Figure 2G-I). Nuclear staining with 
DAPI observed a difference in cell number after 18 hours of network-formation 
(Supplemental figure 2, online). Network-formations with Tnfaip8l1 knockdown showed a 
reduction in the number of cells, as seen by the reduction of nuclei. In contrast, 
overexpression of Tnfaip8l1 showed a higher number of cells compared with control and 
sham conditions. These findings provide evidence for a pro-angiogenic function of 
Tnfaip8l1. 
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(G) Lentiviral infected HUVECs were cultured in a 2D matrigel to induce network-formation. Tubules were 
visualised by Calcein-AM dye fluorescence and were subsequently assessed by fluorescence microscopy. 
Knockdown of Tnfaip8l1 showed a decrease in angiogenic capacity of HUVECs as indicated by a decrease in (H) 
number of tubules and (I) number of junctions. (H, I) In contrast, Tnfaip8l1 overexpression increased the 
angiogenic capacity of HUVECs (n = 4 for each group; * P < 0.05 versus control, § P < 0.05 versus sham). 
 
 
Tnfaip8l1 enhances in vivo endothelial sprouting in zebrafish larvae and the murine 
retina 
Next, we addressed the in vivo function of Tnfaip8l1 in the developing vasculature of 
zebrafish larvae. We used an ATG and UTR MO that silenced the zebrafish orthologue of 
Tnfaip8l1. Tg(Fli1:eGFP)y1 zebrafish larvae were injected with either the ATG or UTR 
MO. Both Tnfaip8l1 targeting MOs diminished the formation of ISVs (Figure 3A, C). 
Angiographies at 2.5 dpf in Tnfaip8l1-silenced zebrafish larvae confirmed the absence of 
functional ISVs, indicated by the lack of luminal flow (Figure 3B). 
Furthermore, the effect of Tnfaip8l1 was also assessed during postnatal angiogenesis in 
the murine retina model. Tnfaip8l1 knockdown in retinas from mice pups - using targeting 
siRNA - reduced Tnfaip8l1 mRNA expression levels by 68% compared with scrambled 
non-targeting siRNA transfected controls (Figure 3D). Overexpression in vivo was assessed 
using adenovirus - containing the full-length cDNA of murine Tnfaip8l1. Tnfaip8l1 
expression was increased 1.8 fold after adenoviral injections compared with sham 
adenoviral injections (Figure 3D). Neither knockdown, nor overexpression of Tnfaip8l1 
affected the mRNA expression of Tnfaip8 and Tnfaip8l2 in murine retinas as verified by 
qPCR analysis (Figure 3E, F). Evaluation of the retina vasculature by whole-mount 
Chapter 8 
 
 218 
isolectin GS-IB4 staining showed a reduction of the vascular network upon Tnfaip8l1 
silencing compared with scrambled non-targeting siRNA (Figure 3G). In contrast, 
overexpression of Tnfaip8l1 in the retina resulted in increased vascular network-formation 
compared with sham adenoviral infection (Figure 3G). Combined, these in vivo data clearly 
demonstrate that Tnfaip8l1 plays a vital role in angiogenesis. 
 
 
Figure 3. Tnfaip8l1 enhances in vivo endothelial sprouting in zebrafish larvae and the murine retina. (A) 
Confocal analysis of Tg(Fli1:eGFP)s843 zebrafish larvae at 1 dpf showed normal development of the vasculature in 
uninjected larvae. Tnfaip8l1 larvae displayed normal development of the major blood vessels, but had abnormally 
formed ISVs. (B) Angiographies at 2.5 dpf in Tnfaip8l1-silenced zebrafish larvae demonstrated normal flow in the 
vasculature with the exception of the lacking ISVs. Abnormally formed ISVs still showed some perfusion. (C) 
Quantification of zebrafish larvae with normal or abnormal vasculature after morpholino silencing (n = 150 per 
group; * P < 0.05 versus control). 
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(D) Tnfaip8l1 mRNA expression during postnatal retinal vascular development in mice was reduced after 
transfection with Tnfaip8l1 targeting siRNA, whereas the expression of (E) Tnfaip8 and (F) Tnfaip8l2 remained 
unchanged. Adenoviral overexpression of (D) Tnfaip8l1 did not affect the expression of (E) Tnfaip8 and (F) 
Tnfaip8l2 (n = 5 per group; * P < 0.05 versus sham). (G) Knockdown of Tnfaip8l1 in the murine retina from day 2 
after birth greatly diminished the vascular network at day 7 compared with sham treated retinas. Overexpression of 
Tnfaip8l1 in these retinas enhanced the complexity of the vascular network. 
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Tnfaip8l1 inhibits endothelial cell apoptosis without affecting the cell cycle 
Since Tnfaip8l1 is implicated in angiogenesis, we studied the effects of Tnfaip8l1 on EC 
specific apoptosis and cell cycle progression. Flow cytometric analysis of apoptosis by 
Annexin V/PI staining revealed that Tnfaip8l1 knockdown promoted apoptosis in HUVECs 
under normal growth conditions, resulting in approximately a 2 fold increase of both early 
and late apoptotic cells in subconfluent cell cultures compared with sham transfected 
HUVECs (Figure 4A-D). In confluent cell cultures the apoptotic effect of Tnfaip8l1 
knockdown was not observed (data not shown). In addition, overexpression of Tnfaip8l1 in 
subconfluent HUVEC cultures diminished both early and late apoptosis under normal 
growth conditions compared with sham transfected HUVECs (Figure 4A-D). The different 
effect on apoptosis found between confluent and subconfluent HUVECs suggested a 
difference in expression. Using qPCR analysis this idea was confirmed, subconfluent 
HUVECs showed a higher mRNA expression of Tnfaip8l1 compared with confluent 
HUVECs (Supplemental figure 3A, online). Cell cycle progression of HUVECs was 
assessed by PI flow cytometric analysis. Neither knockdown, nor overexpression affected 
cell cycle progression in cultured HUVECs (Figure 4E-G). 
 
 
Figure 4. Tnfaip8l1 inhibits endothelial cell apoptosis without affecting the cell cycle. (A) Representative flow 
cytometric analysis of apoptosis in HUVECs 5 days after lentiviral infection. Knockdown of Tnfaip8l1 enhanced 
apoptosis of HUVECs under normal culture conditions. Apoptosis of HUVECs was diminished by overexpression 
of Tnfaip8l1. (B-D) Quantification of (B) living, (C) early apoptotic and (D) late apoptotic HUVECs (n = 8 per 
group; * P < 0.05 versus naïve). 
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(E) Representative flow cytometric analysis of the cell cycle in HUVECs 5 days after lentiviral infection. 
Knockdown or overexpression of Tnfaip8l1 did not affect the cell cycle in HUVEC. Quantification of the (F) G1 
and (G) combined S–G2-phase after cell cycle analysis in HUVECs (n = 8 per group; * P < 0.05 versus naïve). 
 
 
To evaluate if Tnfaip8l1 is involved in regulating apoptosis during vascular 
development, we assessed apoptosis in murine retinas using a TUNEL staining. Tnfaip8l1 
silencing revealed an increase in the number of TUNEL-positive nuclei compared with 
scrambled non-targeting siRNA (Figure 5A, B). Vice versa, overexpression of Tnfaip8l1 in 
the retina resulted in a reduction in apoptotic nuclei compared with sham adenoviral 
infection (Figure 5A, B). These data suggest that Tnfaip8l1 may aid new vascular growth 
by providing protection to ECs from apoptosis. 
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Figure 5. Tnfaip8l1 inhibits in vivo apoptosis in the murine retina. (A) Representative TUNEL staining of 
retina sections depicting apoptotic cells. Knockdown of Tnfaip8l1 in the murine retina model enhanced the 
number of apoptotic cells compared with sham treated retinas at day 3 post-injection. Overexpression of Tnfaip8l1 
in these retinas reduced the number of TUNEL-positive cells. (B) Quantification of TUNEL-positive cells in the 
retina (n = 5 per group; * P < 0.05 versus sham). 
 
 
Tnfaip8l1 diminishes TNFα and FasL-induced endothelial apoptosis 
Since DED-containing proteins - like the Tnfaip8 family - reduce DED-containing receptor-
mediated apoptosis - including TNFα and FasL-mediated apoptosis - we proceeded with an 
in-depth analysis of Tnfaip8l1 to establish its role in these types of apoptotic signalling. 
Flow cytometric analysis of apoptosis in subconfluent HUVECs revealed that transgenic 
expression of Tnfaip8l1 inhibited apoptosis, as shown by a decrease in both early and late 
apoptotic cells compared with sham transfected HUVECs in response to TNFα (Figure 6A-
D) or FasL stimulation (Figure 6E-G). Knockdown of Tnfaip8l1 in combination with TNFα 
or FasL stimulation further enhanced EC apoptosis, but provided unquantifiable results due 
to the minimal amount of cells detected. In confluent HUVEC cultures, similar effects were 
observed after TNFα stimulation, but in a lesser degree than seen in subconfluent HUVECs 
(Supplemental figure 3B-D, online). Combined, these data validate that Tnfaip8l1 plays a 
crucial role in TNFα and FasL-triggered apoptosis, especially in proliferating ECs. 
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Figure 6. Tnfaip8l1 diminishes TNFα and FasL-induced endothelial apoptosis. (A) Representative flow 
cytometric analysis of apoptosis in lentiviral infected HUVECs 8 hours after TNFα stimulation. TNFα-induced 
apoptosis was reduced in HUVECs with Tnfaip8l1 overexpression. (B-D) Quantification of (B) living, (C) early 
apoptotic and (D) late apoptotic HUVECs after TNFα stimulation of subconfluent cultures (n = 5 per group; * P < 
0.05 versus naïve). (E-G) Quantification of (E) living, (F) early apoptotic and (G) late apoptotic HUVECs after 
FasL stimulation of subconfluent cultures (n = 5 per group; * P < 0.05 versus naïve). 
 
 
Tnfaip8l1 reduces caspase 8 activity and activated caspase 3 levels 
Since a family member of Tnfaip8l1 diminishes DED-containing receptor-mediated 
apoptosis by inhibiting caspase 8 activity, which subsequently reduces activated caspase 3 
levels, we also investigated whether Tnfaip8l1 inhibits caspase 8 activity, influence the 
amount of caspase 8 and the downstream activated caspase 3. Therefore, we carried out 
protein expression analysis on TNFα-stimulated HUVEC cultures. Tnfaip8l1 
overexpression (as validated by Figure 7A, D) did not affect the level of activated cleaved 
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caspase 8 (Figure 7B, D). In contrast, cleaved caspase 3 levels were significantly reduced 
by 59% compared with sham lentivirus treated HUVECs (Figure 7C, D). Next, we 
measured caspase 8 enzyme activity using an IETD-pNA cleavage assay. Transgenic 
Tnfaip8l1 expression inhibited caspase 8 enzyme activity by 54% compared with sham 
lentivirus treated HUVECs (Figure 7E). Taken together, these observations clearly indicate 
that Tnfaip8l1 protects ECs from TNFα-induced apoptosis by directly intervening in the 
caspase 8 - caspase 3 activation pathway. 
 
 
Figure 7. Tnfaip8l1 reduces caspase 8 activity and activated caspase 3 levels. (A) Protein expression of 
Tnfaip8l1 is increased after lentiviral overexpression in HUVECs. (B) Protein expression of activated caspase 8 is 
not affected by Tnfaip8l1 overexpression. (C) Protein expression of activated caspase 3 is decreased by Tnfaip8l1 
overexpression. (D) Representative immunoblots of Tnfaip8l1, activated caspase 8 and activated caspase 3 in 
lentiviral infected HUVECs 8 hours after TNFα stimulation. (E) Tnfaip8l1 overexpression diminished caspase 8 
activity in lentiviral infected HUVECs 8 hours after TNFα stimulation (n = 5 per group; * P < 0.05 versus sham). 
 
 
Tnfaip8l1 is upregulated in cardiac endothelial cells after myocardial infarction 
Apoptosis of vascular cells during an ischemic cardiac event plays an important role in the 
recovery of heart function. Previous studies reported a local rise in TNFα19 and an increase 
in cleaved caspase 3 levels20 after MI, suggesting that regulation by the Tnfaip8 subfamily 
may be involved. To investigate if Tnfaip8l1 is indeed involved in the initial phase after an 
MI, we carried out immunohistological analysis of murine cardiac tissue, 2 days after the 
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induction of an MI. Tnfaip8l1 protein expression was clearly enhanced in the capillaries 
after an MI compared with sham operated animals (Figure 8A, B). This was further 
supported by laser capture of the ECs from these hearts, followed by qPCR analysis. 
Tnfaip8l1 mRNA expression in murine ECs was significantly upregulated 2 days after 
induction of MI compared with sham operated animals (Supplemental figure 4, online), 
providing an indication that high Tnfaip8l1 levels might be important in this disease. 
 
 
Figure 8. Tnfaip8l1 is upregulated in cardiac endothelial cells after myocardial infarction. (A) Protein 
expression of Tnfaip8l1 in murine hearts after MI induction. Endothelial Tnfaip8l1 expression (red) is increased 
after MI as seen by co-localisation with lectin (green). (B) Quantification of Tnfaip8l1 expressing endothelial cells 
after an MI in murine hearts (n = 5 per group; * P < 0.05 versus sham operated animals). 
 
 
Next, we evaluated if the mouse data would reflect the human condition. We therefore 
carried out immunohistological evaluation of Tnfaip8l1 expression in human MI samples 
and revealed that Tnfaip8l1 protein expression was increased after an MI (Figure 8C). 
Further in vitro analysis showed that the endothelial expression of Tnfaip8l1 is not 
enhanced by hypoxia, but rather by increasing levels of TNFα (Supplemental figure 5A, B, 
online). These data suggest that Tnfaip8l1 is involved in an inflammatory reaction after an 
human ischemic event and would be a potential target for development of therapeutics. 
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(C) Representative cross sections of normal human heart tissue or heart tissue that has suffered an MI. Tnfaip8l1 
protein expression is increased after MI in human cardiac tissue (red fluorescence). 
 
 
 
Discussion 
 
In the current study, we demonstrate that Tnfaip8l1 stimulates vascularisation by promoting 
EC survival by inhibition of DED-containing receptor-mediated apoptosis. Our data 
showed that Tnfaip8l1 is specifically expressed in both embryonic and adult vasculature. 
Tnfaip8l1 is predominantly expressed in ECs, in contrast to its family members Tnfaip8 
and Tnfaip8l2 that show preferential expression in other vascular cell types. Moreover, the 
vascular expression is preserved in different species. Loss of Tnfaip8l1 inhibited 
angiogenesis, as indicated by the in vitro data obtained from 2D matrigel network-
formation assays and the in vivo data from the murine retina model and zebrafish larvae 
development. In contrast, overexpression of Tnfaip8l1 resulted in enhanced angiogenesis in 
in vitro Matrigel cultures and in vivo models. The observed effects of Tnfaip8l1 on 
angiogenesis could be attributed to inhibition of DED-containing receptor-mediated EC 
apoptosis by inhibition of caspase 8 enzyme activity, resulting in reduced levels of cleaved 
caspase 3. 
We identified Tnfaip8l1 in a screen for new molecular regulators of vascularisation 
during murine development by gene expression profiling. Although functions of its family 
members Tnfaip8 and Tnfaip8l2 have been described13-15, thus far no biological function 
has yet been attributed to Tnfaip8l1. Our data showed that Tnfaip8l1 is highly expressed in 
angioblasts and ECs, and is preserved between species, suggesting functional importance in 
ECs, especially during blood vessel development. This was confirmed by further gain- and 
loss-of-function studies both in vitro and in vivo in human ECs, zebrafish larvae and 
newborn mice pups, demonstrating that the function of Tnfaip8l1 was evolutionary and 
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functionally preserved. In vitro experiments also demonstrated that gain- and loss-of-
function of Tnfaip8l1 did not alter the level of its family members Tnfaip8 and Tnfaip8l2, 
and thus is not compensated by its family members in ECs, excluding possible redundancy. 
This was further supported by data obtained from studies in vivo in which neither 
knockdown, nor overexpression of Tnfaip8l1 in murine retinas affected the gene expression 
of family members Tnfaip8 and Tnfaip8l2. 
Angiogenesis is dependent on the dynamic balance between pro-angiogenic and anti-
angiogenic factors. One essential issue during angiogenesis is EC survival. Actually, many 
of the known pro-angiogenic and anti-angiogenic factors function at least partly by 
regulating EC survival and apoptosis.1,2 Pro-angiogenic growth factors - including VEGF, 
Ang1 and FGF - are well known for their effect on EC proliferation. However, they also 
stimulate the expression of anti-apoptotic proteins like survivin, thus inhibiting EC 
apoptosis.21-23 Inhibition of VEGF signalling results in enhanced EC apoptosis and reduced 
angiogenesis.24 In contrast, anti-angiogenic factor Thrombospondin 1 (TSP1) functions by 
binding to CD36, activating downstream caspase 3 and enhancing EC apoptosis. 
Interestingly, the anti-apoptotic effect of TSP1 is restricted to proliferating ECs and was not 
observed in quiescent ECs, suggesting that proliferating ECs are more sensitive to 
apoptosis.25 
In line with these findings, we observed that in non-confluent EC cultures, Tnfaip8l1 
knockdown resulted in an increase of apoptotic cells, whereas overexpression of Tnfaip8l1 
reduced the apoptosis in HUVECs, suggesting that Tnfaip8l1 has an anti-apoptotic effect in 
proliferating ECs. Similar to TSP1, we found that Tnfaip8l1 had no effect on apoptosis in 
confluent cell cultures. This suggests that the anti-apoptotic effect of Tnfaip8l1 may only 
apply to proliferating ECs. This was further supported by the higher expression of 
Tnfaip8l1 in proliferating ECs compared with quiescent ECs. 
In addition, we found that cell cycle of HUVECs was not altered by Tnfaip8l1 
expression, implying that the observed effects were only caused by EC apoptosis and not 
partially by influencing proliferation. Other investigators have previously reported that 
knockdown of Tnfaip8 also reduced viability of microvascular ECs, but did not mention if 
this was in dividing or confluent cells.26 
The effect on apoptosis by Tnfaip8l1 in vitro was further supported by the data 
obtained in vivo from mice retinas. Knockdown of Tnfaip8l1 enhanced the number of 
apoptotic cells in the treated retina, as visualised by TUNEL staining. In comparison, 
overexpression of Tnfaip8l1 in the eye reduced the number of TUNEL-positive nuclei. 
The family member Tnfaip8 was previously implicated to inhibit DED-containing 
receptor-mediated apoptosis in cancer cells.13,14 Two well-known mechanisms of apoptosis 
are potentially involved in this process: the FasL pathway and the TNF-mediated 
pathway.27 During pathological angiogenesis, peak levels of these pro-apoptotic ligands 
accumulate and provide the perfect microenvironment for the Tnfaip8l1 activity, but also 
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during physiological angiogenesis there is evidence for a possible involvement of the 
Tnfaip8 subfamily. Several in vivo studies in mice with a deficiency in the TNFα or FasL 
signalling have shown that loss of these signalling cascades reduces EC apoptosis and 
enhanced physiological angiogenesis in murine retinas.28-30 We also observed enhanced EC 
apoptosis in our in vitro cultures in response to TNFα and FasL stimulation. In vivo, TNFα 
and FasL secretion tend to be facilitated by non-ECs. In vitro, the cultured ECs can become 
a source of these apoptotic ligands in response to stress, as indicated by our findings, and 
thus contributing to their own cell death. 
Our in vitro data in which we demonstrate that transgenic expression of Tnfaip8l1 
could diminish ECs from TNFα and FasL-induced apoptosis, point towards a crucial role in 
ensuring survival of especially dividing ECs in response to stimulation by these pro-
apoptotic ligands. 
In the early stages of DED-containing receptor-mediated apoptosis, the death-inducing 
signalling complex (DISC) is formed, which consists of the multimerised death receptors, 
Fas-associated death domain (FADD) and caspase 8.31,32 This complex cleaves and 
activates caspase 8, which in its turn activates caspase 3 by cleavage, ultimately resulting in 
the execution of apoptosis.33 In our study, we could not observe an effect of Tnfaip8l1 on 
the processing of caspase 8, as shown by Western blot, suggesting that Tnfaip8l1 works 
downstream of DISC formation. Indeed, we observed that Tnfaip8l1 reduced caspase 8 
activity. We found that in addition to the reduced caspase 8 activity, the amount of 
activated caspase 3 was reduced as well, suggesting that Tnfaip8l1 functions as inhibitor of 
activated caspase 8. In line with our data, other investigators have shown that family 
member Tnfaip8 also reduced apoptosis in cancer cells by inhibition of caspase 8 activity 
and thus subsequently reduce caspase 3 activation.14 The other family member Tnfaip8l2 
has also previously been linked to caspase 8 activity in the immune homeostasis15, again 
underlining the role of this family in the regulation of caspase 8. As mentioned before, 
family member Tnfaip8 function was previously described in microvascular ECs: 
knockdown of Tnfaip8 was reported to reduce the expression of VEGFR-226, a well known 
regulator in EC survival and mitogenesis.34 In light of our findings, these reports suggest 
that Tnfaip8l1 and Tnfaip8 both are capable to promote EC survival through two distinct 
processes. 
EC survival and proliferation are crucial in repairing and maintaining the myocardium 
after an infarction.6,7 Early after MI the cardiac tissue produces high levels of TNFα18, 
possibly creating a hostile environment for the proliferating ECs, making them more 
sensitive for apoptosis. In our murine MI model, we observed a strong upregulation of 
Tnfaip8l1 in cardiac ECs. Evaluation of human heart tissues showed similar results. 
Tnfaip8l1 protein expression increased in human cardiac tissue after an infarction. In vitro, 
we observed that this endothelial specific increase is a result of enhanced TNFα expression 
and not by the ischemia itself. These findings suggest a role for Tnfaip8l1 during the 
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neovascularisation response following an MI, making it a potential target for new 
therapeutic approaches to stimulate or protect the vasculature after an ischemic insult. 
Currently, we are generating a mouse line with inducible EC specific knockdown of 
Tnfaip8l1 to study its role in MI. 
Similarly to ischemia, tumours are known to produces high levels of TNFα.35 
Angiogenesis is a key feature of a growing tumour36, giving rise to the thought that 
Tnfaip8l1 may play a role in EC survival during tumour angiogenesis. Further studies in 
Tnfaip8l1 will elucidate the function of this endothelial prevalent anti-apoptotic protein in 
disease onset and progression. 
In summary, the current study allocates for the first time the biological function of 
Tnfaip8l1 and demonstrates that Tnfaip8l1 acts as a potent inhibitor of DED-containing 
receptor-mediated apoptosis in ECs. Tnfaip8l1 inhibits the activation of caspase 3 by 
reducing caspase 8 activity, leading to enhanced EC survival and vascular growth, both in 
developmental vascular network-formation, as well as in neovascularisation after an adult 
ischemic event. 
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Development of the vascular network consist of the differentiation of angioblasts into 
endothelial cells (EC) and the assembly into primitive vascular tubules, followed by the 
formation of new capillaries by sprouting from pre-existing small blood vessels. In addition 
to normal embryonic development of the vascular network, vessel formation contributes 
also to the pathogenesis of diseases like atherosclerosis, myocardial infarction and cancer. 
Identifying the molecular players in the regulation of angiogenesis provides further insight 
in the progress of many diseases and aids the development of novel therapies. 
 
 
Gene expression analysis 
 
To identify new molecular players involved in angiogenesis, we carried out a genome-wide 
microarray screen for genes specifically expressed in Flk1-positive angioblasts at 
embryonic day (E)10.5 and 11.5 of vascular development during mouse embryogenesis. 
Upregulated genes were further verified in zebrafish by whole-mount in situ hybridisation 
and subsequent morpholino (MO)-knockdown technology to assess its biological function, 
which was validated in a murine retina model. In depth analysis of the molecular 
mechanism took place by in vitro assays, while the functional implications of the gene was 
eventually elucidated in knockout mice. 
Gene expression analysis resulted in a list of candidate genes involved in the regulation 
of angiogenesis, including 9430020K01Rik (KIAA1462), Klf7, Tagln2, Thsd1, CCM1-3, 
Tnfaip8l1 and Fgd5. In this thesis, we describe in more detail the biological function of 
these genes in vessel formation. 
 
9430020K01Rik and Klf7 are required for endothelial cell proliferation 
The study described in chapter 2 focuses on the essential role of 9430020K01Rik in EC 
proliferation during vascular development. In spite of missing an one-to-one orthologue to 
zebrafish to verify the biological function of 9430020K01Rik, the gene was very interesting 
because of its association with coronary artery disease (CAD), which has been found 
previously.1 Knockdown of 9430020K01Rik in the murine retina model suppressed blood 
vessel formation in the retina. Similar results were found in 9430020K01Rik-knockout 
mice, in which vascular density was also diminished in cardiac tissue. This phenotype was 
validated by in vitro 2D matrigel experiments. Further characterisation of the role of 
9430020K01Rik in cultured ECs revealed that cell proliferation was decreased, due to a 
blockade in G1–S-phase transition after 9430020K01Rik knockdown. Based on liquid 
chromatography-mass spectrometry (LC-MS), we identified catenin (cadherin-associated 
protein), delta 1 (CTNND1) as a binding partner of 9430020K01Rik. Both proteins were 
co-localised at the cell membrane. It has been shown that free CTNND1 in the cytoplasm 
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forms a complex with RhoA-GDP, which results in the inhibition of GDP dissociation.2 We 
hypothesised that complex formation of 9430020K01Rik with CTNND1 lowers the affinity 
of CTNND1 for RhoA-GDP and allows activation of RhoA-GDP by local guanine 
nucleotide exchange factors (GEF). Loss of 9430020K01Rik will result in less RhoA 
activation and downstream signalling, which is indeed reflected by our studies in cultured 
ECs. RhoA signalling regulates cell cycle progression or EC proliferation through G1–S-
phase transition by two distinct pathways: via (i) Rho-associated coiled-coil containing 
protein kinase (ROCK) or (ii) the mammalian homolog of Drosophila diaphanous (mDia). 
Mainly changes in ROCK activity were associated with an increased risk of CAD by 
causing endothelial dysfunction and subsequent damage of the intimal layer. Loss of 
9430020K01Rik could result in less EC turnover to repair endothelial damage, accelerating 
the progress of atherosclerosis. The activity of ROCK is inhibited by cytoplasmic 
p21Cip1/Waf1, a member of the Cip/Kip family of cyclin-dependent kinase (CDK) inhibitors.3-
5 The expression of p21Cip1/Waf1 is regulated by Krüppel-like factor 7 (Klf7), suggesting a 
potential role of Klf7 in EC proliferation. In our research, described in chapter 3, EC 
proliferation was indeed inhibited by Klf7 due to a blockade in G1–S-phase transition. 
However, this time the phenotype was effected by overexpression of the target gene, 
indicating an opposite effect of 9430020K01Rik and Klf7 on the RhoA-ROCK pathway 
(Figure 1). In spite of this, both genes were upregulated around 8 to 9 days post-fertilisation 
(dpf) of murine embryonic development: at 8 dpf 9430020K01Rik was highest upregulated 
compared with Klf7, whereas at 9 dpf it was the other way around. Taken together, a peak 
of Klf7 expression next to an increase in 9430020K01Rik expression may indicate a 
negative feedback loop or fine tuning mechanism of cell cycle progression by Klf7. In 
addition, Klf7 has been identified recently as one of the core regulators of several pathways 
associated with the onset or progression of CAD.6 For this reason Klf7 and 
9430020K01Rik can be both of great interest for the development of novel therapies against 
CAD. 
 
The role of Tagln2 during endothelial cell migration 
One of the next steps after ROCK or mDia activation in RhoA-regulated EC proliferation 
are changes in cell shape and cellular contractility, both generated by actin cytoskeleton 
dynamics.3 Modulation of the actin cytoskeleton is important during different phases of the 
cell cycle, including cytokinesis - physical separation of daughter cells at the end of mitotic 
cell division (M-phase).7 In non-dividing cells there is a significant role for actin 
cytoskeleton flexibility in many different processes, like EC migration and vascular 
integrity. In chapter 4 we describe the role of Transgelin 2 (Tagln2) in EC migration. 
Knockdown of Tagln2 in zebrafish resulted in ectopic sprouting of intersegmental vessels 
(ISV) at a later stage of development. Also in a murine retina model and in vitro migration 
assays we observed an increase in cell migratory properties after downregulation of Tagln2. 
Discussion and conclusion 
 
 239
Similar results of enhanced cell motility has been found in hepatocellular carcinoma cells 
(HCC), where inactivation of Tagln2 led to less actin depolymerisation.8 For that reason 
Tagln2 is also known as a tumour suppressor gene. Cancer cell spreading as well as tumour 
vascularisation are decisive factors in disease progression. Because of the late moment of 
ectopic sprouting of ISVs during zebrafish development, we hypothesised that migratory 
deficiencies were the result of a prolonged angiogenic behaviour of ECs within the ISVs. 
Normally, angiogenic behaviour is induced by VEGFR-2 signalling to make cells more 
sensitive for directional clues in their environment and is downregulated after tip cell fusion 
of two newly formed vessel branches. Prolonged VEGFR-2 signalling - reflected by 
increased VEGFR-2 synthesis - results in enhanced cell motility.9-12 In our study, VEGFR-2 
synthesis in cultured ECs was indeed increased after Tagln2 silencing. This would suggest 
that Tagln2 not only suppress cell motility through actin-binding and depolymerisation, but 
also by a negative feedback loop on VEGFR-2 signalling in migratory cells. 
The actin-binding affinity of Tagln2 is regulated via PFTK1-dependent 
phosphorylation. PFTK1 - also known as CDK14 - is mainly active during the G2–M-phase 
of the cell cycle and forms a complex with cyclin Y. The activity of a broad spectrum of 
cyclin-CDK complexes is inhibited by Cip/Kip family members, including p27Kip1, which is 
a downstream effector of the earlier mentioned RhoA signalling pathway. During 
cytokinesis at the end of the M-phase, RhoA signalling stimulates actin filament 
formation.5,7,8,13 Taking these observations in consideration, RhoA-mDia may activate the 
ubiquitin ligase SKP2 and subsequent p27Kip1 degradation, releasing the inhibition on 
cyclin-CDK complexes, allowing CDK14 to lower the actin-binding affinity of Tagln2 
followed by actin depolymerisation in dividing cells (Figure 1). 
 
Vessel stabilisation and the role of Thsd1 and CCM proteins 
In the second part of this thesis, the research focuses more on vascular integrity and vessel 
stabilisation. Actin cytoskeleton flexibility and its regulation play an important role in this 
process. In chapter 5 we explain the role of Thrombospondin type I domain 1 (Thsd1) as 
regulator of endothelial barrier function during angiogenesis. Knockdown of Thsd1 in 
zebrafish and in the developing retinal vasculature of neonatal mice resulted in vascular 
haemorrhages. In a cultured monolayer of Thsd1-silenced ECs we showed that cell-cell 
barrier function was diminished in a transwell permeability assay. The endothelial barrier 
function is determined by cell morphology and junctional strength. Exposing the molecular 
mechanism we demonstrated that Thsd1 mediates Rac1 activation via CRT-LRP1 complex 
binding and downstream signalling via the FAK-PI3K cascade. Next to RhoA, Rac1 is also 
one of the small GTPases of the Rho family, which regulates the assembly of the actin 
cytoskeleton and related cell morphology. Rac1 activity plays a crucial role in the process 
of cell spreading by lamellipodia formation, while it suppress RhoA-induced stress fibre 
formation.14,15 Analysis of the actin cytoskeleton during cell adhesion of Thsd1-silenced 
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ECs showed a clear delay in actin cytoskeleton spreading as compared with non-targeting 
siRNA transfected and untransfected controls. In addition, activation of Rac1 preserves 
cell-cell junction formation and thereby endothelial barrier function.16,17 Based on immuno-
histochemistry we indeed observed a reduced co-localisation of VE-cadherin with the actin 
cytoskeleton at the junctional sites, which suggests a weakening of the cell-cell junctions. 
Actin cytoskeleton reorganisation and strengthening of the cell-cell junctions due to Thsd1 
expression may not only increase endothelial barrier function, but can also indicate the 
entrance of a quiescent EC phenotype. The last is also characterised by a reduction in 
VEGFR-2 signalling.18 In chapter 4 we showed that VEGFR-2 signalling was negatively 
regulated by Tagln2. Taken together, it should be interesting to analyse Tagln2 activity at 9 
dpf of murine embryonic development, because of the high expression level of Thsd1 at 
this day. As shown in Figure 1, Thsd1 will not only activate Rac1 signalling, but also 
diminish the RhoA pathway, which may eventually lead to an increase in Tagln2 activity 
and subsequent downregulation of VEGFR-2 signalling. 
In addition of Thsd1, other proteins are involved in the regulation of the endothelial 
barrier function, including cerebral cavernous malformation (CCM) proteins 1-3. Mutations 
in these genes lead to the development of abnormal vascular structures particularly in the 
brain, also known as capillary-venous malformations. An overview from molecular 
pathogenesis to genetic counselling and clinical management is described in chapter 6. We 
noticed that CCM1-3 all have an essential role in the regulation of the Rho-GTPases, 
arranging cell polarity and adhesion to the extracellular matrix (ECM) and neighbouring 
cells. Especially RhoA is inhibited by CCM1-3 (Figure 1), suggesting less stress fibre 
formation and an increase in cell spreading, which results in enhanced endothelial barrier 
function.19,20 CCM proteins are also involved in focal adhesion assembly, vessel maturation 
and vessel quiescence, as shown by the inhibitory effect of CCM1 on ICAP1α binding 
affinity to integrin, preventing blockage of integrin signalling, and the modulating effect of 
CCM2 on the actin cytoskeleton flexibility. In summary, CCM1-3 as well as Thsd1 play 
essential roles in vessel stabilisation. 
 
The role of Fgd5 and Tnfaip8l1 in endothelial cell apoptosis and vessel regression 
After vessel stabilisation aberrant vessels will regress by apoptosis - also known as vascular 
pruning - which is studied in the last part of this thesis. The study described in chapter 7 
focuses on the role of FYVE, RhoGEF, and PH domain-containing 5 (Fgd5) in EC 
apoptosis. Fgd5 is a member of the FGD family of GEFs which regulates Cdc42 
activity.21,22 Based on co-immunoprecipitation and Cdc42 GEF-activity assays, we 
observed that Fgd5 also binds and activates Cdc42. From previous studies it is known that 
Cdc42 can induce apoptosis via phosphorylation of p21-activated serine/threonine kinase 
(PAK), while a more recent study has demonstrated that PAK blocks apoptosis via 
inhibition of caspase 8 signalling and degradation of the Bcl2 family proteins.23-25 Given 
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these contradictory results, we hypothesised that Fgd5 may induce apoptosis via an 
alternative pathway. qPCR analysis determined that knockdown of Fgd5 was associated 
with downregulation of the Notch pathway genes, which leads to diminished transcription 
of Hey1 and p21Cip1/Waf1. Hey1 is associated with p53-mediated apoptosis, while p21Cip1/Waf1 
blocks cell cycle progression.26-28 Indeed, we observed that overexpression of Fgd5 resulted 
in p21Cip1/Waf1-mediated cell cycle arrest and subsequent cell death induced by the Hey1-p53 
pathway, which could be rescued by Hey1 knockdown (Figure 1). In addition, 
overexpression of Fgd5 resulted in a shift of the VEGFR-1 versus VEGFR-2 expression 
ratio, which leads to a more quiescent phenotype of ECs. The effect of Fgd5 on EC 
proliferation, apoptosis and VEGFR-2 signalling supports a regulatory role of Fgd5 in 
vascular pruning. 
In chapter 8 we described the role of Tumour necrosis factor alpha inducible protein 8 
like 1 (Tnfaip8l1) in apoptosis which is opposite in comparison with Fgd5. During vascular 
development, EC survival is important to prevent to early regression of newly formed blood 
vessels. Mainly proliferating ECs are more sensitive to apoptosis.29 Knockdown of 
Tnfaip8l1 inhibited angiogenesis in vitro as well as in vivo, while overexpression of 
Tnfaip8l1 enhanced vascular development. Unravelling the molecular mechanism showed 
that Tnfaip8l1 mediates a reduction of caspase 8 activity, which results in reduced levels of 
cleaved caspase 3 (Figure 1). Caspase 3 normally activates ROCK1, which finally results in 
membrane blebbing, one of the first events in the execution phase of apoptosis.30,31 The 
observed anti-apoptotic effect of Tnfaip8l1 was only found in proliferating cells. In 
addition, Tnfaip8l1 had no effect on the cell cycle itself. Just like Fgd5, expression of 
Tnfaip8l1 during murine development is highest around 9 dpf. However, Fgd5 is mostly 
active in the aberrant vessels, while Tnfaip8l1 is more active in proliferating ECs and 
sprouting vessels. Further, it is important to realise that the same period of embryonic 
development in human compared with mice is relatively fourteen-times longer. To gain 
more insight into the exact moment of co-expression of different genes during murine 
development, we have to fine tune at E9, because all genes described in this thesis, except 
Tagln2, were highly upregulated then. 
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Figure 1. Overview of the biological function of genes involved in angiogenesis. Simplified reproduction of the 
molecular pathways that link up the genes involved in the regulation of angiogenesis described in this thesis. The 
pathways shown are based on studies in cultured ECs. Signalling from p27 to CDK14 is uncertain and remains to 
be elucidated. Red/orange arrows indicate the level at which these pathways are regulated in a positive or negative 
way by the examined genes (see text for more details). 
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Therapeutic implementation 
 
The leading cause of death in the world are cardiovascular diseases. Hypertension, 
smoking, dyslipidemia and diabetes mellitus are important risk factors for (ischemic) CAD 
and stroke.32 Scientific progression made it increasingly clear that genetic aberrations also 
play an important role in the aetiology of vascular pathologies. For that reason, insight in 
the genetic regulation of cardiovascular development can provide clues to develop novel or 
additional therapies. Some of the genes identified in our microarray screen are already 
associated with cardiovascular diseases, such as 9430020K01Rik and Klf7 which were 
recently identified with several pathways associated with the onset or progression of 
CAD.1,6 Both genes are involved in the regulation of ROCK activity (Figure 1). Clinical 
studies has demonstrated a correlation between elevated ROCK activity and impaired 
endothelial function in CAD patients.33,34 Thus, inhibition of ROCK might be an attractive 
therapeutic target. Animal studies with the ROCK inhibitor Y-27632 showed indeed limited 
atherosclerotic plaque formation, whereas treatment with fasudil in patients with CAD 
showed a reduction of the overactivity of ROCK.35-38 Interestingly, the ‘pleiotropic’ effects 
of statins - one of the main pharmacological options in the treatment of atherosclerosis - are 
also due to inhibited ROCK activity via indirect inhibition of the small GTPases of the Rho 
family.39 In addition to the overactivity of ROCK, neovascular integrity further determines 
the progression and destabilisation of atherosclerotic lesions, since extravasation of 
erythrocytes from newly formed vessels leads to an increase in inflammatory response, 
expansion of the necrotic core and intraplaque haemorrhaging. Inward vessel growth 
sprouted from the vasa vasorum is driven by intraplaque hypoxia and subsequent VEGF 
secretion, another important therapeutic target.40,41 VEGF blockage using monoclonal anti-
VEGF antibodies is mainly studied in tumour angiogenesis. These blockers inhibit vascular 
branching and induces vessel destruction, which leads to tumour starvation. However, 
aggravation of hypoxia may also promote tumour invasiveness. Paradoxically, vessel 
normalisation and stabilisation of the vessel wall must prevent this.42,43 Here, Thsd1 may 
have a beneficial role. After that, Thsd1 may also diminish the progression of 
atherosclerotic plaque vulnerability. Delivery of Thsd1 in mice already showed a lower 
percentage of intraplaque erythrocytes and a decrease in intraplaque Dextran-FITC leakage 
(chapter 5). In addition, new techniques have been developed to deliver angiogenic factors 
via cell beads containing genetically modified mesenchymal stem cells. Animal studies 
already showed a potential therapeutic benefit of this new approach after infusion in acute 
myocardial infarction.44 In future cell bead studies that incorporate EC protective genes, 
Tnfaip8l1 may also be a potential candidate for overexpression, since it is upregulated 
during the neovascularisation response following myocardial infarction. Finally, it is 
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important to realise that the outcome of molecular interference in the signal transduction 
pathways depends on many different factors, including: 
 
 the level at which these pathways are interrupted: blockage of a receptor may influence 
a wide range of different pathways, while further downstream the effect is more 
directed 
 the intracellular location of the target protein: for example, in the nucleus p21Cip1/Waf1 
inhibits cyclin-CDK complexes, whereas located in the cytoplasm p21Cip1/Waf1 will 
inhibit ROCK activity5 
 the phase of the cell cycle in which a cell will be: for example, proliferating cells are 
more sensitive for Tnfaip8l1 than quiescent cells 
 the availability of alternative pathways: blockage of a specific pathway may be rescued 
by an alternative one 
 interaction between different cell types: in this thesis the research was focused on ECs 
only, but blood vessels are build up of distinct cell types. For example, in vessel 
stabilisation not only an increase in stabilisation of cell-cell junctions between ECs is 
important, but also the attraction of pericytes 
 
Therefore, it’s very precise to recover an imbalance of pro-angiogenic and anti-angiogenic 
factors. Genes described in this thesis may not only be a therapeutic target, but can also be 
used in personalised medicine to provide a genetic profile of hereditary risk factors in the 
development of cardiovascular diseases. Based on these information, preventive 
interventions can be considered. 
 
 
Conclusion 
 
This thesis describes the biological function of genes involved in the regulation of 
angiogenesis. Gain- and loss of function studies have been carried out in ECs for each gene 
separately. However, the regulation of vascular development is a balance of pro-angiogenic 
and anti-angiogenic factors, which linked up accurately in different cell types. Therefore, 
multifactorial analyses in ECs and subsequent the vasculature as a whole will be the next 
step. 
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Summary 
 
Cardiovascular diseases are a major cause of death in the Western world. To gain more 
insight into the origin of these diseases, first of all it is important to understand normal 
development and functioning of the cardiovascular system in more detail. During 
embryonic development, the vascular network is formed by the assembly of tubular 
structures out of single cells (vasculogenesis) from which new vessel branches will develop 
(angiogenesis). These processes are regulated by proteins which building plan is encoded 
by our genetic material. Such part of genetic material - coding a specific protein - is also 
known as a gene. Changes (mutations) of a gene may result in the formation of a non-
functioning protein and subsequent disturbances in blood vessel development. This thesis 
describes the search for genes involved in blood vessel development and their role within 
this process. 
The identification of genes involved in blood vessel formation started with the isolation 
of cells from the vessel wall of mouse embryos at the embryonic stage of blood vessel 
development. Gene expression profiles of these isolated cells were determined. To validate 
gene expression in the developing vascular network, the expression of the zebrafish 
orthologues were examined. When positive, the genes were silenced one-by-one. Once a 
disturbance in blood vessel development occurred, the findings in the zebrafish were further 
validated in the developing retinal vasculature of neonatal mice and in primary cultures of 
human umbilical vein endothelial cells (HUVEC). In total, seven genes were studied in 
more detail in this thesis. 
 
Chapter 2 describes the function of 9430020K01Rik (KIAA1462). Previous research has 
shown a link between mutations in this gene and the development of cardiovascular 
diseases. Silencing of 9430020K01Rik in the developing retinal vasculature of neonatal 
mice resulted in suppressed blood vessel formation. Supplementary research in HUVEC 
showed a disturbance in the regulation of cell proliferation. Many different proteins are 
involved in this process. These proteins can bind to each other and subsequently influence 
their activity. A series of proteins that stimulate or inhibit each other’s activity, is also 
known as a signalling cascade. By using molecular techniques, it has been determined that 
9430020K01Rik binds CTNND1 in order to influence the RhoA signalling cascade, which 
finally regulates cell proliferation. Knockdown of 9430020K01Rik in HUVEC resulted in a 
decrease of ROCK activity - an important protein in the RhoA signalling cascade. From 
literature it is known that disturbances of ROCK activity could be linked to the onset of 
cardiovascular diseases. 
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Chapter 3 describes the function of Klf7. Overexpression of Klf7 in HUVEC resulted 
in an increased activity of p21Cip1/Waf1. It is known that p21Cip1/Waf1 has an inhibitory effect 
on ROCK activity and in that way blocks cell proliferation. Supplementary research 
showed indeed a decrease of cell proliferation in HUVEC overexpressing Klf7. 
Chapter 4 describes the function of Tagln2. Silencing of Tagln2 in zebrafish showed an 
apparently normal development of the vasculature. During a later stage of embryonic 
development excessive sprouting of intersegmental vessels occurred. Tagln2 depletion in 
the murine retinal vascular development model resulted in increased migration of the 
vascular plexus toward the retinal border. Since these effects occurred at a later stage of 
embryonic development, we hypothesised that the process of vessel development 
continuous as a result of remained sensitivity of vascular cells to growth promoting factors 
in the environment. From literature it is known that these remained sensitivity is caused by 
overexpression of specific receptors (VEGFR-2) at the cell surface. Indeed, Tagln2-
silenced HUVEC showed an overexpression of VEGFR-2. Based on these findings, we 
conclude that Tagln2 plays an important role in preventing excessive sprouting of new 
blood vessels. 
Chapter 5 describes the function of Thsd1. In zebrafish as well as in the murine retinal 
vascular development model, Thsd1 depletion resulted in vascular haemorrhaging, possibly 
by a loss of vascular integrity. The barrier function of the vessel wall is determined by cell 
shape and binding strength between two cells. Silencing of Thsd1 in HUVEC resulted in 
impaired actin cytoskeleton organisation and a weakening of cell-cell junctions. The actin 
cytoskeleton eventually determine cell shape. Molecular research showed an interaction of 
Thsd1 with the CRT-LRP1 complex and downstream Rac1 signalling. It is known that 
Rac1 signalling regulates actin cytoskeleton organisation and the binding strength between 
two cells. Beside the strong effects of Thsd1 knockdown on vascular integrity under normal 
conditions, massive bleeding were also found in atherosclerosis after silencing of Thsd1, 
which may result in an increase of disease progression. In mice, we have shown that 
overexpression of Thsd1 resulted in less haemorrhages of atherosclerotic plaques. This 
provides opportunities for the development of new therapies. 
Chapter 6 provides an overview of the aetiology of vascular malformations in the brain 
caused by mutations in the three CCM genes (CCM1-3). These genes regulates different 
signalling cascades which finally determine cellular binding strength between two different 
cells or between the cell and its surrounding structures. Disturbances in binding strength 
could result in blood vessel dilatation and subsequently haemorrhaging. 
Chapter 7 describes the function of Fgd5. Overexpression of Fgd5 in HUVEC resulted 
in an increase of programmed cell death, also known as apoptosis. It is known that Fgd5 
belongs to a protein family which regulates the Cdc42 signalling cascade. An important 
protein in this signalling cascade is PAK. In literature a discussion is going on about the 
stimulating or inhibiting effect of PAK on apoptosis. Based on the contradictory findings, 
Summary 
 
 255
we suspect that Fgd5 regulates an alternative signalling cascade to stimulate apoptosis. 
Research has shown that this is the p53 signalling cascade. After that, Fgd5 also impaired 
cell proliferation and stimulate cell quiescence, due to a proportionately decrease of the 
amount of VEGFR-2 at the cell surface and a subsequent impaired sensitivity to growth 
promoting factors in the environment. Based on these findings, we conclude that Fgd5 
stimulates vascular pruning. 
Chapter 8 describes the function of Tnfaip8l1. In zebrafish as well as in the murine 
retinal vascular development model, Tnfaip8l1 depletion resulted in impaired vessel 
formation. Supplementary research in HUVEC showed an increase of apoptosis, while on 
the other hand overexpression of Tnfaip8l1 in HUVEC resulted in a decrease of apoptosis. 
These effects were only found in dividing cells. It is known that dividing cells are more 
sensitive to apoptosis. Molecular research showed that Tnfaip8l1 inhibited caspase 8 
activity. Caspase 8 normally induce the apoptotic signalling cascade. Based on these 
findings, we conclude that Tnfaip8l1 has a protective role against apoptosis in developing 
and newly formed blood vessels. 
 
Taken together, this thesis showed the function of seven genes involved in the development 
of new blood vessels. The current findings may form a foundation for future medical 
developments. One of the possibilities is the improvement or development of new therapies 
to promote vessel growth after cardiac ischemia, or inhibition of vascular development on 
the other hand to impair tumour growth. Another possibility is genetic screening in patients 
and their families. Based on genetic testing, it is also possible to determine whether 
someone has a genetic predisposition for the development of cardiovascular diseases. 
However, there is still a long way to go… 
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Samenvatting 
 
Hart- en vaatziekten vormen een belangrijke doodsoorzaak in de westerse wereld. Om meer 
inzicht te krijgen in het ontstaan van deze ziekten, is het van belang om allereerst de 
normale ontwikkeling en het functioneren van het hart- en vaatstelsel beter te begrijpen. 
Tijdens de embryonale ontwikkeling ontstaat een netwerk van bloedvaten door het 
samenkomen van losse cellen die een buisvormige structuur vormen (vasculogenese) van 
waaruit zich nieuwe bloedvaten vertakken (angiogenese). De aansturing van deze processen 
geschiedt door eiwitten waarvan het bouwplan vastligt in het erfelijk materiaal. Zo’n stukje 
erfelijk materiaal dat codeert voor een specifiek eiwit, wordt ook wel gen genoemd. 
Veranderingen (mutaties) in een gen kunnen zorgen voor een niet goed functionerend eiwit, 
waardoor een verstoring kan optreden in de vorming van nieuwe bloedvaten. Dit 
proefschrift beschrijft de zoektocht naar genen betrokken bij de aanleg van nieuwe 
bloedvaten en hun functie binnen dit proces. 
De zoektocht naar genen betrokken bij vaatvorming begon met het isoleren van cellen 
uit de bloedvatwand van muizenembryo’s in de periode waarin het netwerk van bloedvaten 
wordt gevormd. In deze cellen is gekeken welke genen op dat moment actief waren. 
Vervolgens is onderzocht of deze genen eveneens actief waren in het vaatstelsel van de 
zebravis. Indien dit het geval was, werden deze genen stuk voor stuk uitgeschakeld. Zodra 
er hierdoor een verstoring optrad in de vorming van nieuwe bloedvaten, werden deze genen 
verder bestudeerd in het oog van de muis en in menselijke donorcellen afkomstig uit de 
bloedvatwand van een navelstreng (HUVEC). In totaal worden er in dit proefschrift zeven 
genen nader bestudeerd. 
 
In hoofdstuk 2 wordt de functie van 9430020K01Rik (KIAA1462) beschreven. Eerder 
onderzoek heeft al een verband aangetoond tussen mutaties in dit gen en het ontstaan van 
hart- en vaatziekten. Uitschakeling van 9430020K01Rik in het oog van de muis zorgde 
voor minder bloedvaten in het netvlies. Aanvullend onderzoek in HUVEC liet zien dat er 
een verstoring was opgetreden in de aansturing van celdeling. Bij het delen van een cel zijn 
vele verschillende eiwitten betrokken. Deze eiwitten kunnen aan elkaar binden en zo 
elkaars activiteit beïnvloeden. Een aaneenschakeling van eiwitten die elkaars activiteit 
stimuleren of remmen, wordt ook wel signaalroute genoemd. Middels moleculaire 
technieken is vastgesteld dat 9430020K01Rik bindt aan het eiwit CTNND1 en op deze 
wijze de RhoA signaalroute aanstuurt, waardoor uiteindelijk celdeling kan plaatsvinden. 
Uitschakeling van 9430020K01Rik in HUVEC deed de activiteit van ROCK, een 
belangrijk eiwit in de RhoA signaalroute, afnemen. Vanuit de literatuur is bekend dat 
afwijkingen in de activiteit van het eiwit ROCK, het ontstaan van hart- en vaatziekten tot 
gevolg kan hebben. 
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In hoofdstuk 3 wordt de functie van Klf7 beschreven. Een verhoogde hoeveelheid Klf7 
in HUVEC zorgde voor een toegenomen activiteit van het eiwit p21Cip1/Waf1. Bekend is dat 
p21Cip1/Waf1 een remmend effect heeft op de activiteit van het eiwit ROCK en op deze wijze 
celdeling kan blokkeren. Vervolgonderzoek toonde inderdaad een blokkade van de 
celdeling aan van HUVEC met een verhoogde hoeveelheid Klf7. 
In hoofdstuk 4 wordt de functie van Tagln2 beschreven. Uitschakeling van Tagln2 in 
de zebravis liet aanvankelijk een normale aanleg van het vaatstelsel zien. Pas in een later 
ontwikkelingsstadium trad er een wildgroei van bloedvaten rondom de wervelkolom op. In 
het oog van de muis zorgde uitschakeling van Tagln2 ervoor dat het netwerk van 
bloedvaten zich veel sneller verplaatste richting het uiteinde van het netvlies. Aangezien 
deze effecten pas optreden in een later ontwikkelingsstadium, veronderstelden wij dat het 
proces van vaatgroei mogelijk door bleef gaan doordat de bloedvaten gevoelig bleven voor 
groei stimulerende factoren in de omgeving. Vanuit de literatuur is bekend dat een 
verlengde waarneming van deze factoren wordt veroorzaakt door een verhoogde productie 
van specifieke antennes (VEGFR-2), gepositioneerd aan de buitenkant van de cel. HUVEC 
waarin Tagln2 was uitgeschakeld liet inderdaad een verhoogde productie zien van VEGFR-
2. Op basis van deze bevindingen concluderen wij dat Tagln2 een belangrijke rol speelt bij 
het voorkomen van een overmatige groei van nieuwe bloedvaten. 
In hoofdstuk 5 wordt de functie van Thsd1 beschreven. Zowel in de zebravis als in het 
oog van de muis had uitschakeling van Thsd1 het optreden van bloedingen tot gevolg, 
mogelijk door een verstoring van de barrièrefunctie van de bloedvatwand. Deze 
barrièrefunctie wordt bepaald door de vorm van de cel en de bindingssterkte tussen twee 
cellen. Uitschakeling van Thsd1 in HUVEC resulteerde in een vertraagde opbouw van het 
celskelet en een verzwakking van de cel-cel verbindingen. Het celskelet bepaald de 
uiteindelijke vorm van de cel. Moleculair onderzoek toonde aan dat Thsd1 bindt aan het 
CRT-LRP1 eiwitcomplex en op deze wijze de Rac1 signaalroute aanstuurt. Bekend is dat 
deze signaalroute de opbouw van het celskelet en de bindingssterkte tussen twee cellen 
reguleert. Niet alleen onder normale omstandigheden liet de uitschakeling van Thsd1 een 
duidelijk effect zien op de vaatstabilisatie, maar ook gedurende aderverkalking zorgde een 
verminderde productie van Thsd1 voor bloedingen. Dergelijke bloedingen bij 
aderverkalking kunnen het verloop van de ziekte doen versnellen. In muizen hebben we 
kunnen aantonen dat een verhoogde hoeveelheid Thsd1 het aantal bloedingen bij 
aderverkalking kan laten doen afnemen. Dit biedt mogelijkheden voor de ontwikkeling van 
nieuwe therapieën. 
In hoofdstuk 6 wordt een overzicht gegeven van het ontstaan van vaatafwijkingen in de 
hersenen, veroorzaakt door mutaties in de drie CCM genen (CCM1-3). Deze genen sturen 
meerdere signaalroutes aan die de bindingssterkte tussen twee cellen en tussen de cel en 
zijn omgeving bepaald. Een verstoring in deze bindingssterkte kan zorgen voor verwijding 
van het bloedvat met mogelijk bloedingen tot gevolg. 
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In hoofdstuk 7 wordt de functie van Fgd5 beschreven. Een verhoogde hoeveelheid 
Fgd5 in HUVEC zorgde voor een toename van geprogrammeerde celdood, ook wel 
apoptose genoemd. Bekend is dat Fgd5 onderdeel uitmaakt van een eiwitfamilie die de 
Cdc42 signaalroute aanstuurt. Een belangrijk eiwit in deze signaalroute is PAK. Er bestaat 
in de literatuur discussie of dit eiwit apoptose nu stimuleert, dan wel remt. Gezien deze 
tegenstrijdige bevindingen, verwachtten wij dat Fgd5 mogelijk een alternatieve signaalroute 
aanstuurt om zo apoptose te bevorderen. Onderzoek heeft aangetoond dat het hier gaat om 
de p53 signaalroute. Verder zorgt Fgd5 via deze signaalroute ervoor dat cellen minder 
delen en juist meer tot rust komen. Dit wordt mede bereikt doordat verhoudingsgewijs de 
hoeveelheid VEGFR-2 aan de buitenkant van de cel afneemt, waardoor de cellen minder 
gevoelig worden voor groei stimulerende factoren in de omgeving. Alle bevindingen in 
ogenschouw nemende, concluderen wij dat Fgd5 zorgt voor het verwijderen van het teveel 
aan nieuw ontstane bloedvaten. 
In hoofdstuk 8 wordt de functie van Tnfaip8l1 beschreven. Zowel in de zebravis als in 
het oog van de muis had uitschakeling van Tnfaip8l1 een vermindering van het aantal 
bloedvaten tot gevolg. Aanvullend onderzoek in HUVEC liet een toename van apoptose 
zien. Daarentegen zorgde een verhoogde hoeveelheid Tnfaip8l1 in HUVEC voor een 
afname van apoptose. Deze effecten werden alleen waargenomen in delende cellen. Bekend 
is dat delende cellen gevoeliger zijn voor apoptose. Moleculair onderzoek toonde aan dat 
Tnfaip8l1 de activiteit van het eiwit caspase 8 remt. Dit eiwit induceert normaal gesproken 
de signaalroute die apoptose bevorderd. Op basis van deze gegevens concluderen wij dat 
Tnfaip8l1 een beschermende rol heeft tegen apoptose van nog ontwikkelende of net nieuw 
gevormde bloedvaten. 
 
Samengevat laat dit proefschrift de functie zien van een zevental genen bij de aanleg van 
nieuwe bloedvaten. De huidige bevindingen kunnen de basis vormen voor medisch 
vervolgonderzoek. Zo valt te denken aan het ontwikkelen van nieuwe of verbeteren van 
reeds bestaande therapieën ter bevordering van de vaatgroei na een hartinfarct, of juist de 
remming van vaatgroei bij de bestrijding van tumoren. Ook in het erfelijkheidsonderzoek 
bij patiënten kunnen deze bevindingen een grote rol spelen. Middels genetisch onderzoek 
naar mutaties in deze genen kan mogelijk in de toekomst nog nauwkeuriger bepaald worden 
of iemand een erfelijke aanleg heeft voor het ontstaan van hart- en vaatziekten. Vooralsnog 
ligt er echter nog een lange weg voor ons open… 
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Curriculum Vitae 
 
Remco Haasdijk (1978) studeerde biologie aan de Rijksuniversiteit Groningen en de 
Radboud Universiteit Nijmegen, waar hij cum laude afstudeerde. Ook behaalde hij aan deze 
universiteit zijn artsexamen. Hij werkte als arts-assistent op de afdeling kindergeneeskunde 
en klinische genetica. In 2008 startte hij met zijn promotieonderzoek in het laboratorium 
voor Experimentele Cardiologie van het Erasmus MC te Rotterdam onder leiding van dr. 
H.J. Duckers. Zijn vrije tijd verdeelt hij over zijn grote passies wandelen en het bezoeken 
van balletvoorstellingen. 
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Summary of PhD training and teaching 
Name PhD student  Remco Haasdijk 
Erasmus MC Department  Experimental Cardiology 
Research School   COEUR 
PhD period   May 2008 - April 2014 
Promotor   Prof.dr. D.J.G.M. Duncker 
Supervisors   Dr. H.J. Duckers 
    Dr. C. Cheng 
 
PhD training 
 
 
Year 
 
Workload 
(ECTS) 
 
General academic skills 
 Course in Animal Experimentation 
 GCP training 
 ‘Basiscursus regelgeving en organisatie voor klinisch onderzoekers’ 
(BROK) 
 English Biomedical Writing and Communication 
 
 
 
2001 
2010 
2010 
 
2011 
 
 
 
3.0 
0.3 
0.5 
 
4.0 
 
 
Research skills 
 Practical introduction to laser scanning microscopy (OIC) 
 
 
 
2008 
 
 
 
0.6 
 
 
In-depth courses 
 ‘Grasduinen in Genome Browsers’ (MolMed) 
 Vascular Biology (Netherlands Heart Foundation) 
 Molecular Biology in Cardiovascular Research (COEUR) 
 Intensive Care Research (COEUR) 
 Pathophysiology of Ischemic Heart Disease (COEUR) 
 Cardiac Function and Adaptation (Netherlands Heart Foundation) 
 Cardiovascular Medicine (COEUR) 
 
 
 
2007 
2008 
2009 
2009 
2009 
2009 
2009 
 
 
 
0.6 
2.0 
1.5 
1.5 
1.5 
2.0 
1.5 
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Year 
 
Workload 
(ECTS) 
 
Presentations 
 Symposium Dutch Atherosclerosis Society, Ede, The Netherlands 
(poster) 
 COEUR PhD course (oral) 
 Dutch-German Joint Meeting, Rotterdam, The Netherlands (poster) 
 COEUR PhD day (poster) 
 COEUR PhD course (oral) 
 American Heart Association, Orlando (Florida), USA (poster) 
 Keystone Symposium, Snowbird (Utah), USA (poster) 
 
 
 
2009 
 
2009 
2010 
2010 
2011 
2011 
2012 
 
 
 
0.3 
 
1.5 
0.9 
0.8 
1.5 
0.3 
0.3 
 
 
National and international conferences 
 National 
- Symposium Dutch Atherosclerosis Society, Ede, The Netherlands 
- Cardio Vascular Conference, Noordwijkerhout, The Netherlands 
 International 
- Dutch-German Joint Meeting, Rotterdam, The Netherlands 
- American Heart Association, Orlando (Florida), USA 
- Keystone Symposium, Snowbird (Utah), USA 
 
 
 
 
2009 
2011 
 
2010 
2011 
2012 
 
 
 
 
 
0.3 
 
 
1.2 
1.5 
 
 
Seminars and lectures 
 COEUR research seminars 
- Gene and cell based therapies of CV disease 
- Imaging of carotid bifurcation atherosclerosis 
- Surgical and percutaneous aortic valve implantation: 
indications, techniques and follow-up 
- Hypertension 
- New developments in percutaneous revascularisation 
- Novel aspects of intensive care research 
- Left ventricular hypertrophy and genetics 
- Identification of novel genetic regulators of vessel formation 
 
 
 
 
2008 
2008 
2009 
 
2009 
2009 
2009 
2009 
2011 
 
 
 
 
0.4 
0.4 
0.4 
 
0.4 
0.4 
0.4 
0.4 
0.4 
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Teaching activities 
 
 
Year 
 
Workload 
(ECTS) 
 
Supervising Bachelor/Master theses 
 Student of LILLE 1 University - Science and Technology, Lille, France 
(F. Moreaux) 
 Student of Avans Hogeschool, Breda, The Netherlands 
(J. Vermeer) 
 Student of Avans Hogeschool, Breda, The Netherlands 
(E. van Reenen) 
 
 
 
2009 
 
2011 
 
2012 
 
 
 
 
1.4 
 
1.4 
 
1.4 
 
 
 Total 35.0 
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‘Alvorens de Universiteit van Rotterdam te verlaten en als geneeskundige/bioloog het 
maatschappelijk leven in te treden rust op mij de plicht, een voor mij hoogst aangename 
plicht, een woord van hulde en dank te richten tot de Hoogleeraren van de natuur- en 
wiskundige en van de geneeskundige faculteiten, aan wie ik mijne opleiding te Rotterdam, 
Utrecht, Amsterdam, Nijmegen, Leuven en Groningen heb te danken. Gretig vat ik de heden 
mij geschonken gelegenheid aan, U allen, Hooggeleerde Heeren! openlijk mijn’ hartelijken 
dank te zeggen èn voor de bijzondere welwillendheid, waarmede Gij mij van den aanvang 
tot het einde van mijn studietijd zijt te gemoet gekomen, èn voor het onderwijs dat ik van U 
heb mogen genieten. Zonder die welwillendheid zou het mij niet mogelijk zijn geweest den 
stap te doen, noch minder dien te volbrengen, waartoe ik den moed gevoelde te besluiten!’ 
 
Bovenstaande tekst is gebaseerd op de uiting van dank door mevrouw Dr. Aletta H. Jacobs 
(1854-1929) op 8 maart 1879 in haar academisch proefschrift - Over localisatie van 
physiologische en pathologische verschijnselen in de groote hersenen (Stads- en Handels-
Stoomdrukkerij van L. Oppenheim, Groningen) - ter verkrijging van den graad van Doctor 
in de geneeskunde aan de Rijksuniversiteit te Groningen. Zij vormt voor mij een groot 
voorbeeld. 
 
Geheel in deze traditie zou ik daarom dank willen brengen aan een ieder die mij heeft 
gevormd gedurende mijn academische loopbaan. 
 
Erasmus MC Rotterdam 
Prof.dr. Duncker, beste Dirk-Jan, fijn dat je als promotor wilde optreden. Je scherpe blik 
was een waar genoegen! 
Dr. Duckers, beste Eric, het was een bijzondere ervaring om onder jouw leiding 
werkzaam te mogen zijn geweest! De congresbezoeken in Amerika en de afdelingsborrels 
bij jou thuis heb ik zeer gewaardeerd. 
Mevr. Dr. Cheng, beste Caroline, dank voor al de steun die je mij hebt gegeven zodat 
dit proefschrift tot een goed einde mocht komen! 
 
Hubrecht Instituut Utrecht 
Prof.dr. Schulte-Merker, dear Stefan, thank you for the pleasant cooperation. The zebrafish 
work that takes place within your research group, forms an important foundation for this 
thesis. I would also like to thank you for being a member of the supervisory committee. 
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Vrije Universiteit Amsterdam 
Dr. Van Nieuw Amerongen, beste Geerten, dank dat ik gebruik mocht maken van de ECIS 
faciliteiten bij je op het lab. Ook Jan van Bezu en Robert Szulcek wil ik bedanken voor hun 
ondersteuning bij de experimenten. Met veel plezier heb ik mijn werkzaamheden bij jullie 
mogen uitvoeren! Zonder het VU-busje naast de telefoon bij mijn beide grootouders en zo 
vele anderen zou dit niet mogelijk zijn geweest. 
 
Radboudumc Nijmegen 
Prof.dr. Kollée, onder uw leiding kon ik op de afdeling kindergeneeskunde mijn klinische, 
alsmede mijn onderzoeksvaardigheden tot ontplooiing brengen. 
Dr. Van Heijst, beste Arno, dank voor je enthousiaste begeleiding. Je toonde altijd een 
grote betrokkenheid bij het wetenschappelijk onderzoek! Door jouw vertrouwen in mij, kon 
ik mij vormen tot een klinisch onderzoeker. Tijdens de periode van het onderzoeksproject 
bij jou op de afdeling neonatologie bood je me altijd de krenten in de pap aan, waaronder 
een symposiumbezoek in Aachen, het houden van een mondelinge voordracht op het NVK-
congres te Veldhoven en de vele werkbesprekingen met professor Tibboel in het Sophia 
Kinderziekenhuis te Rotterdam, maar ook het neonataal transport per ambulance vanuit Oss 
vond ik een geweldige ervaring. Je stelregel: ‘maak het jezelf niet te moeilijk’ heb ik helaas 
pas veel te laat ter harte genomen, maar al doende leert men. Dank voor alles! 
Mevr. Van Wolferen, beste Corrie, jij mag in deze rij zeker niet ontbreken. Dank voor 
je ondersteuning en bemoediging als het wel eens tegenzat. Je attendeerde me altijd weer op 
de lichtpuntjes als ik ze soms even niet meer zag. Met een groot genoegen kijk ik terug op 
de NVK-congressen welke ik samen met jou mocht bezoeken. Je hebt me hier leren 
‘shoppen’ bij de industrie, waarvan ik nog vele malen plezier heb gehad bij andere 
wetenschappelijke bijeenkomsten. Ook stelde je me in de gelegenheid om te netwerken 
tijdens het informele deel van het congres. Niet alleen tijdens het werk bood je de nodige 
ondersteuning, maar ook bij het lopen van de Nijmeegse vierdaagse. Ik keek altijd uit naar 
je sms’jes. Zonder dit zou ik de ‘Via Gladiola’ nooit hebben gehaald. In één woord 
geweldig! 
 
Radboud Universiteit Nijmegen 
Prof.dr. Flik, beste Gert, vaak denk ik nog terug aan de woorden die je hebt gesproken 
tijdens de uitreiking van het doctoraal diploma Biologie. Deze hebben een diepe indruk op 
mij achtergelaten. Je bent iemand die de waarde van mensen inziet! Iedereen bij jou op de 
afdeling organismale dierfysiologie is van even groot belang, ongeacht rang of stand. Met 
zeer veel plezier heb ik me dan ook gestort op de stage die ik bij je mocht lopen. Ook aan 
de uitreiking van de L.M. van Nieuwenhovenprijs koester ik warme herinneringen. Veel, 
veel dank! 
 
Dankwoord 
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Dr. Klaren, beste Peter, werkoverleg met jou was altijd heel gezellig. Je bood de ruimte 
om met eigen ideeën te komen en stuurde bij waar nodig. De deur van je kamer stond altijd 
open en ik kon dan ook met al m’n vragen bij je terecht. Dank voor alle sprankelende 
momenten! 
 
Katholieke Universiteit Leuven (België) 
Mevr. Prof.dr. Darras, dank voor de geboden gastvrijheid bij u op het Laboratorium voor 
Vergelijkende Endocrinologie. Het was mij een waar genoegen de Vlaamse normen en 
waarden te mogen ervaren. Ik heb mij dan ook erg thuis gevoeld bij u op het labo! 
Dr. Van der Geyten, beste Serge, vele goede gesprekken hebben wij mogen voeren op 
een van de gezellige terrasjes in Leuven. Op het labo heerste ook altijd een goede sfeer. 
Met veel humor kon je dingen uitleggen. Het mooiste was toch wel dat we voor het scannen 
van de gelelectroforese in witte jas buitenom naar de buren moesten. Ook van de labuitjes 
naar de Belgische Ardennen heb ik erg genoten, waarvoor mijn dank! 
 
Rijksuniversiteit Groningen 
Prof.dr. Luiten, onder uw toezicht is in de eerste twee jaar van de studie Biologie de basis 
gelegd waarop mijn verdere academische loopbaan rust. 
 
Susan en Carien, dank dat jullie mijn paranimfen wilden zijn. 
 
Al deze mensen hebben mij in academisch maar ook in persoonlijk opzicht gevormd tot wie 
ik nu ben. De grootste les die ik van hen allen heb mogen leren, is dat elke ontmoeting - hoe 
lang of hoe kort deze ook is - van waarde is en je doet laten veranderen. Carl Gustav Jung 
(1875-1961) verwoorde dit als volgt: ‘De ontmoeting tussen twee persoonlijkheden is als 
het contact tussen twee chemische stoffen. Indien er een reactie optreedt, zullen beiden 
veranderen.’ 
 
Verder dank aan al diegenen die ik hier niet met naam en toenaam heb genoemd, maar 
zonder wie dit proefschrift nooit tot stand zou zijn gekomen. 
 
Tot slot wil ik nog in het bijzonder mijn ouders bedanken voor alle ruimte die zij mij geven 
om mijn dromen te verwezenlijken, maar bovenal dank aan de Ene die nooit loslaat het 
werk waaraan zijn hand eenmaal begonnen is… 
 
Remco 
 
 
 
 
